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introduction
Melanoma is a type of skin cancer that arises from melanocytes. More than 95% of all melano-
mas occur in the skin, but rarely in the pigmented cells of the eye, meninges or mucosa. This 
thesis will only regard the invasive cutaneous malignant melanomas.1
ePidemiology
The incidence of melanoma has rapidly increased over the past decades and is continuing to do 
so. In Europe the rate of incidence began to increase in the 1950s in the more affluent Northern 
European countries due to life style changes such as; more extreme sun behaviour especially 
in young children, travelling to sunny destination and sun bed use.2-5 Across western countries 
the incidence of melanoma increased with minimal 3% annually (4-5% in the Netherlands).
The highest incidence rates for melanoma have been reported for Australia, with an esti-
mated age-standardized rate of 40.2 cases per 100 000 people in 2008.6 This can be explained 
by citizens of Australia originating from Irish immigrants with a fair skin (skin type I-II), now 
being exposed to excessive UV-radiation. Skin cancer is the third most common cancer (exclud-
ing basal cell carcinoma) in the Netherlands. It is estimated that one out of six Dutch citizens will 
develop any type of skin cancer during their life time of which 10% will develop a melanoma. 
Melanoma is the third most common type of skin cancer in the Netherlands affecting relatively 
young people (average age of diagnosis around 53 years). In 2006, 1531 men 1949 women were 
diagnosed with melanoma, with an age standardized rate of 8.5 per 100 000 for men and 11 per 
100 000 for women.2 Incidence rates are increasing with ~4% annually. Therefore, public health 
campaigns are trying to raise public awareness and are informing people to avoid sunlight 
during the middle of the day, wear protective clothing (long sleeves, head), use sun cream and 
parents to protect themselves and especially their children.
In contrast to the continuing rise in melanoma incidence, mortality due to melanoma seems 
to have stabilized in some countries in the last few years most likely due to increased awareness 
among patients and physicians resulting in early detection. However, melanoma remains the 
most deadly type of cutaneous malignancy with approximately 500 deaths in the Netherlands, 
annually.
carcinogenesis
The exact pathogeneses of cutaneous melanoma is still unknown. Epidemiological studies 
have shown that sun exposure and genetic predisposition seem to play a role in the develop-
ment of melanoma.7
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Exposure of the skin to UV light is a well established risk factor for the development of cutane-
ous melanoma. DNA damage formation after UV exposure is thought to result in malignant 
transformation of melanocytes. There is limited information regarding which wave lengths 
of the UV spectrum are responsible for these effects. The carcinogenic properties of short-
wavelength UV light such as UVB have been well known. Because of its wavelength UVB is 
absorbed in the epidermis which can cause DNA damage in keratinocytes, which subsequently 
leads to C-T or CC-TT transitions. Also, true generation of oxidative stress and merging with the 
p53 pathway, UVB may lead to degradation in the DNA.8
In recent years however, there have been some indications that UVA might play a role in the 
development of melanomas as well, as retrospective studies indicate that the use of tanning 
beds, which mostly contain high dose UVA emitters, increase the risk of melanoma. UVA can 
deeper penetrate the skin. In contrast to UVB, UVA might play an indirect role in the develop-
ment of melanoma. It is thought that UVA leads to the production of reactive oxygen species 
(ROS) that subsequently leads to oxidative damage, single- and doublestrand breaks (SSBs and 
DSBs). It can cause DNA damage by indirect photosensitizing reactions and produce secondary 
photoreactions of the existing photoproducts. UVA is also known to induce the photoproduct 
8-oxo-7, 8-dihydro-2¢-deoxyguanosine (8oxoG) and CPDs in human skin. Overall, UVA contrib-
utes more to the formation of recurrent or hotspot mutations at methylated CpG sites in the 
mammalian genome than UVB.8
risk factors
It is now widely accepted that increased UV exposure is associated with a higher risk of mela-
noma. This insight is based on several different epidemiological observations. Epidemiological 
studies have shown that excessive, intermittent and chronic sun exposure at different age peri-
ods affects melanoma development. Especially, short intense periods of sun exposure in early 
childhood or adolescence, with burning of the skin, appears to be a risk factor for cutaneous 
melanoma, whereas high levels of cumulative UV exposure has been associated with lentigo 
maligna melanoma.9 Chronic UV exposure may be protective of other types of melanoma.10
Secondly, people with a fair pigment status (hair, skin, eye colour) are at increased risk.7 
Melanoma rates are also higher at locations with lower latitude, especially among Caucasian 
immigrants, for example reflecting in the incidence rates of Australia en the US. Equally, naevi 
(which may be precursors of melanoma) are induced by higher levels of solar exposure.
More importantly, patients with impaired DNA repair of UV induced damage or with poly-
morphisms in several pigment related genes are at a high risk of developing melanoma. 11 Five 
to ten percent of all melanomas are in patients with FAMMM (familial atypical multiple mole 
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melanoma syndrome). In 25-40% of these patients a mutation of the tumor suppressor gene 
cyclin-dependent kinase inhibitor 2A (CDKN2A) is found, and in a few a mutation in the cyclin 
dependent kinase 4 (CDK4) gen. Patients with FAMMM have a life time risk of 70% to develop 
a melanoma.
Also mutations in tumor suppressor genes like c-kit, CDKN2A, p53 and BRAF, have been 
reported to increase the risk of melanoma. However, it is still unclear, how important mutations 
of these genes are as a risk factor for melanoma.
clinical examination
Early detection of thin melanomas is a key factor in improving survival from melanoma. The 
clinical diagnosis of cutaneous melanoma continues to be based on a visual inspection of the 
skin. A history of itching or change in the color, shape, size of a pigmented lesion over time is 
one of the most sensitive clinical sign for melanoma. These characteristics of melanoma are 
summarized within the ABCDE-rule of melanoma; wherein the Asymmetry, Border, Color, Diam-
eter and Evolvement of a melanocytic lesion are assessed and scored. Melanomas usually show 
asymmetry in shape with an irregular border. Melanomas can have different colors, besides 
different shades of brown or black; red, blue, grey, hypopigmentation and/or depigmentation 
can be seen as a sign of regression, in up to two thirds of melanomas. About half of these 
melanomas arise in pre-existing nevus.12-14 A diameter greater than 0.5 cm is also suggestive 
for a melanoma. Finally, the “E”’ is referred to as evolvement of a pigmented lesion over time.
Another accepted concept is the “ugly duckling sign” introduced by Grob and Bonerandi 
(1998)15 which indicate that nevi in the same individual tend to resemble one another; a malig-
nant melanoma will then often deviate from the individual’s nevus pattern.
Dermatoscopy (i.e., using a magnification of 10X and polarized light) is of great importance in 
making all these characteristics of a melanoma more distinct, while inspecting a pigmented 
lesion. It raises the sensitivity to 91% and specificity to 86% of the diagnoses of melanoma in the 
hands of experienced physicians.16 With use of the ABCD-rule and dermatoscopy, pigmented 
lesions are scored with the help of several algorithms (e.g. the rules of Wilhelm Stolz) to make a 
distinction between a benign, atypical mole or a malignant melanoma. A higher score makes a 
pigmented lesion more suspect for melanoma.
histology
A diagnostic excision is performed when a lesion is suspect for melanoma. It is important to 
know if the lesion is in situ or not. An in situ melanoma can be seen as a precursor lesion of 
Cynthia BW 7.indd   11 28-09-11   13:35
Introduction
1
12
an invasive malignant melanoma. The melanocytes are showing some deformation but they 
are still within the epidermis. When atypical melanocytes are growing past the epidermal 
layer (through the basal membrane), into the dermis it becomes an invasive malignant type 
of melanoma. During this process there are 2 major ways of growth; (1) radial growth indicates 
the initial tendency of a melanoma to grow horizontally within the epidermal and superficial 
layers. During this phase there is no evidence of angiogenesis. With time, the pattern of growth 
changes to (2) vertical growth phase. The melanoma now grows downward into the deeper der-
mal layers of the skin as forming a tumor that lacks cellular maturation, without any tendency 
for the cells to become smaller as they descend into the reticular dermis. During this phase 
angiogenesis is present.
A pathologist uses Breslow thickness (or Clark level) to express the extent of invasion. These 
measures are directly correlated to the prognosis of a patient. Microscopic ulceration of the 
melanoma as well as the mitotic index are also important prognostic factors (17; Table 1-2).
There are 4 major types of melanoma; superficial spreading, nodular, lentigo maligna 
melanoma and acral lentiginous melanoma. Superficial spreading melanoma (SSM) is the most 
common type of cutaneous melanoma in fair-skinned individuals; approximately 70% of all 
cutaneous melanomas are superficial spreading. SSM is followed by nodular melanomas (15%), 
lentigo maligna melanomas (10%) and acral lentinous melanoma (5-10%)
staging
Tumor staging of melanoma is an important step for estimating a patients’ prognosis and 
deciding on therapy approach. Following a histological confirmed diagnosis of melanoma a 
sentinel node procedure can be offered to a patient with a malignant melanoma of a Breslow 
depth >1.20mm, to detect early lymph node metastases, which may affect a patients cancer 
stage. It remains controversial whether the sentinel node procedure should be offered to all 
patients and whether it affects patients’ survival. Furthermore, additional image-forming, such 
as X-ray, CT-scan or PET scan, can be done on indication to detect distant metastases, although 
one should be aware of the low predicting value. 18
Next, melanomas can be staged by the AJCC (American Joint Committee on Cancer) clas-
sification or TNM classification. (Table 1 and 2) This classification is based on the Breslow depth, 
lymphnode metastases and whether or not there are distant metastases.17
Prognosis
In 2006, 749 people died of skin cancer in the Netherlands, of which 85% died due to mela-
noma. Next to Breslow thickness, ulceration of the tumor, lymph node metastases and visceral 
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metastases, the prognosis for men is two times lower than for women. Especially men above 
the age of 65 have a higher mortality due to melanoma and a significantly lower 5-year survival 
rate. The 5-year survival rate is 90% for women but only 81% for men. When there are lym-
phnode metastases the 5-year survival rate drops to 40%. Involvement of lymph nodes and the 
occurrence of metastases increase the risk of mortality by 9.2 times and 11.2 times, respectively.
treatment
The primary treatment of melanoma is surgery. A re-excision is performed on the primary 
melanoma site after histological confirmation, with an appropriate margin determined by the 
Breslow depth (varying between 0.5 and 2 cm). After this procedure only follow-up to detect 
recurrence of melanomas is indicated.
table 1: TNM staging categories for cutaneous melanoma according AJCC classification 2009
classification thickness (mm) ulceration status/mitoses
T
Tis NA NA
T1 ≤ 1.00
A: without ulceration and mitosis <1/mm2
B: with ulceration or mitosis ≥ 1/mm2
T2 1.01-2.00
A: without ulceration
B: with ulceration
T3 2.01-4.00
A: without ulceration
B: with ulceration
T4 >4.00
A: without ulceration
B: with ulceration
n no. of metastatic nodes nodal metastatic Burden
N0 0 NA
N1 1
a. micrometastases*
b: macrometastases¥
N2 2-3
a. micrometastasis*
b: macrometastases¥
c: In transit metastases/satellites without metastatic nodes
N3
4+ metastatic nodes, or in 
transit metastases/satellites with 
metastatic nodes
m site serum ldh
M0 No distant NA
M1a
Distant skin, subcutaneous or 
nodal metastases
Normal
M1b Lung metastases Normal
M1c
All other visceral metastases
Any distant metastases
Normal
Elevated
NA, not applicable: LDH, lactate dehydrogenase. *Micrometastases are diagnosed after sentinel lymph 
node biopsy. ¥Macrometastases are defines as clinically detectable nodal metastases confirmed 
pathologically
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Effective treatment of metastasized melanoma is quite limited which makes the prognosis 
of these patients insufficient. The mainstay of patients with distant metastases is systemic 
therapy. The systemic agents that have been used include chemotherapy (e.g. darcabazine /
temozolomide, cisplatin, vindesine/vinblastine, BCNU/fortemustine, and taxol/taxoterel) , 
immunotherapy (IFN-alpha) and combination of biochemotherapy. Preferably patients are 
treated as part of well-controlled clinical trials.19
New targeted therapies have been introduced with the discovering of tumor suppres-
sor gene mutations. Sorafenib was the first BRAF target therapy to be studied in metastatic 
melanoma, but has not shown major clinical effects. A more promising BRAF kinase inhibitor 
is vemurafenib, with response rates over 50% in patients with metastatic melanoma with the 
BRAF V600E mutation.20-21 A recent phase 3 study showed a overall survival of 84% in the 
vemurafenib group compared to 64% in the group treated with dacarbazibe. Response rates 
were 48% for veramufenib and 5% for dacarbazine.20
table 2: Anatomic stage groupings for cutaneous melanoma according to the AJCC 2009
clinical staging Pathological staging
T N M T N M
0 Tis N0 M0 0 Tis N0 M0
IA T1a N0 M0 IA T1a N0 M0
IB T1b
T2a
N0
N0
M0
M0
IB T1b
T2a
N0
N0
M0
M0
IIA T2b
T3a
N0
N0
M0
M0
IIA T2b
T3a
N0
N0
M0
M0
IIB T3b
T4a
N0
N0
M0
M0
IIB T3b
T4a
N0
N0
M0
M0
IIC T4b N>N0 M0 IIC T4b N>N0 M0
III Any T N>N0 M0 IIIA T1-4a
T1-4a
N1a
N2a
M0
M0
IIIB
IIIC
T1-4b
T1-4b
T1-4a
T1-4a
T1-4a
T1-4b
T1-4b
T1-4b
Any T
N1a
N2a
N1b
N2b
N2c
N1b
N2b
N2c
N3
M0
M0
M0
M0
M0
M0
M0
M0
M0
IV Any T Any N M1 IV Any T Any N M1
Clinical staging includes microstaging of the primary melanoma and clinical /radiologic evaluation of 
metastases. By convection, it should be used after complete excision of the primary melanoma with clinical 
assessment for regional and distant metastases.
Pathological staging includes microstaging of the primary melanoma and pathological information about 
the regional lymph nodes after partiel(i.e. sentinel node biopsy) or complete lymfadenectomy. Pathological 
stage 0 or stage IA patient are the exception;they do not require pathologic evaluation of their lymph 
nodes
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Ipilimumab blocks cytotoxic T-lymphocyte-associated antigen 4 to enhance an antitumor 
T-cell reponse. A phase 3 study among HLA-A*0201 positive patients showed a improvement in 
survival among patients treated with ipilimumab and glycoproteine 100 peptide vaccine (10.0 
months) compared to patients receiving only glycoproteine 100 (6.4 months).However severe 
immune related adverse events occurred in 10-15% of patients treated with ipilimumab.19
follow-uP
The follow-up of patients with a history of melanoma differs across the world and is debated. 
This is partly due to ever increasing incidence of melanoma, as well as the lack of agreement 
regarding the reasons for and frequency of follow-up. Reasons for follow-up of melanoma 
patients include: detection of recurrent melanomas, diagnosis of new potential malignant 
lesions, reassurance of the patient and/or instructing patients for self-examination of the skin. 
However, melanoma patients are often not involved in the debate on follow-up. The frequency 
of follow-up might be limited when patients are capable to detect recurrence of second pri-
mary melanomas themselves.
A collaboration of the European Dermatology Forum (EDF), The European Association of 
Dermato-Oncology (EADO) and the European Organizaztion for Research and Treatment of 
Cancer (EORTC) have made a guideline for clinicians across Europe. They describe a great varia-
tion between different guidelines varying from 2 to 4 times per year for 5 to 10 years.22-24 In stage 
I to II melanoma, the intent is to detect early loco-regional recurrence. A follow-up frequency 
of every 3 months for the first 5 years followed by a follow-up visit once every 6 months for the 
6th to 10th year period after diagnosis, is considered adequate. In patients with a thin melanoma 
(breslowdepth <=1mm) six monthly intervals are considered sufficient. 22 Clinical follow up is 
standard, but the guideline suggests a possible benefit in additional ultrasonography.22
table 3: Frequency of follow-up according to Dutch melanoma guideline (2005)*
Breslow thickness time after diagnosis frequency of follow-up
< 1.00 mm 3 months after surgery One single appointment
> 1.00 mm Year 1 Once every 3 months
Year 2 Once every 4 months
Year 3-5 Once every 6 months
>2.00mm Year 1 Once every 3 months
Year 2 Once every 4 months
Year 3-5 Once every 6 months
Year 6-10 Annually
* Supplemental tests as indicated
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Compared to other melanoma guideline the Dutch melanoma guideline of 2005 is one of 
the most conservative. The frequency of follow-up, advised by the Dutch melanoma guideline 
of 2005 is presented in table 3.18
aims of the thesis
In this thesis we have attempted to describe the incidence of melanoma in the Netherlands and 
Europe, the impact it has on patients’ lives as well as its societal impact. We also describe results 
of a cross-sectional study on the follow-up of melanoma patients.
The aims of this thesis are:
- To give an overview of the recent trends in epidemiology of melanoma
- To asses patients’ perspectives of having been diagnosed with melanoma
- To asses the societal burden of melanoma
To asses the role of melanoma in the skin cancer epidemic in the Netherlands, an overview 
of all types of skin malignancies and their trends in incidence in the Netherlands is given in 
chapter 1 based on routinely collected cancer registry data of the Netherland Cancer Registry 
South. Chapter 2 focuses on melanoma, by describing incidence rates and trend in incidence 
of melanoma across Europe, based on data provided by several European population-based 
cancer registries that are member of the European Network of Cancer Registries. In Chapter 3 
we reviewed the Health Related Quality of Life of melanoma (HRQoL) patients to get an insight 
of the impact melanoma can have on a patients’ live. This review shows that there was little 
known on the HRQoL of melanoma patients and only a few studies were population based 
and in large patient groups. This lead us to initiate a cross-sectional study on HRQoL among 
562 Dutch melanoma survivors (chapter 4). Furthermore, we evaluated patient characteristics 
and follow-up characteristics of melanoma patients, to identify if they could be of influence on 
their HRQoL.
We investigated whether or not Type D personality is more common among Dutch 
melanoma patients with worse HRQoL (chapter 5). Type D personality would imply a tendency 
towards negative affectivity (e.g. worry, irritability, gloom) and social inhibition (e.g. reticence 
and a lack of self-assurance), which might result in difficulty coping with their diagnosis.
Chapter 6 and 7 describe how patients with melanoma are treated by their physicians and 
whether or not this is to the patients’ satisfaction and/or according to the melanoma guideline. 
In chapter 8 we tried to quantify the impact of melanoma on society as burden of disease 
derived from the World Health Organization (WHO) guidelines to assess burden of disease.
A general discussion with current perspectives (chapter 9) concludes this thesis.
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The incidence and trends 
of cutaneous malignancies 
in the Netherlands 
1989-2005
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aBstract
Epidemiology of rare cutaneous malignancies in the general population is poorly documented. 
This descriptive study aimed to estimate the incidence and trends of all skin malignancies 
between 1989 and 2005. Data on skin tumors were extracted from the Netherlands Cancer 
registry (except for basal cell carcinoma (BCC) data—only available from Comprehensive 
Cancer Centre South) and categorized according to the International Classification of Diseases 
for Oncology, third edition, codes. Age-standardized incidence rates (European standardized 
population rate, ESR) per 100,000 person-years were calculated per year and for the period 
between 2001 and 2005. Estimated annual percentage changes (EAPCs) were estimated by 
Poisson regression models. A total of 356,620 skin tumors were diagnosed between 1989 
and 2005. Excluding BCC, squamous cell carcinoma (SCC), and melanoma, the remaining skin 
tumors constituted about 2% of all skin malignancies. The incidence of melanoma showed 
the steepest increase (EAPC, 4.0%), and ESR was close to that observed for SCC (EAPC, 2.3%) 
between 2001 and 2005 (17.1 versus 19.6). Hematolymphoid tumors (ESR=0.74) were mainly 
cutaneous T-cell lymphomas (60.8%). No significant increases in incidence were observed for 
lymphomas, and appendageal, fibromatous, and myomatous carcinomas during 1989–2005. 
In addition to keratinocytic cancers and melanoma, there is a wide variety of skin tumors that 
constitute <2% of all skin malignancies. The incidence of UV-related skin tumors increased 
significantly and more steeply than did those of other skin malignancies.
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introduction
Cutaneous malignancies are often categorized in non-melanoma skin cancer (NMSC) and 
cutaneous melanoma. NMSC is commonly used to address basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC), which are keratinocytic cancers, but the category of NMSC 
comprises a wide variety of skin tumors.
The incidence of skin tumors varies geographically and is relatively well documented for 
melanoma, SCC and to a lesser extent BCC in different international samples of the general 
population 1-4. The frequency of occurrence of the less common cutaneous malignancies 
such as cutaneous B- and T-cell lymphomas, soft tissue sarcomas (e.g., dermatofibrosarcoma 
protuberans [DFSP]), sebaceous carcinoma and Merkel cell carcinoma is poorly documented. 
The studies that mention the incidence rates of these rare skin malignancies are mainly using 
data from the Surveillance, Epidemiology and End Results (SEER) program, which registers 
pathology reports of nine areas that cover about 10% of the US population 5-9. Currently there 
are over 16.5 million Dutch citizens, of whom the majority is white. The Netherlands Cancer 
Registry registers all their pathologically confirmed cancers since 1989. According to the Neth-
erlands Cancer registry (www.ikcnet.nl) skin cancers (excluding BCC) rank 4th among the most 
common cancers in the Netherlands with 9,681 cases in 2007, but mortality is low (European 
standardized mortality rate = 0.3 per 100,000 person-years).To our knowledge, this is the first 
population-based study to provide incidence rates for all the major subtypes of skin cancers. 
Other studies have mainly focused on BCC, NMSC and melanoma 3, 10-13.
The objective of this descriptive epidemiological study is to provide absolute numbers and 
incidence rates of all skin cancer groups and their trends between 1989 and 2005 in the general 
Dutch population.
results
In total an absolute number of 356,620 cutaneous malignancies were registered in the Nether-
lands Cancer Registry between 1989 and 2005 (including the first primary BCCs from only one 
registry). The overall European standard population rate (ESR) was 126.31 per 100,000 person-
years including the estimated first primary BCC rate for the Dutch population. In men and 
women, the ESR of cutaneous malignancies (excluding BCC) in 2005 was 52.4 and 39.2 /100.000 
person years, respectively. The ESR of all skin tumors but BCC among people aged 60 years or 
more for 2005 was 27.4 and 16.5 per 100.000 person-years among people younger than 60.
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Basal cell carcinoma
In the Netherlands, the estimated absolute number of people with a first primary BCC (ICD-O3 
morphology codes 8090-8110) that occurred between 1989-2005 was 254,157 (based on an 
extrapolation of age-specific rates in the Comprehensive Cancer Centre South to the Dutch 
population), reflecting 70.9% of all skin cancers in the general population of the Netherlands 
between 1989-2005. Of the BCC patients, 49.1% was male and had a median age of 67 years. 
In the 5-year-period between 2001-2005, the European standard population rate (ESR) of a first 
BCC was 87.5 per 100,000 person-years and the estimated annual percentage change (EAPC) 
was 3.1% (95%CI 3.0-3.2)- between 1989-2005.
Squamous cell carcinoma
The absolute number of SCCs, which is, like BCC, a keratinocytic cancer, was 57,915 in the study 
period, representing about 16% of skin cancers, including first primary BCCs. The median age 
was 75 years and 62% of patients with SCC were men. More than half of all non-BCC skin can-
cers were SCC and its ESR was approximately 20 (Table 1). The age-adjusted EAPC was 2.3% per 
year and the ESR increased from about 15 to more than 20 between 1989 and 2005 (Figure 1).
Melanoma
In the 16 year study period, 38,647 melanomas were registered, comprising about 11% of all 
skin malignancies including first primary BCCs (Table 1). The median age of melanoma patients 
was 53 years and the majority of patients were women (except for desmoplastic melanomas 
were the majority was male). The ESR of melanoma was 17.1 between 2001-2005, roughly 
double that of 1989 with an EAPC of 4.0% (95%CI 3.8-4.2).
Of the different histological subtypes of melanoma, superficial spreading melanomas was the 
most commonly registered (54.1% of all melanomas) with an ESR of more than 10 /100,000 
person-years (Table 2). Nodular melanomas comprised 15% of all registered melanomas with 
an ESR of 2.36. A total of 1,280 lentigo maligna melanomas (3.3% of all melanomas) were diag-
nosed between 1989 and 2005. Patients with a lentigo maligna melanoma had a median age 
of 71 years and were 15 to 20 years older than those diagnosed with a nodular or superficial 
spreading subtype. The ESR of the remaining specific melanoma subtypes ranged between 
0.02 and 0.16/100.000 person-years.
Haematolymphoid tumors
A total of 2,020 cutaneous haematolymphoid tumors were diagnosed and confirmed by 
pathology reports in the Netherlands between 1989 and 2005. In the period 2001-2005, the 
ESR of these malignancies was 0.74 (Table 1) and the incidence remained stable during the 
study period, after adjusting for age (Figure 1). Of the haematolymphoid tumors, 60.8% were 
T-cell and NK-cell lymphomas, 33.4% of B cell origin and the remaining were non specified. 
Cynthia BW 7.indd   25 28-09-11   13:35
Incidence and trends of cutaneous malignancies in The Netherlands
Ch
ap
te
r 2
26
ta
bl
e 
2:
 E
ur
op
ea
n 
st
an
da
rd
iz
ed
 in
ci
de
nc
e 
ra
te
s f
or
 th
e 
m
os
t c
om
m
on
 su
bt
yp
es
 o
f s
ki
n 
ca
nc
er
s i
n 
th
e 
N
et
he
rla
nd
s, 
19
89
-2
00
5.
g
ro
up
s 
of
 (i
nv
as
iv
e)
 s
ki
n 
tu
m
or
s*
ic
d
o
-3
 c
od
es
to
ta
l n
um
be
rs
 o
f t
um
or
s 
(1
98
9-
20
05
) p
er
ce
nt
ag
e 
w
it
hi
n 
gr
ou
ps
m
ed
ia
n 
ag
e
(2
5-
75
 p
er
ce
nt
ile
)
Pe
rc
en
ta
ge
 
of
 m
en
es
r 
pe
r 1
00
,0
00
 
pe
rs
on
-y
ea
rs
(2
00
1-
20
05
)
m
el
an
om
as
M
 N
O
S
N
od
ul
ar
 M
Su
pe
rfi
ci
al
 s
pr
ea
di
ng
 M
Le
nt
ig
o 
m
al
ig
na
 M
Ac
ro
le
nt
ig
in
ou
s 
M
D
es
m
op
la
st
ic
 M
M
 fr
om
 p
re
-e
xi
st
in
g 
le
si
on
O
th
er
 M
87
20
87
21
87
43
87
42
87
44
87
45
87
40
; 8
74
1;
 8
76
1;
 8
78
0
87
22
; 8
72
3;
 8
77
0;
 8
77
1;
 8
77
2;
 8
73
0
8,
79
0 
(2
2.
7%
)
5,
78
6 
(1
5.
0%
)
20
,9
11
 (5
4.
1%
)
1,
28
0 
(3
.3
%
)
33
4 
(0
.9
%
)
84
 (0
.2
%
)
86
 (0
.2
%
)
1,
37
6 
(3
.6
%
)
53
 (4
0-
67
)
57
 (4
4-
71
)
50
 (3
9-
62
)
71
 (6
1-
79
)
62
 (5
2-
74
)
66
 (5
6-
78
)
54
 (3
8-
68
)
60
 (4
6-
72
)
41
.8
48
.5
39
.2
40
.9
38
.6
57
.1
37
.2
45
.8
2.
91
2.
36
10
.5
5
0.
53
0.
16
0.
04
0.
02
0.
56
so
ft
 ti
ss
ue
 tu
m
or
s
Fi
br
os
ar
co
m
as
88
10
; 8
81
1;
 8
83
0
13
7 
(9
.9
%
)
74
 (6
5-
82
)
65
.7
0.
03
D
er
m
at
ofi
br
os
ar
co
m
a 
pr
ot
ub
er
an
s
88
32
; 8
83
3
1,
06
6 
(7
6.
7%
)
41
 (3
1-
53
)
52
.2
0.
39
Le
io
m
yo
sa
rc
om
a
88
90
; 8
89
1;
 8
89
4;
 8
91
0
11
9 
(8
.6
%
)
64
 (5
1-
77
)
61
.3
0.
06
O
th
er
s
88
00
; 8
80
1;
 8
80
4;
 8
80
5;
 8
84
0;
 8
85
0;
 
89
82
; 9
12
0;
 9
13
3;
68
 (4
.9
%
)
77
 (6
6-
84
)
50
.0
0.
02
a
pp
en
da
ge
al
 tu
m
or
s Se
ba
ce
ou
s 
gl
an
ds
84
10
29
6 
(2
3.
5 
%
)
74
 (6
3-
81
)
58
.1
0.
1
Sw
ea
t g
la
nd
s
84
00
; 8
40
2;
 8
40
3;
 8
40
7;
 8
40
8;
 8
40
9
41
3 
(3
2.
8%
)
72
 (5
9-
82
)
48
.2
0.
15
Ex
tr
am
am
m
ar
y 
Pa
ge
t d
is
ea
se
85
42
11
7 
(9
.3
%
)
74
 (6
6-
82
)
57
.3
0.
04
O
th
er
s 
an
d 
N
O
S
81
40
; 8
41
3;
 8
14
3;
 8
19
0;
 8
20
0;
 8
23
0;
 
82
60
; 8
31
0;
 8
39
0;
 8
40
1;
 8
42
0;
 8
43
0;
 
84
80
; 8
48
1
43
2 
(3
4.
3%
)
69
 (5
7-
80
)
47
.0
0.
14
n
eu
ra
l t
um
or
s
M
er
ke
l c
el
l c
ar
ci
no
m
a
O
th
er
82
40
;8
24
6;
82
47
95
03
; 9
54
0;
 9
56
0;
 9
58
0
71
2 
(9
8.
5%
)
11
 (1
.5
%
)
77
 (6
8-
83
)
62
 (4
7-
78
)
38
.8
63
.6
0.
29
0.
00
Cynthia BW 7.indd   26 28-09-11   13:35
Incidence and trends of cutaneous malignancies in The Netherlands
Ch
ap
te
r 2
27
ta
bl
e 
2:
 E
ur
op
ea
n 
st
an
da
rd
iz
ed
 in
ci
de
nc
e 
ra
te
s f
or
 th
e 
m
os
t c
om
m
on
 su
bt
yp
es
 o
f s
ki
n 
ca
nc
er
s i
n 
th
e 
N
et
he
rla
nd
s, 
19
89
-2
00
5.
 (c
on
tin
ue
d)
g
ro
up
s 
of
 (i
nv
as
iv
e)
 s
ki
n 
tu
m
or
s*
ic
d
o
-3
 c
od
es
to
ta
l n
um
be
rs
 o
f t
um
or
s 
(1
98
9-
20
05
) p
er
ce
nt
ag
e 
w
it
hi
n 
gr
ou
ps
m
ed
ia
n 
ag
e
(2
5-
75
 p
er
ce
nt
ile
)
Pe
rc
en
ta
ge
 
of
 m
en
es
r 
pe
r 1
00
,0
00
 
pe
rs
on
-y
ea
rs
(2
00
1-
20
05
)
h
ae
m
at
ol
ym
ph
oi
d 
tu
m
or
s
B 
ce
ll 
ly
m
ph
om
as
 (L
)
69
 (5
4-
79
)
51
.4
0.
26
D
iff
us
e 
la
rg
e 
B-
ce
ll 
L
96
75
; 9
68
0;
 9
68
4;
 9
73
1;
 9
73
4
38
5 
(1
9.
1%
)
72
 (6
1-
82
)
47
.3
0.
13
Fo
lli
cu
la
r L
96
90
-9
69
7
13
6 
(6
.7
%
)
62
 (5
2-
76
)
55
.9
0.
05
M
ar
gi
na
l z
on
e 
B 
ce
ll 
L
96
99
; 9
67
1
12
2 
(6
.0
%
)
59
 (4
5-
73
)
57
.4
0.
07
O
th
er
 B
-c
el
l L
96
73
; 9
68
7;
 9
68
9
17
 (0
.8
%
)
66
 (2
9-
74
)
64
.7
0.
01
T 
an
d 
N
K 
ce
ll 
ly
m
ph
om
as
 (L
)
65
 (5
2-
74
)
61
.8
0.
43
M
yc
os
is
 fu
ng
oi
de
s
97
00
74
2 
(3
6.
7%
)
64
 (5
3-
73
)
63
.7
0.
2
Sé
za
ry
 s
yn
dr
om
e
97
01
 
38
 (1
.9
%
)
71
 (6
5-
79
)
50
.0
0.
01
Pr
im
ar
y 
cu
ta
ne
ou
s 
CD
30
+ 
T-
ce
ll 
L
97
18
97
 (4
.8
%
)
59
 (4
6-
72
)
62
.9
0.
09
A
na
pl
as
tic
 la
rg
e 
ce
ll 
L
97
14
48
 (2
.4
%
)
58
 (4
2-
71
)
60
.4
0.
02
O
th
er
s
97
05
; 9
70
8;
 9
71
9
16
 (0
.8
%
)
69
 (5
6-
77
)
68
.8
0.
02
N
O
S
97
02
; 9
70
9
29
3 
(1
4.
5%
)
66
 (5
0-
76
)
57
.7
0.
09
Ly
m
ph
om
as
, o
th
er
s 
an
d 
N
O
S
95
90
; 9
59
6;
 9
59
1;
 9
74
1;
 9
75
4;
 9
75
6
12
6 
(6
.2
%
)
71
 (5
7-
80
)
50
.8
0.
05
A
bb
re
vi
at
io
ns
: E
SR
, E
ur
op
ea
n 
st
an
da
rd
iz
ed
 in
ci
de
nc
e 
ra
te
s; 
IC
D
-O
3,
 in
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
is
ea
se
s f
or
 O
nc
ol
og
y,
 th
ird
 e
di
tio
n;
 L
, l
ym
ph
om
a;
 N
O
S,
 n
ot
 o
th
er
w
is
e 
sp
ec
ifi
ed
; M
. m
el
an
om
a;
 W
H
O
, W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n
* 
Sk
in
 c
an
ce
r g
ro
up
s a
cc
or
di
ng
 W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n 
(W
H
O
; L
eB
oi
t e
t a
l, 
20
06
)
Cynthia BW 7.indd   27 28-09-11   13:35
Incidence and trends of cutaneous malignancies in The Netherlands
Ch
ap
te
r 2
28
About 60% of the cutaneous T-cell lymphomas (CTCL), were classified as Mycosis Fungoides 
(with an ESR of 0.20/100,000 person-years), 7.9% were primary CD30+ lymphomas and 3.1% of 
the patients with CTCL had Sézary syndrome (Table 2). Of the cutaneous the B-cell lymphomas 
(CBCL), diffuse large and follicular B-cell lymphomas (38.0% and 24.9%, respectively) were the 
most common subtypes. Patients with CBCL were roughly 5 years older than those with CTCL 
(median age 64 vs. 69 years). Except for diffuse large BCL and Sezary syndrome, the majority 
(between 55.9 and 68.8%) of patients were male for each of the subtypes of haematolymphoid 
tumors.
Other rare skin cancer subtypes
World Health Organization (WHO) groups of cutaneous malignancies that were registered 
more than 1,000 times in the study period were appendageal and soft tissue tumors (1,258 and 
1,390, respectively) with an ESR of more than 0.40 for both subtypes (Tables 1 and 2). In total, 
723 neural tumors of the skin were recorded (ESR 0.29). In contrast to the soft tissue tumors, 
the incidence of appendageal and neural tumors increased significantly with 2.8% and 2.3% 
annually, respectively, in the 16 year study period (Figure 1).
More than three quarters of the soft tissue tumors of the skin were dermatofibrosarcoma 
protuberans (DFSP) (1,066 Dutch patients between 1989-2005) with an ESR of 0.39. Almost all 
neural tumors were Merkel cell carcinomas. About a third of the appendageal tumors were 
recorded to derive from sweat glands (ESR 0.1) and a quarter from sebaceous glands. Extramam-
mary Paget disease was registered in 117 Dutch people between 1989 and 2005. Appendageal 
and neural tumors mainly occurred among people aged 70 years or older, whereas the median 
age at diagnosis of cutaneous sarcomas was 45 years (Table 1). Less than 40% of patients with 
a Merkel cell carcinoma was male.
Between 1989 and 2005, less than 0.5% of the recorded skin cancers were without a pathol-
ogy specification and their proportion decreased significantly (-2.1% annually [95%CI -3.9, 
-0.2]) over time.
discussion
Among the approximately 15 million Dutch citizens, more than 350,000 skin malignancies 
have occurred between 1989 and 2005. It was estimated that 1 out of the 6 Dutch citizens 
will develop a skin tumor in their life time14. The keratinocytic skin cancers (BCC and SCC) and 
melanoma together comprise more than 98% of all skin tumors. The ESR of these three cutane-
ous malignancies are comparable to these reported previously of the same Dutch population 
and of other Northern European countries 1, 3, 10, but are substantially lower than in geographic 
regions such as Australia and parts of the US 15.
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Between 1989 and 2005, the incidence rates of melanoma and SCC steadily increased and 
almost doubled. Interestingly, the rate of increase of melanoma seemed to accelerate in the 
last decade and is closing in on the SCC rates. Other UV-related skin cancers such as Merkel cell 
carcinoma and appendaeal tumors also increased significantly and more rapidly than other 
non-UV-related tumors such as cutaneous lymphomas and sarcomas. This discrepancy confirms 
TRENDS IN INCIDENCE OF SKIN CANCER IN THE NETHERLANDS, 
EXCLUDING BASAL CELL CARCINOMAS, 1989-2005
Year of diagnosis
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0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
10,0
15,0
20,0
25,0
Squamous cell carcinoma, EAPC 2.3% (95%CI: 2.2%; 2.5%)
Cutaneous malignant melanoma, EAPC 4.0% (95%CI: 3.8%; 4.2%)
Appendageal tumors, EAPC 1.4% (95%CI: 0.3%; 2.5%)
Haematological tumors, EAPC 0.8% (95%CI: -0.1%; 1.7%)
Soft tissue tumors, EAPC 0.8% (95%CI: -0.3%; 1.9%)
Neural skin tumors, EAPC 5.1% (95%CI: 3.5%; 6.6%)
Other skin tumors, EAPC -0.6% (95%CI: -10.5%; 9.4%)
Skin tumors, not otherwise specied, EAPC -2.1% (95%CI: -3.9%; -0.2%)
figure 1. Trends in incidence of skin cancer in the Netherlands, excluding basal cell carcinomas, 1989-2005.
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that changed UV-exposure patterns may be the driving force behind the steep increases of 
types of cutaneous malignancies that are known to be related to UV exposure. This observation 
suggests that, besides a potential influence of surveillance and awareness, there must be a true 
increase in the occurrence of BCC, SCC and melanoma and not just a diagnostic shift 16.
Of the less common skin malignancies, CTCL, CBCL, DFSP, appendageal tumors and Merkel cell 
carcinoma had the highest incidence rates. Our findings show remarkable similarities to other 
studies, often from the US using SEER data, despite differences in the distribution of demo-
graphic characteristics and geographic locations. The observed ESR of 0.43 for CTCL was in the 
range of reported incidence rates from Western populations (0.13-0.90 /100,000 inhabitants) 
6, 17-18. In accordance with SEER data, CBCL accounted for just over a third of the cutaneous lym-
phomas and the observed ESR was very close to the one in a US study 5. The incidence of DFSP 
detected in this study (ESR=0.39) and its stability over time is comparable to that documented 
in four US studies using SEER data 7, 9, 18-19. Both in our study and in US population-based studies 
20-21, the incidence rates of Merkel cell carcinoma were about 0.30 /100,000 inhabitants, with an 
almost three folds increase over the past two decades which primarily affected elderly people. 
The Dutch and US incidence of sebaceous carcinoma were comparably low and constant over 
time (about 0.10/100,000 person-years) 22-23. In accordance with our findings, the majority of 
these patients were elderly Whites.
Our study is the first to present a comprehensive overview of the descriptive epidemiology of 
all WHO skin tumor groups including estimates of specific rare cutaneous malignancies in the 
same time period and region (except for BCC that was only recorded in the South East of the 
Netherlands). Moreover, it supplements epidemiologic data on rare skin tumors from the SEER 
data and provides a European perspective on the occurrence of these malignancies in a gen-
eral population sample. To minimize misclassification bias, which may have been introduced 
because of the long study period, the tumors were coded according to the ICD-O3 classification 
for skin malignancies 24-25 and categorized in WHO skin tumor groups in collaboration with a 
certified pathologist (Senada Koljenović). Nevertheless, misclassification may have occurred, 
but the percentage of NOS skin tumors was only 0.47%, which is in concordance with interna-
tional observations, suggesting that the impact of this bias is limited. Using many sources of 
information (pathology reports, hospital discharge information, clinical records, etc), the Dutch 
cancer registries have demonstrated to include most cancers, their records are assumed to be 
complete since 1989. 26. Still some underreporting may have occurred as some skin cancers 
might have been treated without being pathologically confirmed. For some of the skin cancer 
types, stratified trend analyses were not possible because of the limited number of cases. No 
information by ethnic background or skin color was available.
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In summary, the keratinocytic cancers and melanoma form the overwhelming majority of cutane-
ous malignancies. The remaining skin tumors constitute about 2% of all malignancies and are pre-
dominantly lymphomas, DFSP, appendageal tumors and Merkel cell carcinomas with incidence 
rates comparable to those observed in the US. The incidence rates of UV-related skin tumors 
increased significantly and more steeply than those of other, non-UV related, malignancies.
methods
In the Netherlands all pathology laboratories are affiliated to the PALGA Foundation, which 
registers all histopathology and cytopathology reports. The Netherlands Cancer registry, 
comprising nine Comprehensive Cancer registries, receives weekly reports of PALGA on all 
pathological confirmed cancers since 1989, covering more than 95% of all cancers in the 
Netherlands. Using ICD-O3 codes presented in table 1, skin tumors were extracted from the 
Netherlands Cancer Registry between 1989 and 2005, except for BCCs, which were registered 
in the Comprehensive Cancer Centre South only. According to the ICD-O3 classification 24-25, 
skin tumors were grouped in keratinocytic cancers (BCC and SCC excluding in situ lesions), 
melanomas, appendageal, haematolymphoid, soft tissue, neural tumors and others and non 
specificied malignancies as suggested by the most recent World Health Organization (WHO) 
classification of skin tumors 27. Only invasive lesions were included in the analyses.
The absolute number of newly diagnosed cancers were recorded (and estimated in the case of 
BCC) for the whole Dutch population. Age-standardized incidence rates were calculated using 
the European Standard Population (ESR) and expressed per 100,000 person-years for each year 
between 1989-2005 and for the last five years (2001-2005), separately.
`For the most common malignancies in each of the WHO skin tumor groups, we estimated the 
annual percentage change (EAPC) in number of incident cases by constructing Poisson regres-
sion models with a log-link, modeling the observed number of cases as a function of year of 
diagnosis, adjusting for age and using the ln(population size) per age group and year as offset 
variable. The EAPC was calculated with a 95% confidence interval (CI). P-values were two-sided 
and considered significant if less than 0.05. The analyses were performed using SPSS version 
15.0, using generalized linear models.
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aBstract
Backgrounds: Melanoma has become a significant health problem in most Caucasian popula-
tions. The most recently available data from cancer registries always have a delay of approxi-
mately 6 months, but for the sake of validity, often of a few years and they are not always 
published in easily accessible ways. The 2 main objectives of this study were to determine the 
incidence and trends in incidence of melanoma and predict incidence rates for 2010 and 2015.
methods: A retrospective database analyses was performed on data from 30 European Cancer 
registries that were members of the European Network of Cancer Registries and participated in 
Cancer Incidence in 5 continents. Predictions were mostly made with use of projection models 
that were linear in time.
results: Data was provided by 30 registries of 23 countries in Europe of which most of them had 
data available from 1990 up to 2006. Overall the incidence of melanoma is rapidly rising and 
will continue to do so. The incidence among women in Europe was generally higher than men. 
The highest incidence rates were seen for Scandinavian countries and north-western countries 
like the UK, Ireland and the Netherlands. The lowest incidence rates were seen for Portugal and 
Spain, but these estimates were derived from only a few cancer registries. Relatively low inci-
dence rates were also seen for Poland. Poland also had the highest mortality: incidence ratio.
conclusion: In conclusion, incidence rates of melanoma are expected to continue rising. These 
trends are worrying in terms of disease burden, and, particularly in eastern European countries, 
in terms of the number of people that are expected to die due to melanoma.
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introduction
Cutaneous malignant melanoma (melanoma) represents 4% of skin cancers but is responsible 
for 80% of skin cancer deaths and all together 1-2% of all cancer deaths 1. It has become a 
significant problem in Caucasian populations, with one in 6 persons developing skin cancer in 
their lifetime, of whom 10% has a melanoma. A recent study predicted that the incidence of 
melanoma in the Netherlands, will probably become higher than that of squamous cell carci-
noma 2. Through initiatives like the European Network of Cancer Registries (ENCR) it is possible 
to analyse and publish data from population based cancer registries throughout Europe to 
identify epidemiologic trends and associated survival for many cancer types 3. These show that 
melanoma already has become a significant health care problem across Europe often appear-
ing in the top 10 of most commonly occurring cancers. A study of de Vries et al. showed marked 
increases in incidence of and mortality from melanoma, but with indications of stabilising trends 
in some Northern European countries 4. A study including data mainly from the 1990s showed 
that stage at diagnosis of melanoma was higher in the former communist countries compared 
to the northern and western European countries. The most recently available data from cancer 
registries always have a delay of approximately 6 months, but often of a few years and they are 
not always published in easily accessible ways, and usually do not contain information on stage 
at diagnosis. The two main objectives of this study are (1) to determine the recent incidence of 
melanoma, overall and by sex across Europe and (2) to analyze time trends in incidence and 
predict incidence rates for 2010 and 2015. Moreover, we inspected mortality:incidence ratios 
for melanoma across Europe as a proxy for the stage distribution of melanomas across Europe.
methods
Data collection
European population-based cancer registries (both National/Regional), members of the Euro-
pean Network of Cancer Registries (ENCR: http://www.encr.com.fr/), and participating in Cancer 
Incidence in 5 Continents 5-6 were contacted to determine interest in study participation. Those 
who replied positively and had at least 10 years of data available, with most recent data from 
2004 or later were included for the analyses. A retrospective database analysis was performed 
on data obtained from 30 European Cancer registries.A quality assessment was performed 
on the participating registries (missing data, collected variables etc). Standard cancer registry 
procedures and coding rules, described in Cancer Incidence in 5 Continents were applied in all 
the included registries. The national and regional registries all fulfil the rules regarding patient 
privacy etc. Cancer Registries record tumour and patient characteristics based on pathological 
reports or clinical information available. Mortality data was obtained from the mortality data-
base of the World Health Organisation.
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Statistical Analysis
The predicted numbers of newly diagnosed cases with melanoma per European country in 
2010 and 2015 were estimated by first projecting the incidence rates on the basis of observed 
rates from 1990 (or first year available after 1990) until the most recently available year (mostly 
between 2004 and 2007) by 5-year age categories and sex, according to the methods devel-
oped by Dyba et al.7-8, and multiplying these rates in the population forecast for these periods, 
provided by the cancer registries themselves or derived from Eurostat. For the analysis only 
invasive melanomas were included.
The method developed by Dyba et al consists of 4 different submodels, 2 out of which are 
linear in time, and 2 are log-linear in time. Data was fitted to the 4 different models and the best 
fitting model was used for the projections. Besides the linear component in time trends, age 
effects observed in the historical data are incorporated in the modeling. The two models for 
increasing trends and fitted the best for our projections were:
I: Rap=Aa (1+Dp)
II: Rap=Aa +Dap
Where Rap = cap /nap is the expected value of incidence in age group a and period p, nap is 
the number of person years, cap the number of cases. Where Aa is the age-component of age 
group a, D is the general drift parameter for all age groups, and Da is the drift parameter for age 
group a.
The collected data were combined with population-data from the whole population in 
order to estimate incidence rates when registries covered a non-national, regional catchment 
area only. Population sizes as reported by Eurostat were used to transform the projected age-
specific incidence rates into expected numbers of new cases by age and sex by 2010 and 2015. 
Both European standardized rates (ESR) and absolute numbers were reported.
Age-specific incidence numbers were divided by the age-specific total population. Euro-
pean standardized rates were then calculated by multiplying the age-specific incidence rates 
with the standard European population data (http://seer.cancer.gov/stdpopulations/), and 
expressed per 100,000 person-years. This rate would have been found if the population of a 
country had the same age-composition (proportion of total population in each five year age 
class) as a hypothetical European population.
Upon analyzing the data on stage at diagnosis we noted that not all cancer registries docu-
mented stage information uniformly and regularly and different staging classifications were 
used by the various registries (varying from Breslow thickness, Clark level, TNM classification or 
loco-regional vs. advanced disease). Most registries that did collect information by stage had 
large proportion of patients with missing information on stage. Therefore, rather than report-
ing the incomplete stage-distribution we decided to inspected mortality:incidence (M:I) ratios. 
Mortality data was obtained from the mortality database of the World Health Organisation. 
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M:I ratios were calculated by dividing age-standardised mortality rates by age-standardised 
incidence rates. A higher M:I-ratio means that probably more melanoma patients die due to 
melanoma compared to other countries with lower M:I-ratios.
results
Data was provided by 23 European countries, of which most of them had data available from 
1990 up to 2006. (Table 1) Overall the incidence rates of melanoma have increased markedly 
and will continue to do so. (Table 2) The difference in predicted rates and numbers between the 
selected models and the other three models was small (approximately 20-30% by 2015), except 
when one of the other models showed a lack of fit to the observed data (results not shown). 
Highest incidence rates were observed in Northern Europe, and lowest in Southern Europe.
Overall mortality rates were higher for men than for women. The highest mortality rates for 
men were seen in Norway. For women, mortality rates were slightly higher in the Scandinavian 
countries (except Finland), the Netherlands, Poland and Slovakia.
The highest M:I ratios for both men and women were seen for countries of Eastern Europe, 
in particular Poland with a M/I ratio of 0.53 for men and 0.43 for women. Northern and Western 
Europe had relatively low M:I ratios for both men and women. Ireland had the lowest M:I ratio 
for men (0.16), Scotland and Italy had lowest M:I ratios for women (0.09 and 0.10 respectively).
(Fig 1)
Northern Europe (Denmark, England, Estonia, Finland, Iceland, Ireland, Norway, 
Scotland, Sweden, Wales)
Melanoma incidence rates increased rapidly between 1990 and 2007 in the Northern part of 
Europe. (Table 2) In this region, Denmark had the highest incidence rates for men and women 
in 2006, with ESRs of 19.6 for women and 24.0 for men. Estonia had the lowest incidence 
rates (ESR) in Northern Europe, with 10.8 and 11.2 per 100 000 person-years, form men and 
women respectively. Except for Estonia, incidence rates are predicted to continue to increase 
in Northern Europe at least until 2015. The incidence rate for Denmark will increase up to 26.1 
per 100 000 person years for men and 29.9 per 100 000 person years for women. Estonia will 
remain the country in Northern Europe with the lowest incidence rates of 10.7 and 11.3 per 
100 000 person-years for men and women respectively. In 2015, 73 men and 114 are expected 
to be newly diagnosed with malignant melanoma in Estonia. Overall, M:I ratios in Northern 
Europe were rather low, indicating a good survival and probably favorable stage distribution 
at diagnosis.(Fig 1)
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Eastern Europe (Czech Republic, Poland, Slovakia)
Of the Eastern European countries data was provided by the cancer registries of Czech Repub-
lic, Poland and Slovakia.(Table 1) Czech Republic had the highest incidence rates and Poland 
the lowest (Table 2). For men the incidence rate in the Czech Republic was 17.8 per 100 000 
person years in 2007 and is expected to increase to 19.7 in 2010 and 22.5 per 100 000 person-
years by 2015. For women in the Czech Republic this will be 15.8 and 17.8 per 100 000, by 
2010 and 2015, respectively. This translates into 1428 men and 1268 women newly diagnosed 
with melanoma in 2015. The incidence rates for Poland will also increase but might remain the 
table 1: Participating Cancer Registries
country registry period
size of registry 
population
national 
coverage
Part of europe
Estonia Estonian cancer registry 1990-2006 1343314 100% Northern europe
Finland Finnish Cancer Registry 1990-2007 5288730 100% Northern Europe
Germany Saarland 1990-2006 1046777 1.3% Western Europe
Iceland Icelandic Cancer Registry 1990-2008 315459 100% Northern Europe
Ireland Ireland 1994-2007 4439750 100% Northern Europe
Malta Malta National Cancer 
Registry
1993-2008 409092 100% Southern Europe
Poland Polish Cancer Registry 1999-2007 38115967 100% Eastern Europe
Portugal North Region 1996-2005 3280199 31% Southern Europe
Slovakia Slovakia 1990-2005 5387285 100% Eastern Europe
Spain La Rioja 1993-2005 301084 1% Southern Europe
Spain Girona 1980-2007 658984 1.60% Southern Europe
Spain Basque country 1990-2004 2110626 5.8% Southern Europe
Spain Navarra 1990-2004 607859 1.2% Southern Europe
Spain Tarragona 1990-2004 663455 0.3% Southern Europe
Switzerland Geneve 1990-2006 443145 2.4% Western Europe
Switzerland 1990-2008 3531102 100% Western Europe
UK UK registries; 1990 - 2006 100% Northern Europe
UK England 1990 - 2006 50762945 100% Northern Europe
UK N-Ireland 1990 - 2006 4239848 100% Northern Europe
UK Wales 1990 - 2007 2979975 100% Northern Europe
The Netherlands Netherlands Cancer registry 1989-2007 16381682 100% Western Eurpe
Slovenia Slovenia 1990-2007 2019406 100% Southern Europe
Italy Modena 1990-2007 677672 1.15% Southern Europe
Italy Sondrio 1998-2007 179736 0.3% Southern Europe
Italy Umbria 1994-2006 811830 ? Southern Europe
Publically available
NORDCAN Norway 1990-2006 4709184 100% Northern Europe
  Sweden 1990-2006 9148102 100% Northern Europe
  Iceland 1990-2006 311396 100% Northern Europe
  Finland 1990-2006 5288730 100% Northern Europe
  Denmark 1990-2006 5457405 100% Northern Europe
Scotland   1985-2007 5144200 100% Northern Europe
Czech republic 1977-2007 10322689 100% Eastern Europe
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lowest with 7.2 for men and 5.9 for women by 2015. Eastern Europe showed the least favorable 
M:I ratios, probably indicating a relatively unfavorable stage distribution.(Fig 1)
Southern Europe (Italy, Malta, Portugal, Slovenia, Spain)
Incidence rates for Southern Europe were not available at a national level and provided by 
separate regional cancer registries and combined and extrapolated to national coverage. Data 
was provided by cancer registries of 5 South European countries.(Table1) The cancer registry of 
Northern Portugal reported by far the lowest incidence rates in 2003, with 3.3 per 100 000 for 
men and 5 per 100 000 for women.(Table 2) The highest rates were seen for Slovenia with ESRs of 
17.9 and 19.4 per 100 000 for men and women respectively. These incidence rates are expected 
to continue to rise to an incidence rate of 22.7 for men and 23.8 per 100 000 for women by 2015, 
translating into an expected 289 Slovenian men and 314 Slovenian women newly diagnosed 
with melanoma in 2015. M:I ratios for Southern Europe were generally modest.(Fig 1)
Western Europe (Germany, Switzerland, the Netherlands)
Incidence data for Western Europe (except for Germany) was most complete and this region had, as 
Northern Europe, the highest incidence rates, all ESRs in this region exceeded 10 per 100 000 per-
son years.(Table 2) Germany had the lowest incidence rates and Switzerland the highest. Incidence 
rates for all included Western European countries are expected to increase until 2015. Incidence 
rates for men are expected to be between 15.5 and 26.8 per 100 000 for men by 2015 and between 
12.8 and 25.3 for women. Western Europe showed the most favorable M:I ratios. (Fig1)
  
 
  <0.1 
  >0.1-0.2 
  >0.2-0.3 
  >0.3-0.4 
  >0.4 
 
womenmen
figure 1. Mortality/ Incidence ratios for men (A) and women (B)
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discussion
Projections for melanoma incidence per country were made for the years 2010 and 2015, based 
on the incidence data provided by the participating cancer registries in Europe for the years 
1990 up to 2007. Incidence projections were based on series of at least 10 years of data (as of 
1997), to make projections more stable. Projections showed that the incidence for melanoma is 
expected to continue to rise in all countries.
The incidence of malignant melanoma among women in Europe was higher than men for all 
countries except the Czech Republic, Finland, Ireland, Switzerland, Poland and Slovakia. This 
higher incidence among females is expected to continue until 2015. The highest incidence 
rates were seen for the Scandinavian countries and north-western European countries like the 
UK, Ireland and the Netherlands. The lowest incidence rates were seen for Portugal and Spain. 
However, data on melanoma incidence were provided by only a few cancer registries in the 
latter countries, resulting in small percentage coverage of the whole country. Relatively low 
incidence rates were also seen for Poland.
Stage information would be needed to get a real impression of the stage at diagnosis, indicator 
of melanoma awareness in the population, detection delay and survival of patients diagnosed 
with melanoma across Europe. Unfortunately, information on stage was not regularly recorded 
by most of the cancer registries. For the registries that did have information available on stage 
for a large proportion of patients, there was no uniformity in the way of recording stage infor-
mation of melanoma. The way of recording by stage differed from only recording Breslow thick-
ness or Clark level up to only recording the stage of melanoma at diagnosis not specified by 
TNM-classification. It was therefore impossible to compare the stage distributions between the 
European countries, neither could we project expected incidence of melanoma by 2010 and/or 
2015 by stage. Therefore, to get some impression of the overall survival of melanoma patients 
per country and a rough idea of the stage distribution, we calculated the mortality-incidence 
ratio (M:I-ratio). The higher the M:I-ratio the more melanoma patients die due to melanoma. 
Even though one of the lowest melanoma incidence rates within Europe was found for Poland, 
it had the highest M:I ratios, indicating that, a large proportion of patients diagnosed with 
melanoma in Poland will die from melanoma. This is confirmed by a recent study on survival 
trends of cancers across Europe, reporting one of the lowest survival rates for the cancer reg-
istry of Cracow (67.5 in 2000-2004), but also the slowest improvements in survival with 6.1% 
survival change in the 5-year relative survival between 1990-1994 and 2000-2004 9. One of the 
reasons for this high mortality could be that patients in Poland are likely diagnosed at a more 
advanced stage, when the treatment for these patients is limited 4. On the contrary, Norway 
which had very high incidence rates, had one of the lowest M:I-ratios, although mortality rates 
were relatively high, probably reflecting favourable stage distribution at diagnosis, possibly 
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because of high skin cancer awareness in the general population and among physicians. These 
findings are in line with earlier reports on thicker melanomas occurring in the former com-
munist European countries, and indicate that this unfavourable stage distribution has not yet 
improved substantially 4.
Several studies have shown that most of the increases in melanoma incidence are due to 
strong increases in the occurrence of thin melanomas, resulting in better survival for the group 
of melanoma patients as a whole 10-12. La Vecchia et al. and Ferlay et al. have shown that it is 
expected that melanoma-related mortality will be levelling off. The combination of increasing 
incidence with stabilising mortality indicates strong rises in the number of melanoma survi-
vors.10-12 However, in some European countries, melanoma incidence rates are rising equally 
rapidly for the thick melanomas 13, reason for worry as these are the melanomas that are 
potentially most lethal.
There are several limits to extrapolating incidence rates. The explored time period exceeds 
several decades, but these projections do not take changes in exposure to risk factors into 
account such as; the change in UV-radiation due to changes in sun behaviour or changes in 
the ozone layer. Furthermore these projections are based on former variations in incidence 
rates since 1990 and a slight stabilization in recent incidence rates will have little effect on 
the projected rates by 2010 and 2015. Also, potential effects of primary prevention are not 
considered. Since 2007, men and women aged 35 or older are entitled for skin cancer screening 
every two years in some countries (e.g. Germany). This might result in even higher incidence 
rates, but could also have a primary and secondary prevention effect, as patients repeatedly will 
be reminded of the development, and risk factors of melanoma.
We used the M:I ratio as measure of ‘severity’ of melanoma, but this measure is more 
frequently used as a quality indicator for cancer registries 14. The M:I ratio is indeed not only 
influenced by the real incidence and mortality but also but the quality of the cancer registry: 
if many incident cancers are missed and many death-certificate-only cases are included, the 
M:I ratio will be much higher then when these melanomas would have been picked up at the 
moment of diagnosis. This might have influenced M:I ratios in our study as well, particularly in 
situations when melanomas would be diagnosed in private clinics, making it more difficult for 
the cancer registry to pick them up. However, most included cancer registries were of good 
quality 6, making the alternative interpretation of M:I ratio as a measure of severity also pos-
sible. It should also be noted that an increase in incidence of advanced stages of melanoma 
can only result in an increase of mortality after a few years. This can lead to a relatively low M:I 
ratio, as mortality runs behind time. However, this is unlikely to be the case for melanoma, as 
mortality from melanoma has been mostly stable for the past ten years. 3
Although unfortunately not all European cancer registries participated in this study, results 
are comparable to that of previously reported incidence rates 10, 13, 15-21.
Especially for Italy and Germany, only a few of the cancer registries participated, either 
because, of the inclusion criteria or because they did not respond to our request to participate. 
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However, there have been some reports on incidence rates of (other regions in) these countries. 
Crocetti et al, evaluated melanoma incidence and trends in incidence in the area of the Tuscany 
Cancer Registry (active in the provinces of Florence and Prato; 1,160,000 residents in 2001) 
between 1987 and 2001. A total of 1977 malignant melanomas were diagnosed in this time 
period (incidence rate of 15.9 per 100,000 for 1997 to 2001). Incidence rates increased in all 
age-groups and time periods, with a mean annual increase of 6.4%. Predicted standardized 
incidence rate for 2002-2006 was 19.2 per 100,000.17
The Cancer Registry of Schleswig-Holstein is one of the largest cancer registries in Germany, 
with 3500 registering institutions, covering a population of 2,8 million inhabitants. Between 
1998 and 2001, 1784 malignant melanomas were diagnosed, with an incidence rate of 12.3 
per 100,000 men and 14.8 per 100,000 women,22 which is slightly higher than the observations 
from the cancer registry of Saarland
Another limitation of this study is related to demographic projections that are dependent on 
population movements; especially immigration and could effect the projections in incidence 
and mortality of melanoma.
Our findings show that incidence rates are expected to continue rising, contrary to earlier 
findings that seemed to indicate a plateauing of incidence rates among the younger popula-
tions, at least in Scandinavia 16, 19, 21.
These trends are worrying in terms of disease burden and costs, and, particularly in the East-
ern European countries, in terms of the number of people that expected to die of a melanoma. 
Mainly in countries where incidence is still modest, caution is warranted as rates are increasing 
and melanomas seem to be detected in relatively late stages causing M:I ratios to be rather 
high. A combination of primary prevention of melanoma and effective early detection and 
treatment remains of high importance.
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aBstract
Melanoma can be considered an emerging chronic disease that may considerably affect 
patients’ lives. The authors systematically reviewed the available literature on health-related 
quality of life (HRQOL) and melanoma. Of reviews and the selected studies, reference lists 
were hand-searched. The quality of the eligible studies was appraised based on 14 previously 
published criteria. Of the 158 abstracts, 44 articles were appraised, resulting in 13 selected 
studies written in English (published between 2001 and 2008). Most studies assessed patients 
from specialised centres with varying, but relatively advanced, disease stages. The most com-
monly used instruments were the SF-36 and EORTC QLQ-C30. Recently, a melanoma-specific 
HRQOL questionnaire [FACT-Melanoma (FACT-M)] was introduced for clinical trial purposes. It 
showed that approximately one-third of melanoma patients experienced considerable levels of 
distress, mostly at the time of diagnosis and following treatment. Systemic therapies affected 
HRQOL negatively in the short term, but to a lesser extent in the long term. Health status and 
patients’ psychological characteristics are associated with higher levels of HRQOL impairment. 
The authors found that the impact of melanoma on patients’ HRQOL is comparable to that of 
other cancers. Accurately assessing HRQOL impairment in melanoma patients is pivotal, as it 
may affect disease management, including therapy and additional counselling, future preven-
tive behaviour and perhaps even prognosis.
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introduction
The incidence of cutaneous melanoma has increased dramatically in the western world in the 
last few decades (4% for women and 5% for men, annually) 1. Despite this rise in incidence, the 
mortality rate seems to be levelling off due to earlier diagnosis 2-3. Approximately 70% of mela-
noma patients have a Breslow thickness of less than 1.5 mm, with a 5-year survival rate of 95%. 
When lymph nodes are involved, the survival rate drops to 20% to 40% 1. Melanoma affects 
relatively young and middle-aged people. Patients with melanoma are more at risk of develop-
ing a new primary melanoma (1.2% to 8.2%), and their-first degree relatives have a twofold 
higher risk of developing melanoma 4. Despite tremendous efforts, melanoma treatment has 
not changed substantially; in most cases it comprises surgery with or without (sentinel) lymph 
node resection. A small group of patients with metastasised disease receive chemotherapy 
and/or interferon therapy (often in clinical trial settings).
About 80% of patients will survive melanoma 1, 3 but remain at-risk for disease progression for 
many years, for which there is no successful therapy. Therefore, melanoma can be considered a 
chronic, life-threatening disease. Additionally, patients are aware that UV exposure is an impor-
tant risk factor for the development of melanoma, which may affect their lifestyles as well as 
social and professional activities 5.
Altogether, these observations suggest that melanoma may have a considerable impact on 
patients` lives, including their health-related quality of life (HRQOL), which the World Health 
Organization (WHO) defines as “an individuals’ perception of their position in life in the context 
of the culture and value system in which they live and in relation to their goals, expectations, 
standards and concerns. This broad ranging concept is in a complex way affected by the persons’ 
physical health, psychological state, level of independence, social relationships, personal beliefs 
and their relationship to salient features of their environment.” Because in approximately 75% 
of patients local surgical excision is an adequate therapy, HRQOL impairment is predominantly 
determined by psychological aspects and, to a lesser extent, by (long-term) therapy-induced 
events, as is often observed in other cancers. The psychosocial issues facing patients with an 
early stage, highly curable disease such as melanoma differ from other types of cancer with 
profound loco regional effects or distant metastases. Although more than 85% of melanoma 
patients rated follow-up surveillance to be worthwhile, they also indicated that little attention 
had been paid to the patients’ well-being during surveillance 6.
The objective of this review is to evaluate, summarize, and discuss the available literature 
concerning HRQOL in patients with cutaneous melanoma.
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methods
Systematic searches were conducted in PubMed, MEDLINE, and The Cochrane Library with the 
assistance of a medical librarian. The search algorithm of MeSH used terms was the following: 
(cutaneous OR skin) AND melanoma AND (quality of life OR life) AND (health status OR health 
status indicators OR survival analysis OR health-related OR health) NOT “non-melanoma.” Restric-
tions were not placed on publication dates or language. Several inclusion and exclusion criteria 
were used (Figure 1). The quality of the eligible studies was assessed using criteria for assessing 
the methodological quality of studies in HRQOL published previously (Table 1) 7. In brief, these 
criteria focus on the methodological aspects of HRQOL studies, e.g., whether inclusion and exclu-
sion criteria are well-formulated, whether responders and non-responders are reported, and 
whether socio-demographics of the responders are known and the score range is between 0 
and 14. The criteria are quite strict; if a certain criterion is not explicitly mentioned, the default is 0.
results
Included studies
Of the 158 abstracts extracted from PubMed, 114 were excluded primarily because they did not 
focus on HRQOL; 44 full articles were reviewed, but only 13 were eligible for this review (Figure 
1). The articles were all in English and published between 2001 and 2008.
Quality of included studies
The included studies varied in quality according to the quality criteria used (Table 1) 7. The 
scores of the eligible studies ranged between 8 and 12 out of a maximum of 14 (67% and 86%, 
respectively) (Table 3).
Study design and population
Of the 13 studies that assessed HRQOL in melanoma patients, 7 were cohort studies, 5 were 
clinical trials, and one was a cross-sectional population-based study. Three studies investigated 
the effects of therapy such as surgery, interferon, or vaccination on patients’ HRQOL. Of the 
10 prospective studies, 8 had a study duration of 4 months or less. Only two studies followed 
patients for more than 2 years after melanoma diagnosis. Six studies were conducted in the 
United States, of which 3 included patients from specialized melanoma clinics. The remaining 
European studies most often included patients from tertiary oncology departments. One ran-
domized clinical trial from the United Kingdom and one cross-sectional study from the United 
States were both population-based. The study size varied between 10 and 674 patients. Five of 
13 studies included less than 100 patients (of which 2 had less than 50 patients), and 4 studies 
had more than 250 patients. The tumour stages varied, but most studies focused on localized 
disease, and only a few focused on metastasised melanoma (Table 3).
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HRQOL measures
A total of 20 different instruments were used in the 13 studies; 7 measured HRQOL, of which 
5 were generic instruments, one was cancer-specific, and one was melanoma-specific (Tables 
2 and 3). The most frequently used generic and cancer-specific HRQOL tools were the SF-36 
(5/13) and EORTC QLQ-C30 (6/13), respectively. In 3 studies, a combination of generic and 
cancer-specific tools was used. In 2 studies, health utilities (HALex and EQ-5D) were used as a 
measure of HRQOL, and in one study a melanoma-specific (FACT-M) tool was used. Recently, 
the FACT-M questionnaire was proposed as “a reliable and valid instrument for patients with 
melanoma that can be used for the assessment of QOL in clinical trials” 8-9.
Inclusion criteria title/abstract: 
• Melanoma 
• Cutaneous or Skin 
• (HR)QOL assessment  
• Any date  
157
Abstracts 
Exclusion  criteria title/abstract: 
• Language other than English (6) 
• Primary / secondary prevention 
of melanoma 
• Treatment of melanoma  
• Etiology of melanoma (n=113) 
Medline
Articles included  for data-extraction 
13 articles 
    N=158 
Exclude duplications 
N=1 
Exclusion criteria full text:
• Topics other than (HR)QOL
  
• Reviews (2) 
The Cochrane
Library 
Pubmed 
 N=0 N=0 
44 articles  
Articles  hand -picked  
N=1 
figure 1. Flow-chart of the systematic search
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In addition to HRQOL, all included studies reported on other psychological and social con-
structs, such as social support and personality structure, but these instruments were beyond 
the scope of this review.
HRQOL impairment in melanoma
The results of the different studies suggested that there are three distinct periods of HRQOL 
impact during the melanoma experience: diagnosis, treatment, and follow-up 10-11. The imme-
diate period following diagnosis (i.e., acute survival phase) was often associated with high levels 
of HRQOL impairment 12-13. Patients reported more pain, less energy, and more interference of 
stressors (physical and emotional) on social activities. Importantly, patients also gave worse 
evaluations of overall personal health. Acute survival is followed by extended survival, which 
is dominated more by fears of recurrence and less by the physical limitations the cancer or its 
associated therapies create 10. In the follow-up phase, psychological distress can interfere with 
screening recommendations and preventive behaviours 11.
A recent study showed that prior to the definite diagnosis of melanoma, patients reported an 
excellent HRQOL. During the diagnostic process, however, insomnia increased, while emotional 
functioning and global health status deteriorated, as measured by standard anxiety scales 
(HADS, STAI-SFF) and the EORTC QLQ-C30 for patients ultimately diagnosed with melanoma 12.
In a surgical randomized clinical trial (RCT) of high-risk melanoma patients, patients with a 3-cm 
excision margin had significantly poorer mental and physical functioning (SF-36) compared to 
those with a 1-cm excision margin 14. After 3 to 6 months, the difference in HRQOL impact 
table 1: List of 14 criteria assessing the methodological quality of HRQOL studies of melanoma patients.
A. Socio-demographic and medical data are described (e.g. age, race, employment status, educational 
status, tumor stage at diagnosis etc.)
B. Inclusion and /or exclusion criteria are formulated
C. The process of data collection is described (e.g. interview or self-report etc.)
D. The type of cancer is described
E. The results are compared between two groups or more (e.g. health population, groups with different 
cancer treatment or age, comparison with time at diagnosis etc.)
F. Mean or median and range or standard deviation of time since diagnosis or treatment is given
G. Participation and response rates for patient groups have to be described and have to be > 75%
H. Information is presented about patient/disease characteristics of respondents and non-respondents or if 
there is no selective response
I. A standardized of valid QOL questionnaire is used
J. Results are described not only for QOL but also for the physical, psychological and social domains
K. Mean, median, standard deviations or percentages are reported for the most important outcome 
measures
L. An attempt is made to find a set of determinants with the highest prognostic value
M. Patient signed an informed consent form before study participation
N. The degree of selection of the patient sample is described
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between these two patient groups was no longer significant, except for a persisting poor scar 
perception in the 3-cm excision group. Predictors of poor scar perception were younger age, 
female gender, a 3-cm excision margin, and poor physical and mental health post surgery. 
Additionally, patients with a 3-cm margin had more complications, a longer hospital stay, more 
skin grafts, and a greater physical impairment.
Three clinical trials assessed the effect of chemotherapeutics and/or interferon therapy on 
patients’ HRQOL 15-17. Patients who received interferon therapy scored significantly lower on 
their HRQOL in terms of functioning and symptoms compared to the (placebo) control group. 
The EORTC QLQ-C30 instrument showed that patients had significantly worse mean scores in 
role functioning (RF), emotional functioning (EM), cognitive functioning (CF), social functioning 
(SF), and global health status compared to patients in a placebo group 16. Although systemic 
drugs (e.g., interferon) decreased patients’ HRQOL during treatment, the overall gain in HRQOL 
was favourable in some patients, especially those with a poor prognosis 17.
In one study, cognitive behavioural intervention significantly decreased distress (i.e., BSI and 
STAI scores) in patients with medium to high baseline levels of distress 18.
Predictors of HRQOL impairment
Several studies have demonstrated that overall health is the most important predictor of 
melanoma’s impact on HRQOL 9, 19-20. Patients with poor health are significantly more likely 
to report higher levels of HRQOL impairment or lower levels of health utility than healthier 
patients. Patients who report poor physical health have a comparable impact to those with 
poor psychological health, and those who experienced both reported the lowest HRQOL scores 
9, 19. Not only is global health a predictor of HRQOL, it also deteriorates after the diagnosis of 
melanoma due to an increase in insomnia and pain 9, 12, 20.
In addition to health status, several psychological factors such as non-cancer life stresses, wish-
ful thinking, and maladaptive coping styles were important determinants of melanoma’s level 
of impact on HRQOL 11. In patients with metastasised melanoma, low levels of social support 
were significantly associated with greater psychological distress and poorer mental HRQOL. 
Additionally, low social support decreased the likelihood of HRQOL adjustment one month 
after treatment 21.
No studies have investigated the HRQOL across gender, age, and all tumour stages, except in 
a surgical RCT in which older individuals were significantly more likely to report lower levels of 
physical functioning, as is expected 14. Women reported significantly higher levels of anxiety 
than men surrounding the diagnosis 12.
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discussion
About one third of patients with melanoma have reported clinically significant levels of distress, 
which is in accordance with findings in other cancers. Distress was highest around the time of 
diagnosis and immediately post–treatment, and decreased over time 12-14. Although increased 
levels of HRQOL impairment is associated with poor recovery and an increase in morbidity and 
maybe even disease progression 6, 8-13, 18-19, 22, relatively few studies have investigated HRQOL 
in melanoma patients. The reviewed studies focused mainly on populations from specialized 
(melanoma or cancer) centers that received additional therapy during short periods of time. 
The impact of melanoma on individuals from the general population who have survived this 
skin cancer for many years is not well documented.
Although the SF-36 is the most widely accepted generic HRQOL tool, its psychometric proper-
ties have not been tested in melanoma patients. A generic instrument allows for comparability 
between melanoma patients, other diseases and cancers, and the general population, as 
normative data exists for many countries. As generic instruments may not be very sensitive 
in detecting effects that are associated with specific diseases (e.g., sun avoidance behaviour 
in melanoma patients affects social functioning), the combination of a generic and specific 
HRQOL instrument is most informative 23.
FACT-M, which is a melanoma-specific HRQOL instrument that focuses on physical domains 
and was designed for clinical trial settings, has recently been validated in 273 melanoma 
patients and showed to be reliable, responsive, and have a good construct and convergent 
validity 8-9. Because the majority of patients diagnosed with melanoma will most likely experi-
ence few limitations in their physical functioning and be much more affected mentally, the 
content of the FACT-M seems especially appropriate for patients with advanced melanomas 
and less for those from the general population. Fear of recurrence and changed lifestyles, due 
to UV avoidance, are likely to be important HRQOL domains that are not fully assessed in any 
of the available HRQOL instruments, which suggests a lack of content validity. Altogether, the 
selection of an appropriate HRQOL instrument remains a trade-off between the psychometric 
properties of the instrument, the study population, and the research objectives of the study 23.
The reported effects of systemic treatment (e.g., interferon) on HRQOL may depend on the 
treated patient population. Patients who agree to participate in a clinical trial and/or receive 
therapy may be more motivated and optimistic, and thus are more likely to report benefit and 
endure more drug-induced toxicity compared to those not receiving systemic treatment. The 
latter issue is confirmed by the fact that some patients on interferon therapy, which is associ-
ated with severe flu-like symptoms, scored their HRQOL during treatment as good 17, 24.
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In cancers that are treated with relatively non-aggressive therapies, have relatively good 
survival rates, and have a high number of years-lived-with-disability, patients’ perspectives 
are very important. In addition to clinical therapy, psychological surveillance after diagnosis 
and therapy may be needed, especially among patients with poor global health status, those 
with certain personality structures (e.g., maladaptive coping styles), and those without a social 
network 11, 21. Although a pilot study suggested that a psycho-educational intervention might 
improve survival in melanoma patients, a large Danish RCT demonstrated no increased survival 
or recurrence-free interval among those who were offered 6 weekly 2-hour sessions of psycho-
education compared to the control group 25-26. In contrast, a few studies have suggested that 
HRQOL impairment, psychological factors, and personality structure may affect survival rate of 
melanoma patients 10, 21. Patients with a “type C” personality (i.e., tending to be cooperative, 
unassertive, and repress negative emotions through anger-avoidance) may also be less likely 
to survive melanoma 10, 21.
conclusion
The proportion of patients with melanoma who report high levels of HRQOL impairment is 
comparable to that observed in other cancers. Optimal measurement of HRQOL in patients 
with melanoma is challenging because of the fairly unique characteristics of the tumour and 
its often straightforward treatment. More specific HRQOL measures could assist physicians in 
identifying patients who are in need of psychological counselling, which may affect treatment, 
follow-up, and patients’ well-being.
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aBstract
objective  To assess the impact of melanoma on the health-related quality of life of patients 
from the general population up to 10 years after diagnosis and its determinants.
design   A cross-sectional Dutch population-based postal survey among patients with mela-
noma for the years 1998 to 2008 using the Eindhoven Cancer Registry.
main outcome measures   The 36-Item Short-Form Health Survey (SF-36), Impact of Cancer 
(IOC) questionnaire and specific melanoma-related questions. The SF-36 scores of the cases 
were compared with normative data. Multiple linear regression models were used to identify 
associated factors of SF-36 and IOC scores.
results  The response rate was 80%. The mean age of the 562 respondents was 57.3 years; 62% 
were female, and 76% had a melanoma with a Breslow thickness of less than 2 mm. The SF-36 
component scores of patients with melanoma were similar to those of the normative popula-
tion. In a multiple linear regression model, stage at diagnosis, female sex, age, and comorbidity 
were significantly associated (P < .05) with the physical and mental component scores. Women 
were significantly more likely to report higher levels of both positive and negative IOC. Time 
since diagnosis, tumor stage, and comorbidity were significant predictors of negative IOC 
scores. Women seemed to adjust their sun behavior more often (54% vs 67%; P < .001) than men 
and were more worried about the deleterious effects of UV radiation (45% vs 66%; P < .001).
conclusion   The impact of melanoma seems to be specific and more substantial in women, 
suggesting that they may need additional care to cope with their melanoma optimally.
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introduction
Although the prognosis is relatively good for about 80% of patients with melanoma, they 
remain at risk for disease progression and have an increased risk of developing subsequent 
melanomas.1-6 A systematic review on the impact of melanoma on patients’ lives that included 
a variety of psychometric measures suggested that a third of patients with melanoma have 
reported clinically significant levels of distress.7 Therefore, melanoma can be considered 
a chronic life-threatening disease that may affect patients’ lives considerably. Because most 
patients are aware that past sun exposure might have played a role in the development of their 
melanoma,8 they are likely to change their lifestyle to minimize UV exposure, which conse-
quently may affect patients’ health-related quality of life (HRQoL) as well.
The HRQoL impact of melanoma is not very well documented.7 Of the 13 eligible studies 
included in a systematic review, most included a relatively small number of patients who were 
almost always treated in specialized centers and assessed impact within 2 years after diagnosis. 
They used a variety of questionnaires assessing patient reported outcomes. Furthermore, 
a comparison of HRQoL impairment was not made between men and women and between 
patients with melanoma and the general population and/or other cancer groups.7 Although 
the Functional Assessment of Cancer Therapy–Melanoma (FACT-Melanoma) and the Skin Can-
cer Index have been introduced, neither of them is well suited to measure melanoma-specific 
HRQoL among the general population of melanoma survivors.7, 9-11 The FACT-Melanoma was 
developed for clinical trial purposes that include high-risk patients who have lower survival 
rates than most patients with melanoma in the general population and who receive additional 
surgical and/or systemic therapy. The Skin Cancer Index was designed for keratinocytic cancers 
and not for melanoma.
The objective of this cross-sectional survey was to investigate the impact of melanoma on 
patients’ HRQoL up to 10 years after diagnosis and the association between HRQoL impairment 
and patient and tumor characteristics. We hypothesized that melanoma survivors would report 
an impaired HRQoL compared with that of the normative Dutch population and that this impact 
would diminish over time and differ across sex. A generic and cancer-specific instrument and 
additional melanoma-specific items were used to evaluate HRQoL and associated factors in a 
large cohort of (long-term) melanoma survivors from the general Dutch population.
methods
Settings and participants
A cross-sectional survey was conducted with the assistance of the Eindhoven Cancer Registry 
(ECR), Eindhoven, the Netherlands. The ECR records data of patients newly diagnosed as having 
cancer in the southeast part of the Netherlands,12 which has a population of about 2.3 million 
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inhabitants and is served by 18 hospital locations and 2 large radiotherapy institutions. Of the 
18 hospitals, 3 large regional hospitals were asked to participate. From the ECR database, all 
patients diagnosed as having melanoma (International Classification of Diseases, Oncology, 
codes C44.0-C44.9 with morphology codes 8720-8790) from January 1, 1998, to August 1, 
2007, in 1 of the 3 hospitals were identified. The time since diagnosis ranged from 6 months 
to a maximum of 10 years, owing to the fact that there is a 6-month delay before tumors are 
completely registered in the ECR.
Patients older than 85 years at the time of the survey were excluded because it was expected 
that they would have difficulty completing a self-administered questionnaire. Deceased 
patients were excluded by linking the database to the Central Bureau for Genealogy, which col-
lects data on all deceased Dutch citizens or permanent residents via civil municipal registries.
The treating physicians of the 3 hospitals informed their eligible patients by sending a 
standardized invitation letter and the questionnaire. Patients were reassured that nonparticipa-
tion would not have consequences for their follow-up or treatment. By returning a completed 
questionnaire, patients consented to linkage of the HRQoL data with those of their disease 
and treatment history as registered in the ECR. Questionnaires were coded for anonymous 
data collection tracking and linkage with the ECR database. Data were collected from February 
through May 2008. The medical ethics committee of Catharina Hospital in Eindhoven gave their 
approval to this study.
Study outcomes
The ECR provided data on melanoma and demographic characteristics of the patients. The 
questionnaire included a generic and cancer-specific HRQoL instrument (36-Item Short-Form 
Health Survey [SF-36] and Impact of Cancer [IOC], respectively) and additional questions 
regarding demographic variables, disease progression, and current comorbidity (adapted from 
the Charlson comorbidity index).13-15 For the SF-36, standard scoring procedures of the 8 scales) 
(ie, Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, 
Role Emotional subscale, Mental Health) were followed where higher scores indicate better 
functioning (range, 0-100).13 Two higher-order component scores for physical (PCS) and mental 
health (MCS) were also calculated. The IOC was developed by Zebrack et al15 in 2006 to measure 
the well-being of long-term cancer survivors and their adjustment to changes. It consists of 
41 questions (5-point response scale), 6 domains (ie, physical, psychological, social, existential, 
meaning of cancer, health worry) with 10 dimensional subscales.14-15 These 10 subscales are 
Physical: Health Awareness (4 items); Physical: Body Changes (5 items); Psychological: Positive 
Self-Evaluation (8 items); Psychological: Negative Self-Evaluation (4 items); Existential: Positive 
Outlook (3 items); Existential: Negative Outlook (4 items); Social: Life Interferences (3 items); 
Social: Value of Relationships (2 items); Meaning of Cancer (5 items); and Health Worry (3 items). 
These subscales were combined to form a higher-order positive or higher-order negative 
scale (range, 0-5) with higher scores indicating a more positive or negative impact of cancer, 
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respectively (Table 1). In addition to these pre-existing validated instruments, several mela-
noma-specific items that assess issues related to treatment, impact on daily life, and follow-up 
were included (based on expert opinion) because these issues were not covered by the SF-36 
or IOC questionnaires (see the subsections titled “Melanoma-Specific Items” and Practical 
Issues Related to Melanoma” in the “Results” section). Responses were categorized as “less,” “the 
same,” “a little bit more,” “more,” or “a lot more.” In the analyses, “more” and “a lot more” were 
combined. To evaluate the physical symptoms experienced due to melanoma or its treatment, 
questions regarding pain, itch, swelling, and numbness with a 3-point scale were included.9 
Several items pertained to the extent to which the diagnosis of melanoma affected patients’ 
sun (exposure) behavior (ie, activity in the sun, worry about the effects of the sun on the skin, 
and sun-protective measures) were included. Furthermore, patients were asked whether appli-
cations for health, life, and disability insurance or home mortgage had been hampered because 
of their melanoma.
table 1: Domains and subscales of the IOC and their coverage.a
domains and subscales contributes to positive 
(+) or negative (–) higher 
order scale of ioc
number 
of items
(n=40)
coverage
Physical
 Health awareness + 4 Concern and care about own health and 
awareness of physical problems
 Body changes - 5 Upset about negative changes and looks 
of the body and decreasing energy
Psychological
 Positive self- evaluation + 8 Personal growth due to the cancer 
experience
 Negative self-evaluation - 4 Anger and guilt concerning the cancer 
experience and feeling of aging
spiritual/existential
 Positive outlook + 3 Increased wisdom and spirituality due to 
cancer experience
 Negative outlook - 4 Worry about future, death and limited 
time left
social
 Value of relationships + 2 Higher value of relationships with family 
and friends including to other survivors.
 Life interference - 3 Loss of activities or negative interference 
with life
meaning of cancer + 5 Wonder why got cancer, reactions to it 
and place in life
health worry - 3 Worries about reduced health and 
sensitivity towards physical symptoms as 
sign of relapse
a See Janssen-Heijnen et al.12
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Statistical analyses
To test for statistical differences, the t test and χ2 test for continuous and categorical variables, 
respectively, were used. The scores of the SF-36 scales were compared with an age- and sex-
matched random normative sample of 1742 Dutch adults from the general population by 
means of analysis of variance.13 The age- and sex-matched sample was drawn from a nation-
wide sample of the Dutch adults to whom the SF-36 was mailed (2800 households drawn at 
random from the national telephone registry). Nonresponders were sent reminder letters after 
2 months and 3 months following initial mailing. In total, 1771 were returned, representing a 
63% response rate, of whom 56% was male.13 We used Norman’s “rule of thumb,”16 which says 
that the threshold of discrimination for changes in HRQoL for chronic diseases seems to be 
approximately half a standard deviation.
Multivariate linear regression analyses were performed to estimate the association between 
SF-36 and IOC scores and independent variables (expressed as standardized β-coefficients and 
95% confidence intervals). Variables were included in the multivariate model if they were signifi-
cantly associated with the outcome in the univariate analysis and/or were considered a priori to 
be of clinical relevance. In these models, age and time since diagnosis were entered as continuous 
variables, tumor stage ranged from I to IV, and presence of comorbidity was binary (yes/no). Four 
levels of education were used, and marital status was categorized as having a partner vs no partner.
A 2-sided P <.05 was considered statistically significant. All statistical analyses were performed 
using SAS statistical software (version 9.1 for Windows; SAS Institute Inc, Cary, North Carolina).Fig 1. Schematic ow diagram of ascertainment of study po pulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excluded: 
-  too ill or incompetent.( n=5) 
-  under the surveillance of a dierent specialist or 
GP(n=12). 
- addresses could not be veri­ed (n=86) 
 
562 patients returned a completed questionnaire  
(80%). 
 
Non respondents: : 
-actively refused, n=17 
-unaware of melanoma, n=1  
-deceased after august 2007, n=4 
-no response, n=115  
 
Total , n=137 (20%) 
 
699 patients were contacted. 
 
Still alive on August 1 st 2007. 
n= 802 (81%).  
Diagnosed with malignant melanoma, between 
January 1998 and August 2007 in one of the 3 
participating hospitals. 
n= 960  
158 patients were diseased on 
1/8/2007 
 
figure 1. Schematic flow diagram of ascertainment of the study population
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results
Study population
Of the 992 patients diagnosed as having cutaneous melanoma in 1 of 3 hospitals between 
January 1998 and August 2007, 802 patients were alive on August 1, 2007 (Figure 1). Of these 
patients, 103 could not be contacted (Figure 1). The remaining 699 survivors received a ques-
tionnaire, and 562 responded (80.4% response rate). The distribution of the demographic and 
melanoma characteristics of the respondents, nonrespondents, and patients with unverifiable 
addresses were similar with respect to sex, Breslow thickness, stage at diagnosis, and initial 
treatment (Table 2). Nonrespondents and patients with unverifiable addresses were generally 
younger (P < .05). On average, nonresponders also had longer survival times.
About 70% of patients had been diagnosed as having stage I melanoma, and 49% had a 
lesion with a Breslow thickness of less than 1 mm (Table 2). Almost all patients underwent 
table 2: Sociodemographic and clinical characteristics of questionnaire respondents , non-respondents 
and patients with unverifiable addresses.
no. (%)
sociodemografic or clinical 
characteristic
respondents non-
respondents
Patients with 
unverifiable 
addresses
P-value
n=562 n=131 n=86
age at time of survey, mean (sd), y 57.2 (SD 14.0) 56.4 (SD 15.6) 51.2 (SD 15.0) 0.001
years since diagnosis, mean (sd) 4.6 (SD 2.6) 5.1 (SD 2.9) 5.3 (SD 2.8) 0.01
gender
Male 212 (38) 54 (41) 33 (38)
Female 350 (62) 77 (59) 53 (62) 0.76
Breslow thickness*
≤ 1.0 mm 275 (49) 61 (47) 39 (45)
1.01-2.0 mm 149 (27) 33 (25) 22 (26)
2.01-4.0 mm 100 (18) 30 (23) 22 (26)
>4.0 mm 32 (6) 5 (4) 3 (3) 0.64
stage at diagnosis
I 400 (71) 87 (66) 56 (65)
II 108 (19) 32 (24) 22 (26)
III 42 (8) 8 (6) 6 (7) 0.71
IV - - -
treatment
Surgery 556 (99) 128 (98) 85 (99)
Sentinal Node 113 (20) 22 (17) 21 (24)
Lymphadenectomy 27 (5) 7 (5) 4 (5)
Systemic therapy 3 (0.5) 1 (0.8) -
Radiotherapy 3 (0.5) - -
Other 29 (5) 7 (5) 4 (5) 0.81
Note: percentages are rounded off to the nearest whole number
* According to the American Joint Committee on Cancer (AJCC) classification.
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local surgical excision, and 20% underwent a sentinel node procedure (SNP). Chemotherapy 
or radiotherapy was administered in less than 1% of patients. No statistically significant dif-
ferences were found for Breslow thickness (P =  .64) and stage distribution (P =  .71) between 
responders, nonresponders, and patients with unverifiable addresses.
The mean ages at diagnosis and at time of survey of the respondents were 52.6 years and 
57.2 years, respectively. Sixty-two percent of respondents were female. Most respondents had 
at least a high school education, were married, had children, and were employed at time of 
survey (Table 3). Of all respondents, 35% reported at least 1 other medical condition: hyperten-
sion, joint complaints, and/or a history of a malignant disease.
36-item short-form health survey
Compared with an age- and sex-matched sample from the general Dutch population, melanoma 
survivors did not report impaired HRQoL as measured by the SF-36 (Figure 2). Interestingly, 
patients with melanoma scored statistically significantly higher on PCS and several subscales 
(Physical Functioning, Role Limitations: Emotional Problems, Mental Health, Bodily Pain, and 
General Health; data not shown) than the general population, but the mean score differences 
were less than half a standard deviation suggesting no clinical significant differences, according 
to Norman’s rule of thumb (Figure 2).16
table 3.: Sociodemographic and clinical characteristics of 562 survivors (respondents).
characteristic no. (%) characteristic no. (%)
age at diagnosis (mean 52.2) marital status
≤30 25 (5) Married 416(74)
30-39 96 (17) Unmarried or never married 55 (10)
40-49 117 (21) Divorced 36 (6)
50-59 145 (26) Widowed 53 (10)
60-69 112 (20) Partner 464 (85)
70-74 36 (6) No partner 84 (15)
>80 28 (4) education level
comorbidity Low(Primary school) 161(29)
Yes 186 (35) High School 242(43)
No 351 (65) Medium (Job training etc.) 103(18)
most frequent co-morbid conditions Higher education ( University etc.) 52(9)
Hypertension 126 (23) Unknown 4(1)
Arthrosis / Arthritis 111 (21) Employment
Malignancy 106 (20) employed 299 (53)
Unemployed 245 (44)
Unemployed (disability) 15 (3)
children
Yes 462 (83)
No 97 (17)
Children at home 183 (39)
Note: percentages are rounded off to the nearest whole number.
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After adjusting for age at time of the survey, years since diagnosis, disease stage, SNP, comor-
bidity, marital status, and educational level in a multivariate analysis, female sex, older age, 
tumor stage, and comorbidity were significantly negatively associated with PCS, whereas an 
SNP was positively associated (Table 4). Female sex and comorbidity were also negatively 
associated with MCS, whereas having a partner was positively associated with MCS. Women 
scored significantly lower (indicating higher HRQoL impairment) than men: 1.8 points (P < .05) 
on the PCS and 2.3 points (P <  .05) on the MCS; however, this was not clinically relevant. In 
addition, female melanoma survivors reported higher impairment on 5 of 8 subscales (Physical 
Functioning, Bodily Pain, General Health, Vitality, and Mental Health; data not shown).
Impact of Cancer
To estimate the impact of melanoma on patients’ psychological well-being in more detail, the 
IOC was included14 (Table 1). The mean scores of patients with melanoma for each subscale of 
the IOC differed from 2.2 to 3.1. The lowest scores were seen on the subscale Social: Life Interfer-
ences, which focuses on cancer- or treatment-related symptoms of the cancer that interferes 
with a patients’ socializing, traveling, or time with family. The highest score of 3.1 was seen on 
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figure 2. The 36-Item Short-Form Health Survey (SF-36) scores of patients with melanoma compared 
with normative population. BP indicates Bodily Pain; GH, General Health; MCS, Mental Component Scale; 
MH, Mental Health; PCS, Physical Component Scale; PF, Physical Functioning; RE, Role Emotional; RP, Role 
Physical; SF, Social Functioning; and VT, Vitality.
Cynthia BW 7.indd   75 28-09-11   13:35
Impact of melanoma on patients’ lives among 562 survivors
Ch
ap
te
r 5
76
the Existential: Positive Outlook subscale, which covers increased wisdom and spirituality due 
to the cancer experience.
In multivariate analyses, female sex was statistically significantly associated with higher-order 
positive and negative scales, suggesting that women experience both a more negative and more 
positive impact of melanoma on their psychological well-being than men (Table 4): compared 
with men, women scored 0.21 points (P <  .05) higher on the higher-order positive scale and 
0.24 points (P <  .001) on the higher-order negative scale. Analyses showed that the trends of 
responses were similar, but that women responded more extremely compared with men (data 
not shown). On the higher-order negative scale, time since diagnosis was significantly associated 
with a negative β-coefficient, which implies that for every year further from diagnosis the patient 
may be less negatively influenced by their cancer. In contrast, more comorbidities and advanced 
melanoma stage (III vs I) were associated with a higher-order negative IOC score (Table 4).
table 4: β-coefficients of multiple linear regression analysis: investigating factors associated with SF-36 
component scales and IOC Higher order scales.
characteristic
sf36 components ioc higher order scales
Pcs mcs Positive scale negative scale
sex
Female vs. male -1.77* -2.34* 0.21* 0.24****
age at time of survey -0.14**** NS NS NS
time since diagnosis NS NS NS -0.03**
stage at diagnosis
II vs. I -2.76* NS NS NS
III vs. I NS NS NS 0.24*
IV vs. I - - - -
snP 2.34* NS NS NS
comorbidity -5.07**** -2.27* NS 0.16**
marital status
Partner vs. single NS 4.06** NS NS
education
High School vs. PS NS NS NS NS
Medium Edu. vs. PS NS NS NS NS
Higher Edu. vs. PS NS NS NS NS
Abbreviations: HRQoL, health-related quality of life; IOC, Impact of Cancer (see table 1); MCS, Mental 
Component Scale; NS, not significant (P>0.05); PCS, Physical Component Scale; PS, Primary School; SF36, 
36- Item Short-Form Health Survey; SNP, sentinel node procedure.
For the SF-36 analysis, positive β-coefficients suggest that characteristics were significantly associated with 
higher SF-36 scores, suggesting an improved HRQoL.
For the IOC, positive β-coefficients on the positive higher order scale suggest that characteristics were 
significantly associated with a higher score meaning a higher positive impact of cancer on a patients’ 
perspective.
* < 0.05
** < 0.01
*** < 0.001
**** < 0.0001
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figure 3. Men’s and women’s attitudes and behaviors since the diagnosis of melanoma. Responses to 
melanoma-specific items in men (A) and women (B). Melanoma-specific items questioned melanoma 
survivors about the extent to which they had changed their sun (exposure) behavior since the diagnosis of 
melanoma.
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Melanoma-specific items
Compared with men, a significant larger proportion of women reported going on vacation to 
sunny destinations less frequently (67% vs 56%, respectively; P = .03). Women were also more 
worried about the effects of sunlight on their skin (66% vs 45%; P <  .001) and that of their 
spouses and children (49% vs 32%; P < .05).
Furthermore, female patients reported seeking shade and/or using sunscreen more often 
than men (67% vs 48%; P < .001) (Figure 3). Most men and women reported using sunscreen 
only in the summer or when the sun shines (83% vs 90%, respectively), with a sun protection 
factor of 20 to 30 or more (69% vs 72%, respectively). Women were more likely to use sunscreen 
more times a day than men (25% vs. 64%; P < .001).
Compared with men, women experienced more pain (26% vs 11%; P < .001), itchiness (26% 
vs. 21%; P = .26), and numbness (29% vs 21%; P = .10) of their scars. Swelling of the scar or one 
of the extremities was reported in approximately 10% of men and women.
Practical issues related to melanoma
Most survivors (94%) stated that their professional situation had not changed after being 
diagnosed as having melanoma. Five percent of survivors indicated that they had changed 
jobs, reduced the number of hours worked, had been retrained, or stopped working entirely 
(including work disability) as a result of their melanoma. Of the 258 patients who attempted to 
obtain health insurance in the survey period, 5% reported having experienced cancer-related 
problems in obtaining health insurance. Thirty-five percent (n = 84) reported difficulties obtain-
ing life insurance, 15% (n = 98) reported problems with obtaining a mortgage, and 18% (n = 38) 
experienced trouble obtaining disability insurance when attempting to obtain one of these.
comment
To our knowledge, this is the first study to investigate SF-36 and IOC scores in a population-
based sample of melanoma survivors, showing relatively little impairment of the generic health 
status and HRQoL. In contrast to our hypothesis, the SF-36 scores were not significantly different 
compared with the normative SF-36 scores of the general Dutch population. This observation 
suggests that generic and even cancer-specific HRQoL questionnaires might not be sensitive 
enough for patients with predominantly low stages of melanoma. More specific, but individual, 
items showed that several UV-related aspects of patients’ lives were affected and that having 
been diagnosed as having malignant melanoma had practical implications for their daily life 
(eg, getting a mortgage, health insurance, or life insurance).
Of the studied determinants, female sex was most strongly associated with HRQoL. Also, in 
the multivariate analyses of SF-36 and IOC scores, older age, comorbidity, and higher tumor 
stage were significant predictors for lower HRQoL.
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We compared the SF-36 scores of patients with melanoma with normative data for the SF-36 
obtained from of a nation-wide random sample of Dutch adults (see the “Methods” section), 
which have been used by several previous studies to compare the SF-36 scores of patients with 
those of the general population.17-18 Though not clinically relevant (statistical differences, <0.5 
SD),16 the scores of several SF-36 domains and components were significantly higher among 
patients with melanoma than those from the general population.19-20 The finding that patients 
show far more variability in the response distribution of the individual melanoma-specific 
items (eg, sun behavior and worry) than in the generic SF-36 may confirm the need to combine 
generic with disease-specific questionnaires.19 Although it seems counterintuitive at first and in 
contrast with our hypothesis, this observation is in accordance with studies investigating other 
cancers showing that patients who had “survived” a cancer rate their generic HRQoL as similar 
or even better than those from the general population.12 Individuals can use various cognitive 
strategies such as belief, posttraumatic growth, or benefit finding to counteract the negative 
effect of illness (eg, melanoma) on their well-being.11 Finding benefit and growth could be 
viewed as part of the so-called response shift. When diagnosed as having a life-threatening 
disease, patients may change their internal standard of what constitutes health and HRQoL 
(recalibration), adjust their priorities (reprioritization), and/or redefine what is important to 
them (reconceptualization) in face of their condition.11, 21
Of the variables studied in multivariate models, female sex was most strongly associated 
with lower SF-36 scores, higher-order negative and positive IOC scores, and more extreme 
responses to melanoma-specific items, which is confirmed by previous studies in melanoma 
and other cancers that show a sex difference in the assessment of HRQoL.7,  11,  22 In clinical 
practice, this observation may imply that women need additional care, including follow-up 
and possibly counseling to optimally cope with their melanoma.8 However, men might be less 
aware of general measures of sun protection and need education about these measures after 
treatment. Besides, other studies that used specific tools to measure anxiety and/or depres-
sion suggest that around a third of patients with melanoma suffer substantially.7 This could be 
reduced by psychological counseling, which might even lead to better survival.23 In addition 
to sex, comorbidity was strongly associated with HRQoL impairment due to melanoma. This 
association has been observed previously in patients with melanoma,7 nonmelanoma skin 
cancers,22 and solid cancers, suggesting that it remains difficult to differentiate the impact of 
different diseases. It seems that the impact of skin cancer is lowered by the presence of multiple 
or severe comorbidities. This observation emphasizes the need to test HRQoL instruments for 
item bias across the presence of comorbidity because an optimal HRQoL tool should not be 
influenced by external factors.19 The finding that older age at time of survey predicted lower 
scores on the physical scales is most likely explained by the presence of other disabilities and/
or an aging effect of the cohort. In the long term, the effect of SNPs was reported as positive on 
the PCS, which is in agreement with other studies suggesting that additional therapy eventually 
increased HRQoL in patients with melanoma.24 The relatively small group of respondents who 
Cynthia BW 7.indd   79 28-09-11   13:35
Impact of melanoma on patients’ lives among 562 survivors
Ch
ap
te
r 5
80
had an SNP reported a higher PCS score than those who did not, which is surprising, as surgical 
complications (eg, lymphoedema and extensive scarring) are likely to impair a patient’s well-
being. This may suggest that patients who choose to undergo additional or even controversial 
investigations and/or therapies may differ from those who received local surgical excision only. 
Although it was initially hypothesized, time since diagnosis did not affect SF-36 scores among 
melanoma survivors, and the effect of additional years after diagnosis was modest for the nega-
tive IOC scale. In other diseases, such as diabetes mellitus, rheumatoid arthritis, non-Hodgkin‘s 
lymphoma, and breast cancer, the effect of time since diagnosis on finding benefit or growth 
is inconsistent.11, 17 The low adjusted R2 scores of the multivariate models that assessed predic-
tors of SF-36 and IOC scores suggest that this analysis suffers from residual confounding (ie, 
multiple HRQoL predictors, such as anxiety, personality type, and coping mechanisms were not 
included in the analysis).7, 13-14,25
Although the effect of melanoma on SF-36 and IOC scores seems to be limited, this cancer 
may have a profound impact on practical issues of patients’ lives and thus affects HRQoL in 
different domains. A small proportion of individuals experienced difficulties in getting health 
insurance as a result of their melanoma, but up to a third of the patients experienced difficulty 
getting life insurance, disability insurance, and/or a mortgage. This type of information is not 
often assessed in patient populations but seems to be highly relevant in patients who have 
survived cancer.
This is the largest cross-sectional, population-based study using cancer registry data to 
investigate the impact of melanoma on patients’ HRQoL and other aspects of their lives. Trask 
and Griffith22 investigated HRQoL among a large group of patients with melanoma ascertained 
from a multidisciplinary melanoma clinic. However, compared with our study, the design of 
their study22 was very different (eg, selected HRQoL measures, domain-specific tools, including 
anxiety and depression scales and categorization of patients), making a comparison between 
the study findings challenging.
A response rate of 80% is very high and in accordance with those of previous studies per-
formed in the southeast part of the Netherlands.17-18 This high response rate and the fact that 
respondents and nonrespondents were comparable suggest that selection bias had a minimal 
effect on the results of this study. Because no specialized melanoma centers were included, the 
generalizability of our findings is likely to be good. The ECR is a well established cancer registry12 
but does not record recurrence or metastasis from/after melanoma. Consequently, the effect of 
these events could not be studied separately. No information was available regarding the social 
economic status (SES) of patients. Higher levels of SES are associated with increased melanoma 
risk and higher HRQoL.26-28 As a proxy for SES, educational level was used; three-quarters of the 
patients had at most a high school degree (Table 2), suggesting a possible overestimation of 
melanoma on HRQoL.
The SF-36 was used because it is the most commonly used HRQoL instrument and has the 
advantage of available Dutch norm data, but it is has not been formerly tested in patients with 
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melanoma.19 To expand the focus of this study, the IOC, which is a relatively new instrument 
(and has not been validated in patients with melanoma) and several single items were added. 
At the time of the survey, the FACT-M, which was intended for the use in clinical trials with a 
focus on physical limitations, had not yet been validated.9-10 An indirect comparison of IOC 
scores suggests that patients’ physical and psychological well-being is likely to be less affected 
by melanoma when compared with breast, prostate, colorectal, or prostate cancer. Patients 
with melanoma scored lower on all of the positive IOC subscales and higher on only 2 of the 
negative subscales (body changes and negative self- evaluation)15 (Table 1).
In conclusion, in a population-based sample of patients who have had malignant melanoma, 
the impact of melanoma seems to be fairly specific and is not driven by (long-term) treatment 
effects that affect generic or cancer-specific HRQoL. Therefore, there is need for a melanoma-
specific HRQoL instrument that gauges the impact of thin and thick melanomas on patients’ 
lives. Female sex and comorbidity were the main predictors of HRQoL impairment in patients 
with melanoma, but other (psychological) factors are likely to play a role as well and need to be 
studied in more detail in future studies.
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aBstract
objective We aimed to investigate the prevalence of Type D personality (the conjoint effects of 
negative affectivity and social inhibition) among melanoma survivors and to obtain insight into 
its effects on health status, impact of cancer and health care utilisation.
methods We selected all patients diagnosed with melanoma between 1998 and 2007 from 
three large regional hospitals in the Netherlands. In total, 699 survivors, alive in January 2008, 
received a questionnaire including Type D personality scale (DS14), impact of cancer question-
naire (IOC) and SF-36 and 80% responded (n =562).
results Twenty-two percent of survivors (n = 125) were classified as Type D. They reported a 
clinically and statistically significant worse general health (57.8 versus 75.6), social functioning 
(73.1 versus 88.7), mental health (61.7 versus 80.6), more emotional role limitations (67.8 versus 
89.4) and less vitality (54.5 versus 72.8) than non-Type D patients. Additionally, they reported 
a statistically and clinically relevant higher impact of cancer on body changes, negative self-
evaluation, negative outlook on life, life interferences and health worry. Furthermore, they were 
more worried about the influence of the sun on their skin and acted accordingly. No differences 
were found in health care utilisation.
conclusions Type D personality has a distinct negative impact on health status in melanoma 
survivors and is an important factor to screen for in clinical practice. Giving special attention to 
these patients is important while they are more likely to experience a strong impact of cancer 
which cannot be explained by socio-demographical or clinical characteristics.
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introduction
The relationship between personality and cancer has been an important topic of many stud-
ies. Major research themes were the association between personality and cancer incidence1-7 
and disease outcomes or mortality.8-10 However, in these studies personality was defined in 
a number of different ways and the results were inconclusive. A personality type that has a 
major impact on cancer incidence, course, disease outcomes and health status has not yet been 
found.
A distressed personality (Type D) is defined by the combination of two personality traits; the 
tendency to experience negative emotions (negative affectivity) and to inhibit self-expression in 
social interaction (social inhibition).11 Hence, individuals with a Type D personality are inclined 
to experience emotional and interpersonal difficulties across time and situations. In the cardio-
vascular field, the Type D is an important research topic. Type D is recognised as an important 
determinant for adverse health outcomes, impaired health status and health-related quality of 
life (HRQoL), several forms of distress (including anxiety, depression and posttraumatic stress) 
and a decrease in health care utilisation in patients with cardiovascular diseases.12-18 More 
recently, similar results have been found in patients with a range of other diseases as well.19-21 
In addition, Type D personality was a prognostic factor for the development of cancer in men 
with established coronary heart disease, who were free of cancer at baseline.22
Although Type D has proven to have much explanatory power to select cardiovascular 
patients at risk for a low health status, this has not yet been studied in cancer patients. The 
aim of this study was to determine if melanoma survivors with a Type D personality report 
a comparable health status, impact of cancer and health care utilisation compared to those 
without a Type D personality. We hypothesised that Type D patients will report a lower health 
status, a more negative impact of cancer and a lower health care utilisation compared to those 
without a Type D personality.
methods
Setting and participants
The study was conducted at the Eindhoven Cancer Registry (ECR), which records data on all 
patients newly diagnosed with cancer in the southern region of the Netherlands.23 The ECR 
was used to select all patients diagnosed with melanoma between 1 January 1998 and 1 
August 2007 from three large regional hospitals. Melanoma was defined using the ICD-0 codes: 
C44.0–C44.9 with morphology 8720–8790. Participants older than 85 years of age at the time 
of survey were excluded, as it was expected that they would have difficulty in completing a 
self-administered questionnaire without assistance. To avoid including deceased patients, our 
database was linked with the database of the Central Bureau for Genealogy, which collects data 
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on all deceased Dutch citizens via the civil municipal registries. Data collection was performed 
between February and April 2008. Approval for this study was obtained from a local certified 
Medical Ethics Committee.
Data collection
Medical specialists sent their (former) patients a letter to inform them about the study and a 
copy of the questionnaire. The letter explained that by returning the completed questionnaire, 
the patient agreed to participate and consented with linkage of the outcome of the question-
naire with their disease history as registered in the ECR. The patients were reassured that non-
participation would not have any consequence for their follow-up care or treatment.
Measures
Patient and tumour characteristics
The ECR routinely collects data on tumour characteristics, including date of diagnosis, histol-
ogy, clinical stage (tumour-node-metastasis clinical classification24), treatment and patient 
background characteristics including date of birth and comorbidity at the time of diagnosis (a 
slightly adapted version of the Charlson comorbidity index25).
In addition, our patient questionnaire also included questions on sociodemographic data, 
including marital status, current occupation, educational level, current comorbidity and disease 
progression (e.g. recurrence, metastasis and new primary tumour).
Type D personality
Type D personality was measured with the 14-item Type D personality scale (DS14).11 The DS14 
is self-administered and takes only a few minutes to complete. The 14 items of this scale are 
answered on a five-point response scale ranging from 0 (false) to 4 (true). Seven of these items 
refer to ‘Negative Affectivity’ or the tendency to experience negative emotions in general (e.g. 
I am often down in the dumps). The remaining seven items refer to the patient’s level of ‘Social 
Inhibition’ or the tendency to inhibit the expression of emotion in social relationships (e.g. I 
am a closed kind of person). The patients were categorised as Type D using a standardised cut-
off score ≥10 on both the negative affectivity and social inhibition subscales, following the 
protocol as previously established.11 The DS14 is a valid and reliable scale with Cronbach’s 
α of 0.88/0.86 and a test–retest reliability over a 3-month period of r = 0.72/0.82 for the two 
subscales, respectively.11
Health status
The Dutch version of the SF-36 questionnaire was used to assess the health status.26 It incorpo-
rates two composite scales – the Physical Component Scale and the Mental Component Scale27 
– derived from eight domains: physical functioning, role limitations due to physical health 
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problems, bodily pain, general health perceptions, vitality, social functioning, role limitations 
due to emotional problems and general mental health.28 According to standard scoring pro-
cedures, the subscales were linearly converted to a 0-100 scale, with higher scores indicating 
better functioning.
Impact of cancer
The impact of cancer was measured with the impact of cancer questionnaire (IOC). The IOC is 
a relatively new instrument developed to measure subtle yet important aspects of the cancer 
survivorship experience that long-term survivors themselves indicate are important.29 The 
instrument consists of 41 items covering 10 subscales; health awareness, body changes, posi-
tive and negative self-evaluation, positive and negative life outlook, life interferences, value of 
relationships, meaning of cancer and health worry. Furthermore, these subscales can be used 
to create two overarching second-order factors inclusive of positive and negative items; the 
‘higher order positive scale’ and ‘higher order negative scale’.30 Internal consistency for these 
subscales ranged from 0.67 to 0.89. All items are scored on a five-point scale through which 
respondents indicate their level of agreement. A higher score on a subscale means stronger 
endorsement of that content area; a high score on a positive scale thus means a higher positive 
impact of cancer, while a high score on a negative scale means a higher negative impact of 
cancer. Subscale scores are created by taking the mean of all items in the subscale. While a 
Dutch version was not available yet, a ‘forward–backward’ procedure was used to translate the 
English language version of the IOC into Dutch.
The impact of cancer was also assessed with questions regarding the impact of melanoma 
on sun behaviour (e.g. activities in the sun) and attitudes towards sun exposure (e.g. worries 
about the influence of the sun) since diagnosis. The response categories were dichotomised in 
our analyses into ‘less’ and ‘same or more’.
Health care utilisation
The items concerning health care utilisation included questions on the number of visits to a 
general practitioner, medical specialist (including those specialists involved in cancer care) and 
other health care professionals. These questions were asked in a similar way as is done via the 
annual monitoring of the health care situation of a random sample (n = ±10.000) of the Dutch 
population by Statistics Netherlands (http://statline.cbs.nl).
This study was done in the Netherlands, where every person has equal access to (specialised) 
health care. According to the Dutch guidelines, melanoma survivors with a Breslow of <1 mm 
are followed up once, survivors with a Breslow >1 will be followed up until 5 years after diag-
nosis and patients with a Breslow >2 will be followed up until 10 years after diagnosis (Dutch 
national melanoma guidelines; http://www.oncoline.nl).
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Statistical analyses
Routinely collected data from the ECR on patient and tumour characteristics enabled us to 
compare the group of respondents, non-respondents and patients with unverifiable addresses, 
using t-tests for continuous variables and chi-square analyses for categorical variables. Dif-
ferences between Type D and non-Type D patients in sociodemographic and clinical charac-
teristics, health care utilisation and the impact of melanoma on sun behaviour and attitudes 
towards sun exposure since diagnosis were also analysed using t-tests for continuous variables 
and chi-square analyses for categorical variables.
Univariate linear regression analyses were carried out to investigate the association of 
sociodemographic variables (age, gender, marital status, educational level and current occupa-
tion) and clinical variables (stage, Breslow, grade, primary treatment, years since diagnosis and 
comorbidity) with the subscale and component scales of the SF-36 and the subscales of the 
IOC. We controlled for these variables in the analysis of covariance (ANCOVA), which was used 
to compare the means of SF-36 and IOC scores between melanoma survivors with and without 
a Type D personality. We used Norman’s ‘rule of thumb’ that the threshold of discrimination 
for changes in health status scores for a chronic disease appears to be approximately half a 
standard deviation.31
All statistical test were two-sided and considered significant if p < 0.05. All statistical analyses 
were performed using SAS (version 9.1 for Windows, SAS Institute Inc., Cary, NC).
results
Patient and tumour characteristics: respondents versus non-respondents
Of the 699 melanoma cancer survivors, 562 (80.4%) returned a completed questionnaire (Fig. 
1). A comparison between respondents, non-respondents and patients with unverifiable 
addresses showed that patients with unverifiable addresses were generally younger (p < 0.001) 
and diagnosed earlier (in years) (p < 0.01) compared to respondents and non-respondents. Fur-
thermore, there were no significant differences between respondents, non-respondents and 
patients with unverifiable addresses regarding gender, Breslow, stage at diagnosis and primary 
treatment (Table 1).
Patient and tumour characteristics: Type D versus no Type D
Twenty-two percent of melanoma patients in this study were classified as having a Type D 
personality. There were no statistically significant differences observed between melanoma 
survivors with and without Type D at the time of the survey in: age, gender, years since diag-
nosis, Breslow, primary treatment, marital status, educational level, current occupation and 
disease progression (Table 2). Melanoma survivors with Type D were more likely to report 
comorbid conditions at the time of questionnaire compared to melanoma survivors without 
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Type D (p < 0.0001). The most frequently mentioned comorbid conditions among patients with 
and without Type D were hypertension (24% versus 23%; p = 0.88) and arthrosis (30% versus 
18%; p < 0.005).
Health status
The analysis of covariance revealed that Type D patients reported statistically significant lower 
scores on all SF-36 scales compared to patients without a Type D personality after adjustment 
for differences in age at the time of survey, gender, marital status, educational level, Breslow 
and comorbidity when necessary (Table 3). These differences were considered clinically 
relevant (>1/2 SD difference) for the subscales general health (57.8 versus 75.6), vitality (54.5 
versus 72.8), social functioning (73.1 versus 88.7), role limitations emotional (67.8 versus 89.4), 
mental health (61.7 versus 80.6) and the mental component summary (43.8 versus 54.0).
Impact of cancer
Analysis of covariance showed that Type D patients reported statistically significant higher 
scores on all IOC subscales, except for the subscales ‘Psychological: Positive Self-Evaluation’ 
(p = 0.80) and ‘Existential: Positive Outlook’ (p = 0.22), after adjustment for differences in age 
at the time of survey, years since diagnosis, gender, marital status, educational level, stage, 
Breslow, primary therapy and comorbidity when necessary (Table 4). These differences were 
960 patients, ≤ 85 years diagnosed and registered with 
melanoma between January 1998 and August 2007, 
diagnosed in one of the three participating hospitals within the 
Eindhoven Cancer Registry
Still alive on August 1 st 2007:802 (81%) patients
A questionnaire was sent to the remaining 699 patients
562 patients returned a completed questionnaire (80 %)
-86 addresses could not be veried
-5 patients were too ill or incompetent
-12 patients received follow-up by a 
dierent specialist/general practitioner
137 (20%) patients did not complete 
the questionnaire, 22 of whom had a 
known reason:
- Actively refused (n=17)
- Did not know they had cancer (n=1)
- Deceased after August 2007 (n=4)
figure 1. Flow-chart of the data collection process.
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table 1: Demographic and clinical characteristics of questionnaire respondents, non-respondents and 
patients who were lost to follow-up
respondents non-respondents
Patients with 
unverifiable 
addresses
p-Value
n = 562 (%) n = 137 (%) n = 86 (%)
mean age (at the time of survey) 57.2 (SD 14.0) 56.4 (SD 15.6) 51.2 (SD 15.0) 0.0013
mean years since diagnosis 4.6 (SD 2.6) 5.1 (SD 2.9) 5.3 (SD 2.8) 0.0105
gender
Male 212 (38) 54 (41) 33 (38)
Female 350 (62) 77 (59) 53 (62) 0.76
Breslowa
≤1.0 mm 275 (49) 61 (47) 39 (45)
1.01–2.0 mm 149 (27) 33 (25) 22 (26)
2.01–4.0 mm 100 (18) 30 (23) 22 (26)
>4.0 mm 32 (6) 5 (4) 3 (3) 0.64
stage at diagnosis
I 400 (71) 87 (66) 56 (65)
II 108 (19) 32 (24) 22 (26)
III 42 (8) 8 (6) 6 (7)
IV – – – 0.71
treatment
Surgery 556 (99) 128 (98) 85 (99)
Sentinal Node 113 (20) 22 (17) 21 (24)
Lymphadenectomy 27 (5) 7 (5) 4 (5)
Systemic therapy 3 (0.5) 1 (0.8) –
Radiotherapy 3 (0.5) – –
Other 29 (5) 7 (5) 4 (5) 0.81
a According to the American Joint Committee on Cancer (AJCC) classification.
table 2. Sociodemographic and clinical characteristics of melanoma survivors.
type d non-type d p-Valuea
n = 125 (%) n = 437 (%)
Age at the time of survey (mean (SD)) 58 (15) 57 (13) 0.24
Age at the time of survey
≤45 years 29 (23) 93 (21)
45–54 years 27 (22) 100 (23)
55–64 years 29 (23) 116 (27)
≥65 years 40 (32) 128 (29) 0.91
Gender
Male 39 (31) 173 (40)
Female 86 (69) 264 (60) 0.07
Years since diagnosis
<1 years 6 (5) 25 (6)
1–2 45 (36) 122 (28)
3–4 28 (22) 121 (28)
≥5 years 46 (37) 169 (39) 0.18
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table 2. Sociodemographic and clinical characteristics of melanoma survivors. (continued)
type d non-type d p-Valuea
n = 125 (%) n = 437 (%)
Stage at diagnosis
I 92 (74) 308 (70)
II 22 (18) 86 (20)
III 7 (6) 35 (8)
IV 4 (3) 8 (2) 0.64
Breslowb
≤1.0 mm 64 (51) 211 (48)
1.01–2.0 mm 34 (27) 115 (26)
2.01–4.0 mm 19 (15) 81 (19)
>4.0 mm 5 (4) 27 (6) 0.38
Primary treatment
Surgery 124 (99) 432 (99)
Sentinal node 20 (16) 93 (21)
Lymphadenectomy 3 (2) 24 (5)
Systemic therapy 0 (0) 3 (1)
Radiotherapy 1 (1) 2 (0)
Other 3 (2) 26 (6) 0.50
Comorbidityc
None 47 (38) 196 (45)
1 41 (33) 132 (30)
2≥2 37 (30) 109 (25) <0.0001
Co-morbid conditions (most frequent)
1. Hypertension 29 (24) 97 (23) 0.88
2. Arthrosis 36 (30) 75 (18) 0.005
Disease progression (self-report)d 12 (10) 67 (15) 0.10
Marital status
Married 89 (71) 327 (75)
Never married 14 (11) 41 (9)
Divorced/widowed 22 (18) 67 (15) 0.85
Education level
Primary school 31 (25) 130 (30)
Secondary school 54 (43) 188 (43)
College/university 26 (21) 77 (18)
Unknown 14 (11) 38 (9) 0.57
Current occupation
Employed 60 (48) 239 (55)
Unemployed 65 (52) 195 (45) 0.16
a  p-value was adjusted for age at the time of survey, years since diagnosis, gender, marital status, 
educational level, stage, Breslow, primary therapy and comorbidity at the time of the questionnaire when 
necessary.
b  According to the American Joint Committee on Cancer (AJCC) classification
c  Adapted Charlson comorbidity index; assessed by self-report at the time of questionnaire
d Recurrence, metastasis and new primary tumour
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also clinically relevant for the subscales body changes, negative self-evaluation, negative life 
outlooks, life interferences, health worry and higher order negative scale.
Type D patients more often reported fewer holidays to sunny destinations since diagnosis 
than non-Type D patients (73% versus 66%; p < 0.01) (Table 4). In addition, Type D patients 
reported undertaking less daily activities in the sun (36% versus 20%; p < 0.001) and spending 
less leisure time outdoors (23% versus 11%; p < 0.0001). Type D patients were also more worried 
about the influence of the sun on their skin compared to non-Type D patients (61% versus 48%; 
p < 0.01). No statistically significant differences were found between Type D and non-Type D 
patients regarding worries about their partner or children’s skin (if applicable), seeking shade, 
wearing protective clothing or using sunscreen.
Health care utilisation
No differences were found between patients with and without Type D in the number of visits 
to a general practitioner (85% versus 83%; p = 0.38) and medical specialist (84% versus 81%; 
p = 0.55) in the past 12 months. Furthermore, melanoma survivors with or without Type D, 
only sporadically (0–3%) used the following additional care services after cancer treatment: 
psychologist, social worker, pastoral care, physiotherapist, CAM, oncology nurse and contact 
with other cancer survivors.
table 3. Health status among melanoma survivors according to Type D personality.
sf-36 mean (sd) p-Valuea
type d non-type d
n = 125 n = 437
Physical functioning 77.8 (26.7) 86.7 (21.0) <0.0001
Role limitations physical 72.4 (39.3) 87.7 (28.6) <0.01
Bodily pain 72.1 (27.3) 83.2 (20.4) <0.0001
General health 57.8 (23.2) 75.6 (20.1) <0.01b
Vitality 54.5 (21.1) 72.8 (17.9) <0.001b
Social functioning 73.1 (24.1) 88.7 (18.2) <0.0001b
Role limitations emotional 67.8 (42.2) 89.4 (26.9) <0.0001b
Mental health 61.7 (19.5) 80.6 (15.0) <0.0001b
Physical component summary 47.8 (10.8) 51.8 (8.4) <0.01
Mental component summary 43.8 (11.1) 54.0 (7.6) <0.0001b
a  p-Value was adjusted for age at the time of survey, year since diagnosis, gender, marital status, 
educational level, stage, Breslow, primary therapy and comorbidity at the time of the questionnaire when 
necessary.
b Clinically relevant difference31
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table 4. The impact of cancer on melanoma survivors according to Type D personality.
type d non-type d p-Value
n = 125(%) n = 437(%)
IOCa,b
Physical: health awareness 3.38 (0.91) 2.99 (0.92) <0.0001
Physical: body changes 2.38 (0.83) 1.84 (0.69) <0.0001c
Psychological: positive self- evaluation 2.76 (0.67) 2.72 (0.76) 0.80
Psychological: negative self-evaluation 2.18 (0.70) 1.72 (0.58) <0.0001c
Existential: positive outlook 3.14 (0.78) 3.06 (0.89) 0.22
Existential: negative outlook 2.86 (0.87) 2.14 (0.83) <0.0001c
Social: life interferences 2.17 (0.78) 1.68 (0.66) <0.0001c
Social: value of relationships 3.02 (0.90) 2.78 (0.93) <0.02
Meaning of cancer 2.91 (0.72) 2.71 (0.79) <0.01
Health worry 3.16 (0.95) 2.57 (0.93) <0.0001c
Higher order positive scale 3.04 (0.61) 2.84 (0.70) <0.01
Higher order negative scale 2.55 (0.66) 1.99 (0.58) <0.0001c
Less activities in the sun (yes)d
Less sun and beach holidays? 88 (73) 255 (66) <0.01
Less occupation/daily activities? 43 (36) 83 (20) <0.001
Less leisure time outdoors? 28 (23) 48 (11) <0.001
Anxiety (yes)e
Own skin? 74 (61) 205 (48) <0.01
Skin of partner (if applicable)? 43 (37) 118 (29) 0.10
Skin of children (if applicable)? 56 (48) 158 (39) 0.07
Protection (yes)f
Seeking shade 76 (63) 254 (59) 0.49
Protective clothing (e.g. long sleeves and hats) 54 (45) 162 (38) 0.20
Use of sunscreen lotion 79 (65) 279 (65) 0.99
a  p-value was adjusted for age at the time of survey, years since diagnosis, gender, marital status, 
educational level, stage, Breslow, primary therapy and comorbidity at the time of the questionnaire when 
necessary.
b  a higher score on a subscale means stronger endorsement of that content area; a high score on a positive 
scale thus means a higher positive impact of cancer, while a high score on a negative scale means a 
higher negative impact of cancer.
c Clinically relevant difference
d  Compared to the period before your melanoma diagnosis, are you less involved in the following activities 
in the sun?
e  Compared to the period before your melanoma diagnosis, are you more worried about the influence of 
the sun?
f Compared to the period before your melanoma diagnosis, do you protect your skin more against the sun?
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discussion
Twenty-two percent of melanoma patients in this study were classified as having a Type D per-
sonality. This is within the range of Type D prevalence in the normal population, which ranges 
from 13% to 24%.11, 32 , 17 Among people with cardiovascular disease, these numbers are more 
elevated; between 27% and 31%.12, 14, 33, 34
Type D patients reported a statistically significant and clinically relevant lower health status 
measured by the SF-36. Because this is the first study to investigate the effect of Type D on 
health status among cancer survivors, comparison with other studies is not possible. However, 
it is known from the literature that the Type D personality construct is associated with a lower 
health status among cardiovascular patients. For example, Type D was associated with a lower 
health status pre- and post-cardiac rehabilitation in a study among 368 coronary artery disease 
patients.35 In addition, Type D patients were more than twice as likely to report a poor physical 
health status and were more than five times as likely to report a poor mental health status one 
year post coronary artery bypass grafting surgery.36 Also, Type D personality was associated 
with more than a three to sixfold increased risk of impaired health status in 186 heart transplant 
recipients 7 years following transplantation.18
This is the first study that reports the effect of personality on the impact of cancer, as mea-
sured by the impact of cancer questionnaire. Having had melanoma had a greater impact on 
body changes, negative self-evaluation, negative life outlook, life interferences, health worry 
and the higher order negative scale of the IOC in Type D patients compared to non-Type Ds. In 
addition, Type D patients were more worried about the influence of the sun on their skin and 
were more likely to adjust their life style than non-Type D patients. A higher impact of cancer on 
Type D patients can possibly be explained by the fact that negative affectivity is one of the main 
characteristics of Type D, which implies that these patients have the tendency to experience 
negative emotions in general. This can perhaps also explain why we did not find a difference in 
the positive IOC subscales (e.g. positive self-evaluation and positive outlook) but did find major 
differences in the negative ones (e.g. negative self-evaluation and negative outlook). Addi-
tionally, negative affectivity might cause Type D patients to estimate their chances of disease 
progression somewhat higher than non-Type D patients, which causes them to act accordingly 
by avoiding the sun more frequently. This could be viewed as a positive consequence of having 
a Type D personality that deserves further research.
A study among heart failure patients found that Type Ds experienced more cardiac symp-
toms but less often reported these symptoms to their cardiologist compared to non-Type Ds.13 
However, in the current study, no differences were found between those with or without Type 
D in the number of visits to a general practitioner. This seems plausible because in the Neth-
erlands, almost everyone visits his/her general practitioner at least once a year so differences 
are hard to find.37 Furthermore, no differences were found between survivors with and without 
Type D in the number of visits to a medical specialist. This may be explained by the fact that 
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there are guidelines on the number of follow-up visits for melanoma patients.37 In contrast to 
the study among heart failure patients in which patients should contact the cardiologist or 
nurse in case symptoms arise. This places the responsibility of making an appointment with 
the patient, not the cardiologist, and therefore leaves more room for someone’s personality to 
interfere with his or her health care utilisation.
This study has some limitations that should be noted. Although information was present 
concerning the initial cancer and treatment characteristics of the non-respondents and patients 
of whom the addresses could not be verified, whether non-respondents declined to participate 
in the study because of poor health remains unknown. In addition, although Type D personality 
is a stable construct,38 the cross-sectional design of our study limits the determination of causal 
association between Type D personality, health status and impact of cancer as baseline health 
status and impact of cancer of patients at diagnosis is not known. Therefore, future longitudinal 
studies with baseline data on Type D personality would be useful in exploring this associa-
tion between Type D personality and health status, and the subsequent adaptation process to 
cancer.
Nevertheless, this is the first study that confirms that Type D is not only associated with a 
lower health status among cardiovascular patients but also plays a major role in cancer patients. 
One of the strengths of our study, as compared with many previous survivorship studies, is the 
high response rate that facilitates generalising the results to the larger population of long-term 
melanoma survivors. In addition, we evaluated a broad spectrum of possible confounding 
factors, including age at the time of survey, years since diagnosis, gender, marital status, educa-
tional level, stage, Breslow, primary therapy and comorbidity at the time of questionnaire. Our 
results are intriguing and warrant further research with a larger group of melanoma survivors 
followed over a longer period of time.
Our study provided insight into the role of Type D personality on health status and impact of 
cancer among melanoma survivors 1/2–10 years after diagnosis. The Type D scale has proven 
to be a useful screening tool in melanoma survivors to identify subgroups at risk for impaired 
health status and impact of cancer. Giving special attention to those patients is important while 
they are more likely to experience a worse health status and stronger impact of cancer than 
non-Type D patients which can-not be explained by socio-demographical or clinical charac-
teristics. Type D might not just be a personality profile that decreases health status among 
cardiovascular patients but is more a vulnerability factor for a lower health status in general. 
So although not the focus of our paper, it demonstrates that personality could play a major 
role in the clinical care for cancer patients. More research on Type D personality among cancer 
survivors is therefore warranted.
acknowledgements: We would like to thank all patients and their dermatologists for their 
participation in the study.
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Madam, The incidence of melanoma is rapidly rising which can lead to an increasing burden for 
health care providers.1 Information provision is one of the most important aspects of support-
ive cancer care. Providing information that is congruent with patients’ needs may lead to lower 
levels of distress, better quality of life, improved patient satisfaction and sense of control.2,3 
More disease knowledge can result in informed decision making and can have positive effects 
on adherence to treatment and follow up, leading to reduced follow-up visits.1 However, one of 
the most frequently reported unmet needs by cancer patients is information disclosure.4 There 
is a discrepancy between the actual information needs of cancer patients and the perception 
of health care providers about the needs of cancer patients.5 Health care providers are often 
still reluctant to give the full amount of information about cancer and its treatment. Melanoma 
patients would appreciate especially more information concerning their diagnosis, treatment 
and skin condition.6
We conducted a cross-sectional study to measure the perceived level of, and satisfac-
tion with, information received by melanoma patients.7 Patients diagnosed with melanoma 
between 1 January 1998 and 1 August 2007 from three regional hospitals were selected. 
Melanoma was defined using the ICD-O codes C44.0–C44.9 with morphology 8720–8790. 
Medical specialists sent their (former) patients a letter to inform them about the study and 
a questionnaire. The EORTC-QLQ-INFO26 questionnaire was used to evaluate the information 
received by melanoma patients.8
Of the 699 melanoma survivors, 562 (80·4%) returned a completed questionnaire. There 
were no demographic or clinical differences between respondents and nonrespondents. 
Demographics and clinical characteristics of participating patients are presented in Table 1.
A large percentage of patients indicated the absence of information about different aspects 
of melanoma, treatment and aftercare (Table 2).
In multivariate linear regression analysis, none of the patient characteristics was significantly 
associated with perceived information provision about the disease. More information about 
medical tests was associated with shorter time since diagnosis (β = −0·10; P < 0·05) and a higher 
stage melanoma (β = 0·19; P < 0·01). More perceived information provision about treatment was 
significantly independently associated with younger age (β = −0·15; P < 0·05), higher stage of 
disease (β = 0·20; P < 0·01) and higher educational level (β = −0·10; P < 0·05). Logistic regression 
analysis showed that satisfaction with information was independently associated with hospital 
of treatment [odds ratio (OR) =  0·49, 95% confidence interval (CI) 0·32–0·76; P < 0·01], high 
educational level (OR = 0·63, 95% CI 0·41–0·99; P < 0·05) and less frequent use of the internet for 
additional information (OR = 0·60, 95% CI 0·39–0·92; P < 0·05).
Patients with a higher disease stage are more likely to undergo more medical tests and/
or treatments due to the increased risk of recurrence and metastasis. Therefore these patients 
might get more attention and information from their health care providers compared with 
patients with stage I melanoma. Also, the majority of melanoma patients receive most informa-
tion immediately after diagnosis. After the completion of treatment the contacts of the patients 
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table 1. Demographics and  clinical characteristics of participating patients (n = 562)
characteristic numbers (%)
Age (years) at time of survey (mean ± SD) 57·2 ± 13·6
Gender, n (%)
 Male 212 (38)
 Female 350 (62)
Time (years) since incidence (mean ± SD) 4·6 ± 2·6
Stage at diagnosis, n (%)
 I 400 (71)
 II 108 (19)
 III 42 (8)
 IV –
Breslow thickness, n (%)
 ≤ 1·0 mm 275 (49)
 1·01–2·0 mm 149 (27)
 2·01–4·0 mm 100 (18)
 > 4·0 mm 32 (6)
Treatment, n (%)
 Surgery 556 (99)
 Sentinal node 113 (20)
 Lymphadenectomy 27 (5)
 Radiotherapy 3 (0·5)
 Systemic therapy 3 (0·5)
 Other 29 (5)
Comorbidity, n (%)
 None 190 (35)
 One 174 (32)
 Two or more 174 (32)
Hospital, n (%)
 Hospital A 168 (30)
 Hospital B 255 (45)
 Hospital C 139 (25)
Marital status, n (%)
 Married 416 (74)
 Never married 55 (10)
 Divorced/widowed 89 (16)
Education level, n (%)
 Higher education 161 (29)
 Intermediate education 242 (43)
 Secondary school 103 (19)
 Primary school 52 (9)
Current occupation, n (%)
 Employed 248 (44)
 Unemployed 311 (56)
Socioeconomic status
 Low 80 (15)
 Intermediate 220 (40)
 High 237 (44)
 Institutionalized 6 (1)
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table 2.  Perceived  information provision characteristics, (n (%))
 
received no 
information
received a little 
information
received some 
information
received a lot of 
information
Disease
 Diagnosis 47 (9) 309 (56) 154 (28) 41 (7)
 Spread of disease 104 (19) 271 (49) 135 (25) 37 (7)
 Cause of disease 203 (37) 226 (41) 103 (19) 17 (3)
 Under control 76 (14) 258 (47) 164 (30) 48 (9)
Medical tests
 Purpose of test 134 (25) 220 (41) 157 (29) 29 (5)
 Course of test 125 (23) 237 (44) 144 (27) 32 (6)
 Results of test 74 (14) 237 (44) 188 (35) 38 (7)
Treatment
 Medical treatment 201 (38) 162 (30) 137 (26) 30 (6)
 Nonmedical treatment 496 (94) 26 (5) 5 (1) 2 (0)
 Expected result 182 (34) 202 (38) 122 (23) 25 (5)
 Side-effects 333 (62) 131 (25) 56 (10) 14 (3)
  Expected results on disease 
symptoms
288 (54) 163 (31) 65 (12) 14 (3)
 Expected results on social life 423 (80) 84 (16) 18 (3) 7 (1)
 Expected results on sexual life 487 (92) 32 (6) 6 (1) 5 (1)
Other services
 Additional help 484 (92) 36 (7) 6 (1) 2 (0)
 Rehabilitation 481 (91) 28 (5) 14 (3) 4 (1)
 Cope with cancer at home 441 (84) 68 (13) 16 (3) 2 (0)
 Psychological assistance 492 (94) 29 (5) 3 (1) 2 (0)
Single items
 Different care locations 472 (91) 38 (7) 9 (2) 3 (0)
 Things to do to get better 399 (76) 92 (18) 25 (5) 7 (1)
  Not satisfied A little satisfied Quite satisfied Satisfied
Satisfaction with information 72 (13) 259 (48) 164 (30) 46 (9)
  Not useful A little useful Quite useful Very useful
Usefulness of information 43 (8) 224 (43) 194 (38) 57 (11)
  Yes No    
Received written information 279 (52) 259 (48)    
Received information on video 
or CD-ROM
4 (1) 538 (99)    
Wanted more information 135 (25) 402 (75)    
Wanted less information 10 (2) 518 (98)    
table 1.  Demographics and  clinical characteristics of participating patients (n = 562) (continued)
characteristic numbers (%)
Follow-up care, n (%)
 General practitioner 11 (2)
 Dermatologist 452 (81)
 Surgeon 138 (25)
 Oncologist/internist 48 (9)
 Other 12 (2)
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with their doctor will diminish,3 while the information need of the melanoma survivor may still 
exist. Patients diagnosed and treated shortly before the completion of the questionnaire might 
have a clearer picture of the information they received and therefore reported to have received 
more information.
Younger and more highly educated melanoma patients are more likely to be actively 
involved in decision-making processes and ask more questions. Older patients are reported 
to be less interested in detailed information and leave the provision of details up to the doc-
tor.9 Likewise, doctors can be prejudiced against older patients. Furthermore, older and less 
educated patients may have more difficulties processing and remembering information they 
receive and may compensate for their reduced cognitive capacity by asking fewer questions to 
their specialist.9
The observed variation in information satisfaction levels between patients treated in differ-
ent hospitals can be explained by the variation in patient-centred information provision, which 
is strongly related to information recall and understanding. Our finding that only 25% of the 
melanoma survivors wanted more information could be explained by the increasing internet 
use of melanoma patients.10 When patients are not satisfied with the information received from 
their health care provider, they will search for additional information on the internet.
Health care providers often have limited time and resources to provide the information 
that melanoma patients require. With growing evidence that well-informed patients are more 
satisfied with their care, and do better clinically, efforts are needed to improve the information 
provision to melanoma patients. Exploration of the patients’ personal information needs must 
lead to a more patient-tailored approach of informing melanoma patients. A good opportunity 
would be the implementation of a survivorship care plan, which aims at providing a cancer 
survivor with a summary of their course of treatment, management of late effects, and strate-
gies for health promotion.
acknowledgments: The present research was supported by the Dutch Cancer Society (UVT 
2009-4349). We thank all patients and their dermatologists for their participation in the study
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aBstract
Background Follow- up of melanoma patients has been a continuing issue for discussion in the 
past years partly due to ever increasing incidence of this disease, as well as the lack of agree-
ment regarding the reasons for and frequency of follow- up. Patients’ perspectives are often not 
included in this continuing discussion on follow-up of melanoma patients.
objective To examine to what extent follow-up is experienced according to the guideline of 
2005, by physicians and melanoma patients in a Dutch population from the south-east area 
of the Netherlands. The patient’s perspective and satisfaction over said follow-up shall also be 
taken into account.
methods Follow-up among melanoma survivors was investigated and compared with the rec-
ommendations of the current Dutch national guideline. All 699 melanoma patients registered 
at the Eindhoven Cancer Registry (between 1998 and 2008), and treated in 3 regional hospitals, 
were contacted via postal mail. The survey questioned about treatment, symptoms, impact on 
daily life and follow-up. Patients with multiple melanomas (n=16) were excluded.
results Response rate was 80%, 418 patients were still under surveillance for their melanoma. 
The average time since diagnoses was 4 years, 71% had stage I melanoma. Almost 80% of 
patients with a Breslow thickness <1mm, reported more frequent follow-up visits than the 
guideline recommends. Only 5% of the patients wanted to reduce their follow-up frequency. 
Eighty percent of patients was under supervision of a dermatologist: physical examination, 
lymph node palpation and/or scar inspection did not regularly occur in 25%, 11% and/or 20%, 
respectively. These proportions were significantly higher among other specialisms.
conclusion Follow-up frequency was higher than recommended by the current melanoma 
guideline in a large group of patients, mainly those with lower Breslow thickness.
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introduction
Follow-up of melanoma patients has been a continuing issue for discussion in the past years, 
partly due to ever increasing incidence of this disease, as well as the lack of agreement regarding 
the reasons for and frequency of follow-up.1-3 Nowadays, the importance of proper follow-up 
and first evaluation at diagnosis is raised as new promising targeted therapies are evaluated for 
the use in melanoma patients.4 Several possible reasons for completing a follow-up of a mela-
noma patient include: detection of recurrent melanomas (namely, spreading of the disease), 
diagnosis of new and potential malignant melanocytic lesions (the risk of developing a new 
melanoma by a melanoma patient varies between 10 – 30%) and/or reassurance of the patient.2 
The 2005 Dutch melanoma guideline recommends that patients with a thin melanoma (Bres-
low thickness <1mm, which includes 70% of melanoma patients) return once for a follow-up 
appointment 1 month after treatment to receive further information. However this is regarded 
by patients and physicians as insufficient.5-8 Follow-up occurs more frequently in patients with 
a melanoma thickness greater than 1.0 mm (13 times in 5 years after diagnosis). Despite the 
prognostic importance of the Breslow thickness, a discrepancy exists between follow-up in 
patients with a thick versus those with a thinner melanoma. A small Dutch cross-sectional study 
consisting of 67 melanoma patients and 25 physicians (both referral and treating physicians), 
showed that few physicians follow the standard follow-up protocol, and that most of patient 
follow-up was conducted in order to assuage the fears of the patient.8 Another study reported 
that three quarters of patients, in whom a recurrent melanoma was discovered, was actually 
discovered by the patient.3 One could therefore view follow-up as unnecessary to detect recur-
rent melanoma. Based upon this assumption, the number of follow-up appointments could be 
reduced, provided that the patient receives the proper information regarding the recognition 
of a recurrent cancer. However, in the same study only 40 percent of patients reported having 
received this information and most patients reported a preference for a follow-up frequency 
of every 3 months. They concluded that further research is needed which takes the patient’s 
perspective and preferences regarding follow-up care after being diagnosed with a melanoma 
into account. 3 The aim of this study is to investigate the current Dutch melanoma guideline, 
and to examine to what extent follow-up is experienced according to the guideline of 2005, by 
physicians and 546 melanoma patients in a Dutch population from the south-east area of the 
Netherlands. The patient’s perspective and satisfaction over said follow-up shall also be taken 
into account.
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methods
Study Design and Participants
Patients selected for inclusion in this study had been registered by the Eindhoven Cancer 
Registry and had been diagnosed with melanoma in one of the three participating hospitals 
between January 1, 1998 and August 1 2007. After cross-checking with the Central Bureau of 
Genealogy, patients over the age of 85 who were still alive in 2008 were invited by the current 
treating physician to participate in this cross-sectional study, which examined the impact of 
melanoma patients’ live. Patients diagnosed with multiple melanomas were excluded from this 
analysis, as follow-up of these patients dependent upon the number of tumors and is therefore 
difficult to objectify. Permission for participation in this study was obtained by returning an 
anonymous questionnaire. Patient information was collected between the months of February 
and May 2008. Permission for completion of this study was granted by the Medical Ethic Com-
mittee of the Catherine Hospital, Eindhoven.
Study outcomes
Information regarding melanoma (date of diagnosis, location, histological type, TNM clas-
sification, treatment) was obtained via the Eindhoven Cancer Registry. Patient questionnaires 
included information regarding demographic variables, disease development and treatment, 
comorbidity, and follow-up. Questions regarding health care usage, such as the number 
of visits to the family practice physician, specialist, or other medical professionals were also 
included in the questionnaire. The questions were phrased similarly to questions posed by 
the Central Bureau of Statistics in the yearly health care census, which is conducted within an 
independent Dutch study population. The type of specialist who had completed the follow-up 
(family practice physician, dermatologist, surgeon, plastic surgeon or oncologist) was recorded 
along with a detailed record of what occurred during the follow-up appointment (e.g. complete 
disrobement for a total skin inspection, scar inspection and palpation of the lymph nodes). The 
answers ranged from always, sometimes, to never (the last two responses were combined in 
the analysis). A follow-up was considered “complete” after a total inspection of the skin, inspec-
tion of the scar, and palpation of the lymph nodes had found place, which are the minimal 
table 1: Frequency of follow-up according to Dutch melanoma guideline (2005)*
Breslow tickness Time after diagnosis Frequency of follow-up
> 1mm Year 1 Once every 3 months
Year 2 Once every 4 months
Year 3-5 Once every 6 months
>2 Year 1 Once every 3 months
Year 2 Once every 4 months
Year 3-5 Once every 6 months
Year 6-10 Annually
* Supplemental tests as indicated
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requirements according to the Melanoma guideline of 1996 and 2005. 5, 9 Follow-ups which 
occurred more frequently than those recommended in the CBO guideline for Melanoma 2005 
(Table 1) were defined as overconsumption 5, representing overuse of healthcare resources.
Statistical Analysis
Significant statistical differences between the distributions of categorical variables were tested 
using a chi-squared test. A 2-sided p-value <0.05 was defined as statistically significant. All 
statistical analyses were completed using SPSS (version 15.0)
results
Study Population
From the 992 patients whom had been diagnosed with melanoma between the dates of Janu-
ary 1998 and August 2007 in one of the three participating hospitals, 81% were still alive per 
August 1, 2007 (Fig.1). From these 802 patients, 103 were not included in the study due to 
sickness and according to the advice from their treating physician (n=5), due to treatment via a 
992 patients diagnosed with melanoma 
between January 1998 and August 2007
802 still alive at 1 February 2008  85 year
Questionnaire send to 699 patients
562 patients returned a completed questionnaire
546 patients eligible for analyses
158 deceased on 1/2/2008
Excluded:
- 5 Mentally or terminally ill
- 12 Under supervision with another 
specialist or F.P
- 86 address unknown
Non-responders:
-17 Actively refused
- 1 wrongfully diagnosed with melanoma
- 4 deceased after August 2007
-115 did not answer Total n=137
Excluded:
16 Patients with multiple melanomas
figure 1 Flow diagram data collection.
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different physician (n=12), or due to change in address (n=86). From the original study popula-
tion, 669 patients remained, of whom 562 completed and returned the questionnaire (80%). 
Sixteen of these patients developed multiple melanomas. From the non-respondent group, 17 
patients actively declined to participate, of whom 4 were deceased after February 2008. One 
patient was incorrectly registered as having been diagnosed with a melanoma.
The average age of the melanoma patient was 52.2 years at the time of diagnosis and 62% 
were female (Table 2). From the respondents, 70% had a high school diploma, 74% were married 
and 52% were employed at the time of the study. From the study population, 34% of patients 
reported having at least one other additional disease. Past history of hypertension, arthritis/
arthrosis, or cancer was reported by 20% of patients. Seventy one percent of patients had been 
table 2.: Sociodemografic and clinical characteristics of respondents.
total 562  % %
age at completion of questionnaire stage at time of diagnosis
(average 57.2) Stage I 400 (71)
≤30 25 (5) Stage II 108 (20)
30-39 96 (17) Stage III 42 (7)
40-49 117 (21) Stage IV -
50-59 145 (26) Unknown 12 (2)
60-69 112 (20) treatment
70-74 36 (6) Surgery 556 (99)
75-79 26 (5) Sentinal Node Procedure 113 (20)
≥80 5 (1) Lymphadenectomy 27 (5)
age at time of diagnosis Systemic Therapy 3 (0.5)
(average 52.2) Radiotherapy 3 (0.5)
≤30 9 (2) Other 29 (5)
30-39 59 (11) comorbidity
40-49 119 (21) Yes 186 (35)
50-59 123 (22) No 351 (65)
60-69 143 (25) marriage status
70-74 43 (8) Married 416 (74)
75-79 47 (8) Unmarried or never married 55 (10)
≥80 19 (3) Divorced 36 (6)
time since diagnosis Widow/Widower 53 (10)
(average 4.6) Partner 464 (85)
< 1 year 31 (6) education
1 - < 3 year 167 (30) Elementary School 161 (29)
3 - < 5 year 149 (27) High School 242 (43)
≥ 5 year 212 (38) College/ Technical schooling 103 (18)
Breslowthickness at time of diagnosis Higher Education (university) 52 (9)
≤ 1 mm 275 (49) work
1.01-2.0 mm 149 (27) Employed 299 (53)
2.01-4.0 mm 100 (18) Unemployed 245 (44)
>4.0 mm 32 (6) Unemployed(disabled) 15 (3)
Unknown 6 (1)
NB: percentages are rounded off to whole numbers.
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diagnosed with a stage I melanoma and 49% of patients had a Breslow thickness < 1mm (Table 
2). Local surgery had been performed on almost all of our patients and 20% had undergone a 
sentinel node procedure. Other treatments were seldom performed on our patient group.
Follow-up
Of the participants, 77% received follow-up treatment for their melanoma at time of the ques-
tionnaire (6 months – 10 year after diagnosis). The 418 patients who were still being followed 
for their melanoma were on average 4.7 years after diagnosis. Within this group, 6% were <1 
year after having been diagnosed, 28% 1– 3 years, 25% 3 – 5 years and 41% 5 – 10 years.
Different physicians
Dermatologists (80%) and plastic surgeons/surgeons (25%) were the most often consulted and 
involved in follow–up care within our study population. However, the physician who had made 
the diagnosis of melanoma and/or removed the tumor was not always necessarily involved in 
follow-up care. Seventy-two percent of patients had their tumors removed by a family practice 
physician and received follow-up care from a dermatologist. Between 90 and 94% of patients 
who had had their melanoma removed by a dermatologist also received their follow-up care 
from this specialist. About half of the melanoma patients who were treated by a plastic surgeon/
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Internal medicine
or oncologist
Other
Who has diagnosed your
melanoma?
Who has removed your melanoma?
Which physician
performs/performed your follow-up
visits?
figure 2: Physicians, who diagnosed, treated and/or performed the follow-up of melanoma patients.
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surgeon were being followed- up by this specialist and the other half were being followed- up 
by a dermatologist (51% and 57% respectively)(Figure 2).
Reported content of follow-up
In order to determine whether a dermatologist actually fulfilled a vital role in the follow-up 
care of melanoma patients, the patients were divided into 2 groups; group 1 consisted of 
patients seen by a dermatologist and group 2 consisted of patients who were not seen by a 
dermatologist. When a dermatologist was involved with the follow-up care of patients, (n=444), 
76% of patients reported being required to disrobe for a complete physical inspection, 89% of 
patients reported that scar inspection occurred and 80% of patients acknowledged that lymph 
node palpation had taken place. Patients in group 1 (those being seen by a dermatologist) 
were significantly more often required to undress for a complete physical inspection than those 
from group 2 who were not seen by a dermatologist (asked to undress 76% vs. 36%, p<0.0001). 
A significant difference was also discovered between the two groups in regards to palpation of 
the lymph nodes, which also occurred more frequently in patients from group 1 than in patients 
from group 2 (80% vs. 64%, p<0.01). However, despite these significant differences between the 
two groups of patients, 24% of the 434 patients from group 1 reported sometimes/never being 
asked to undress, 11% reported that no regular scar inspection took place, and 21% reported 
that little to no lymph node palpation had been performed. Seventy two percent of patients 
from group 2 (n=103) were followed up by a plastic surgeon/surgeon. During the follow-up 
appointments conducted by plastic surgeons/surgeons, 54% of patients reported sometimes/
never having been asked to undress in order to complete a full physical examination and 40% 
of patients reported that lymph node palpation infrequently/never occurred. Furthermore, an 
additional 17% of patients reported infrequently/never having their scar examined during a 
follow – up appointment.
Reported satisfaction
Follow-up was rated as good to very good by 83% of patients. Only 3% of patients rated follow-
up care as being bad to very bad, of whom 16 of these 17 patients had an incomplete follow-up 
(no regular skin examination, scar inspection and lymph node palpation). In addition, 23% of 
patients indicated that they were interested in extra paramedical/medical care after having 
received treatment for their melanoma (5% family practice visits, 3% physiotherapist, 10 % 
medical specialist).
Reported follow-up versus guideline recommendations
Within the past year, 40% of melanoma patients had visited a specialist 1 to 2 times regarding 
concerns about their melanoma and subsequent secondary concerns. Seventeen percent of 
patients reported visiting a specialist 3-5 times within the past year (Table 3). Eighty percent of 
patients with a Breslow thickness < 1mm reported to have had more follow-up appointments 
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than the guideline recommends (Figure 3b). In the second year of having being diagnosed, 
the percentage of excess visits to a specialist decreased, with 39% of patients reporting having 
visited their physician 2 times instead of 3. The trend continues with 19% of patients having one 
follow- up appointment instead of two from the third year up until the fifth year. Twenty nine 
percent of patients with a Breslow thickness > 2mm reported visiting their physician 1 time 
per year, for six to ten years after having been diagnosed, as recommended by the guideline. 
The remaining patients with a Breslow thickness >2mm visited their physician more frequently 
or without a definitive follow-up schema. Almost all melanoma patients (87%) were satisfied 
with the follow-up plan that they had been given. Only 5% indicated that they preferred fewer 
follow-up appointments and 7% preferred to be seen more frequently.
As illustrated in table 4, women more frequently attended follow-up visits than men. In 
addition, patients with a Breslow thickness < 1mm and/or who were under the supervision of a 
dermatologist were more frequently seen for follow-up appointments than recommended by 
the guideline. Furthermore, the hospital wherein the follow-up visit took place may also have 
been an influencing factor.
table 3: Heath care usage by participating melanoma patients.
%
currently receiving follow-up care (n=556)
Yes 77
Not anymore 20
Never 2
number of visits to the f.P in the last 12 mo. due to melanoma (n=545)
0 times 86
1-2 times 11
3-5 times 3
6-10 times 0
>10 times 0
number of visits to a specialist in the last 12 mo. due to melanoma (n=547)
0 times 35
1-2 times 40
3-5 times 17
6-10 times 5
>10 times 2
appointments made for follow-up care of melanoma (n=553)
Every 3 mo. 8
Every 4 mo. 8
Every half year 34
1 time per year 29
Every 2 years 1
No definite appointments 21
NB: Patients with multiple melanomas were excluded. Percentages have been rounded off to whole 
numbers.
F.P. = family practice physician
mo. = months
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discussion
In the case of many melanoma patients, the current Dutch guideline has not to been lived up 
to. A large group of melanoma patients, especially those with a low Breslow thickness, came 
much more frequently for follow-up appointments than advised by the 2005 guideline.5
The current guideline is justifiable on the basis of cost-effectiveness and for the detection of 
a recurrent or new primary melanoma. However, it does little to take the patient’s perspective 
into consideration.3, 10-11 Patients were satisfied with the higher frequency of follow-up care 
that they received and only 5% indicated that they would prefer fewer follow-up appointments. 
Female patients and/or patients under the supervision of a dermatologist and/or patients with 
a Breslow thickness <1mm attended follow-up care more frequently than the guideline recom-
mended. The patient’s perspective, in addition to that of the treating physician, appears to have 
an influence on the amount of follow-up care provided. This was earlier demonstrated in a small 
study of dermatologists and referring physicians who reported scheduling more follow-up 
visits for their own reassurance.8 It is very likely that it is difficult for a patient to comprehend 
that only one follow-up appointment is needed after the removal of a thin melanoma. On the 
other end of the spectrum are patients with a “thick” melanoma (Breslow thickness >2mm), 
who must frequently schedule multiple follow-up appointments, despite the fact that this has 
minimal prognostic value due to the fact that there is no curative treatment for a metastasized 
melanoma that does not require surgical excision (www.oncoline.nl).5 In the 1996 guideline 
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figure 3: Health care consumption of melanoma patients.
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follow-up was not indicated according to Breslow thickness.9 For every Breslow thickness the 
same frequencies applied, as mentioned in the 2005 guideline (Breslow thickness > 1mm), with 
a maximum of 10 years. Patients with a Breslow thickness < 1.5mm who were five years after 
having been diagnosed, were released from the follow-up. In an additional analysis, patients 
were divided into 3 groups: patients diagnosed according to the 1996 guideline (before 2005), 
patients diagnosed in 2005, and patients diagnosed after 2005 (a new guideline appeared 
in 2005). This analysis showed that it appears to be that the frequency of follow-up visits for 
patients with a Breslow thickness <1mm comply more with the guideline of 1996. There were 
no definite differences observed among the guidelines for other Breslow thicknesses. It is pos-
sible that physicians and patients prefer the older guideline, which advised more follow-up care 
table 4: Patient characteristics with regard to overconsumption of health care.
no overconsumption overconsumption
(%) (%)
sex
Woman 59 66
Man 41 34
age categories
<50 32 34
50-65 35 39
≥ 65 33 27
time since diagnosis
<1 years 4 7
1-3 years 27 34
3-5 years 26 26
>5 years 43 33
Breslowthickness
<1 mm 21 77
1.01-2 mm 40 13
2.01-4.0mm 27 8
>4 mm 9 2
Unknown 2 0
follow- up physician*
F.P. 1 1
Dermatologist 67 90
(Plastic)Surgeon 24 7
Internist/Oncologist 6 2
Other 2 0
hospital
1 54 46
2 56 44
3 37 63
* Only patients who received follow-up care by a specified physician.
NB: percentages have been rounded off to whole numbers.
Cat. Age = Categorical age.
F.P. = Family practice physician
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for patients with a Breslow thickness <1mm. Yet another explanation could be that patients 
visit the dermatologist more frequently because of a skin problem other than their melanoma. 
Additional analysis indicated that 20% of all patients who visited the dermatologist too fre-
quently had a past history of another type of skin tumor.
It is not clear which physicians should perform follow-up care and may depend upon the stage 
of the melanoma. It is obvious that the dermatologist, possibly with the help of a nurse prac-
titioner or specialized nurse, should play a central role in the follow-up of melanoma patients, 
primarily due to the nature of the cancer as well as the fact that a great deal of patients are 
diagnosed within the first stages of the disease. In addition, apparently, a more thorough fol-
low-up occurs when a dermatologist participates in the follow-up care of melanoma patients. 
However despite these findings, almost a quarter of patients who were seen by a dermatologist 
reported that they did not receive complete follow-up care, i.e. they were not always given a 
complete physical examination, nor did scar inspection or lymph node palpation take place. 
For patients in a later stage of the disease it might be recommendable to be followed-up in a 
multi-disciplinary setting or should alternate between the care of a surgeon and/or oncologist 
and dermatologist.2, 12
This is one of the largest cross-sectional studies involving melanoma patients within the general 
population. The response rate of 80% was quite high and corresponded with response rates 
reported by other studies conducted in the south of the Netherlands.13-14 However, several 
limitations to this study must be considered. With a cross-sectional study it is more likely that 
patients with a stage III or stage IV melanoma are excluded, considering that these patients are 
often too ill to participate or are deceased. However, this selection primarily includes melanoma 
patients from general population, from which the majority of patients have been diagnosed 
with a melanoma with a Breslow thickness of <1mm. Furthermore, these results can be general-
ized to the rest of melanoma patients in the Netherlands, because none of the patients included 
had been treated in a university hospital or specialized clinic. One additional limitation of this 
study is the possibility of recall bias. It is possible that patients who received the diagnosis of 
melanoma up to 10 years ago were not able to accurately remember and evaluate what level 
of follow-up care that they had received. However, this possible bias does not apply to the 
degree of “overconsumption” of health care, as patients were asked to report the frequency 
of outpatient appointments within the last 12 months. A large number of melanoma patients 
were diagnosed before the introduction of the current guideline, and it is possible, that in the 
case of these patients, physicians followed the 1996 guideline instead of that from 2005. This 
may explain the degree of overconsumption among patients with a melanoma with a relatively 
low Breslow thickness. Patients experience the most anxiety during diagnosis and treatment. 
Reducing the amount of follow-up visits might reduce this anxiety. However, a study by Bas-
tiaannet et al on the burden of diagnostic test in 60 patients with lymph node metastases also 
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showed that patients were more satisfied with follow-up and experiences less burden during 
diagnostic tests when they were well informed.15 This suggests an important role of providing 
patients with accurate information which can prevent additional anxiety during follow-up and 
improve patient satisfaction with care, wich might lead to reduction in of overconsumption of 
health care.
Previous studies have shown that social status is of relevance to the incidence of cancer. 
16-17 Furthermore it might be of relevance to the coping mechanisms of melanoma patients, 
which might result in a higher or lower health care need. Table 2 showed that approximately 
half of the melanoma patients were unemployed and/or had basic education (primairy school 
or high school) which might mean that these patients have more difficulty with understanding 
information given by health care providers and might result in difficulty with coping with their 
disease, which might then lead to higher health care consumption. Unfortunately we did not 
have enough detailed information to make to accurately evaluate this statement.
In conclusion, our findings indicate that a large group of melanoma patients, particularly those 
with a low Breslow thickness, more frequently received followed-up care than is advised by 
the current melanoma guideline. More research is need in order to further investigate why 
this overconsumption of health care resources occurs, and to discover possible predictors for 
overconsumption by patients as well as physicians. It is of the utmost importance that the 
patient’s perspective is taken into account when evaluating the follow-up guideline. At this 
time a prospective study is being conducted in the Netherlands which compares the current 
guideline with an experimental guideline (less frequently follow-up visits and adjusted for 
stage of disease), which includes a patients’ perspective (www.ikno.nk MELFO study).
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aBstract
Background Burden of disease describes loss of health and death due to a disease which has 
not been adequately studied for melanoma.
methods Age- and gender-specific incidence data from all patients diagnosed with melanoma 
in the Netherlands between 1989 and 2006 were obtained from the Netherlands Cancer regis-
try. Mortality numbers and rates were extracted from the Statistics Netherlands database. Life 
tables with the probability of developing a melanoma were calculated per 5-year period with 
use of the DevCan software. The standard life expectancy for both men and women per 5-year 
age group were estimated using DISMOD software. The Years of Life lived with Disability (YLD) 
and Years of Life Lost (YLL) due to melanoma were calculated using these life tables and life 
expectancies. The disability adjusted life years (DALY), a general measure for the burden of a 
disease, was estimated by adding YLD and YLL.
results The incidence of melanoma almost doubled between 1989 and 2006 (cumulative 
incidence rate increased from 1.03-1.31% to 2.02-2.11%). The burden of melanoma to society 
increased rapidly between 1989 and 2006. On average, patients lived 21.6-28.2 years with a 
melanoma diagnosis. Melanoma resulted in a loss of 17.8-20.1 years per before the age of 95, 
for those that died of their melanoma.
conclusions Melanoma is becoming a great burden to Dutch society. Health care providers 
may have to adjust their current policy in treating patients with melanoma.
abbreviations:
yld Years of Life lived with 
Disability
=  number of incident cases x disability weight (0.05) x average duration 
of the disease until remission or death
ayld Average Years of Life lived 
with Disability
= YLD / number of incident cases
yll Years of Life Lost = number of deaths x standard life expectancy at age of death in years
ayll Average Years of Life Lost = YLL / number of deaths
ylm Years Lived with Melanoma =  number of incident cases x average duration of the disease until 
remission or death
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introduction
In the past three decades the incidence of melanoma has markedly increased in people of 
European ancestry. In 2005, melanoma was the 8th most common cancer in men and the 5th 
most common cancer in women in The Netherlands (a total of 3515 cases among 16.4 million 
inhabitants) (www.ikcnet.nl). De Vries et al. have predicted that by 2015 the number of new 
cases per year will exceed 4800.1 Compared with most other malignancies, melanoma affects 
patients at a younger age and has relatively good survival rates for the majority of patients, 
which have improved over time due to early detection.2-5 This implies an increasing number of 
melanoma survivors who live with a cancer diagnosis and its social and psychological effects 
and may utilize health care for medical and psychological reasons related to their melanoma 
history over a prolonged period of time, which can become a great burden for health care 
providers.
Usually, the magnitude of a cancer problem is expressed in incidence and mortality rates and 
numbers of newly diagnosed cancer patients. However, the magnitude of the societal problem 
can also be expressed in a quite different way using Burden of Disease measures that measure 
the disease burden for individuals or populations. These Burden of Disease measures may be 
used for research purposes, public health campaigns and for the allocation of limited health 
care resources.6 The burden of a disease can be estimated by calculating the number of years 
of life lost (YLL), the number of years of life lived with disability (YLD) and Disability Adjusted 
Life Years (DALY).6 These additional measures are of key importance in estimating the burden of 
cancer types that occur in young patients and often have a favorable prognosis.
Only a few studies have investigated the burden of melanoma. Brochez and colleagues 
investigated the burden of melanoma in Belgium, expressed as years of potential life lost and 
showed that in those terms, melanoma was the second most important cancer of all adult-
onset cancers.7 Melanoma resulted in a loss of 8 years before the age of 65 in men and 6 years 
in women. In the United States, the burden of melanoma has also been expressed by years 
of potential life lost and these rates were one of the highest for adult-onset cancers.8 None 
of these studies evaluated changes in the burden over time, nor did they include the part of 
the population aged over 65, which is continuously growing in many European countries and 
therefore represents a population group which is of increasing importance.
In the Netherlands, the burden of melanoma has never been estimated by YLL, AYLL, YLD or 
DALYs. Therefore, we estimated the size of the burden of melanoma within the general Dutch 
society with these four measures using data for 1989-2006 in 4 time periods (1989-1991, 1992-
1996, 1997-2001, and 2002-2006).
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methods
Population
Age- and gender-specific data on newly diagnosed patients with melanoma (ICD-0 codes: 
C44.0-C44.9) were obtained from the Netherlands Cancer Registry, which collects incidence 
and tumor data on all newly diagnosed cancers in the Netherlands from the regional com-
prehensive cancer centers since 1989 (i.e., only first melanoma’s were used for this study). We 
used incidence data for 1989 to 2006. Annual data on age and gender of cancer deaths and 
population composition were obtained from Statistics Netherlands.
Study design
To estimate the burden of melanoma, we calculated Disability Adjusted Life Years (DALYs) by 
adding the number of Years of Life Lost (abbreviated YLL) by a person as a consequence of 
premature death due to melanoma plus the number of Years of Life lived with Disability (abbre-
viated YLD) caused by melanoma by a person. According to Murray et al., one DALY represents 
the loss of one year of life lived in full health. The sum of these DALYs across the population, or 
the burden of disease, can be thought of as “a measure of the gap between the current health 
status and an ideal health situation in which the entire population lives to an advanced age, 
free of disease and disability”.9
Statistical methods
All analyses were performed for 5-year periods (except for period 1989-1991, as data was only 
available for 18 years) and stratified for gender. The cumulative incidence was calculated per 
5-year age group by dividing the number of new patients with melanoma by the total midyear 
population and totaling these age-specific results. European standardized incidence rates (ESR) 
were then calculated by multiplying the age-specific incidence rates with standard European 
population data (http://seer.cancer.gov/stdpopulations/). The DevCan software program, 
which was developed by the National Cancer Institute in the United States, was used to cal-
culate the probability of a person being newly diagnosed with a melanoma during the 5-year 
period by the life table method.10 The life table method, unlike cumulative incidence data, takes 
into account that the cause of death of a melanoma patient might not be related to melanoma. 
Also, this method calculates the probability of being diagnosed with melanoma and dying from 
it, for people without a history of melanoma. For these calculations the following assumptions 
were made:
(a) The incidence of melanoma is constant in each 5-year period;
(b) The probability of death not being caused by melanoma is the same for melanoma patients 
as for people without a history of melanoma;
(c) The data obtained from the Netherlands Cancer Registry and Statistics Netherlands were for 
5-year age groups. To raise the accuracy, DevCan divides these age groups into 10 periods 
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of 6 months. In each 6 month age group the incidence and mortality rates increase in 10 
equal steps and are constant within each 6 month age group. This leads to an exponential 
decrease with age in each 6-month age group. The numbers of patients at risk and the prob-
ability of being diagnosed with a melanoma can therefore be more accurately calculated;
(d) All melanoma specific mortalities are registered with Statistics Netherlands and correctly 
represented by the Comprehensive Cancer Centers.
To estimate YLD, we multiplied the number of incident cases by the average duration a patient 
lives with melanoma in the Netherlands and a weighing factor, determined by the World Health 
Organization (WHO), that reflects the impact of melanoma on health related quality of life on 
a scale from 0 (perfect health) to 1 (dead). Melanoma disease duration was estimated using 
DISMOD.11 YLL corresponds to the number of deaths due to melanoma multiplied by the 
standard life expectancy in the general population at the age which death occurs as estimated 
by a standard life table.6 The average years of life lost (AYLL) were calculated by dividing the 
YLL by the number of melanoma deaths. DALYs were calculated as the sum of the YLL due to 
premature mortality in the population and the YLD for incident cases of the health condition 
(i.e., melanoma). To calculate the actual years a patient lives with their melanoma, the Years 
Lived with Melanoma were calculated (YLM). Therefore, we multiplied the number of mela-
noma patients with their life expectancy at time of diagnosis.
results
Incidence and mortality
Between 1989 and 1991, an annual average of 1603 Dutch citizens was newly diagnosed with 
melanoma (Table 1); this increased to 3171 individuals per year in the period 2002-2006. Of all 
newly diagnosed melanoma patients, 43.3% was male (ESR 15.9 per 100 000 person-years) and 
56.7% was female (ESR 19.5 per 100 000 person-years) (Table 1). Cumulative incidence rates 
almost doubled in men (1.03% in 1989-1991 to 2.02% in 2002-2006) and increased from 1.31% 
to 2.13% in the same time period for women.
Age at diagnosis of melanoma increased over time. Between 2002 and 2006 melanoma was 
mainly newly diagnosed in men above the age of 40 and in women above the age of 25 years 
(Fig. 1).
Mortality slowly increased from 182 to 333 men and 182 to 257 women annually by 2002-
2006. Cumulative mortality rates also doubled up to 0.61% for men and up to 0.40% for women. 
An increase of melanoma mortality was particularly observed for men aged 55 to 65 and 
women >75 years.
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DevCan produced estimations of the probability for a person to develop a melanoma (Table 2) 
and the probability of dying from a melanoma in a certain age group. In 2006, male newborns 
had an overall chance of 1 in 62 to develop a melanoma, for female newborns this was 1 in 50. 
A man of 40 years old had a probability of 1.1% to develop a melanoma before the age of 75 
years. For women, this probability was 1.2%. Men were more likely to die of a melanoma; the 
probability for a 40-year old male to die due to melanoma before the age of 75 was 0.3%. By the 
age of 65, this probability had decreased to 0.1%. Corresponding probabilities for women were 
0.2% for a woman aged 40 and 0.1% for women aged 65.
Years lived with Melanoma (YLM)
The Average Years Lived with Melanoma (AYLM), without adjustments for disability, decreased 
for both sexes, from 23.2 to 21.6 years for men and 29.1 to 28.2 years for women (Table 1 and Fig. 
2). The total years of life lived with melanoma in the general population has rapidly increased. 
For men, a total of 368.0 life-years lived with melanoma per 100 000 inhabitants in 2002-2006 
was estimated compared to 198.7 years in 1989-1991. For women, the YLM rose from 373.3 to 
616.9 (Fig. 2).
table 1: Incidence, mortality and burden of disease of Dutch melanoma patients, according to the period 
of diagnosis
men women
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Number of new melanoma patients 1900 3810 5154 6859 2909 5508 6986 8998
Age standardized incidence rate 8.87 10.08 12.83 15.87 12.25 13.27 15.93 19.53
Cumulative incidence rate 1.03 1.23 1.61 2.02 1.31 1.41 1.73 2.13
Number of melanoma deaths 546 1072 1335 1664 547 965 1068 1293
Age standardized mortality rate 2.62 2.90 3.37 3.84 2.21 2.20 2.22 2.48
Cumulative mortality rate 0.37 0.44 0.53 0.60 0.30 0.31 0.33 0.39
YLL 47 51 61 74 54 53 54 63
YLD 10 11 14 18 19 20 25 31
DALYs 57 63 75 92 73 74 79 94
YLM 199 224 284 368 373 408 495 617
AYLD 1.2 1.1 1.1 1.1 1.5 1.4 1.4 1.4
AYLM 23.2 22.4 21.6 21.6 29.1 28.8 28.3 28.2
AYLL 19.3 18.2 17.9 17.8 22.4 21.5 20.3 20.1
Source: Netherlands Cancer Registry and Statistics Netherlands
* = per 100 000 Dutch inhabitants
YLD:  years lived with disability; YLM: years lived with melanoma; YLL: years of life lost; DALY: disability 
adjusted life years; AYLD: average years lived with disability; AYLM: average years lived with 
melanoma; AYLL: average years of life lost.
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Years of life Lived with Disability (YLD)
The average number of years that a male melanoma patient lived with melanoma, adjusted for 
disability due to melanoma (disability weight: 0.05) decreased from 1.16 years in 1989-1991 to 
1.08 years in 2002-2006. Women had a higher AYLD: 1.46 years in 1989-1991 and 1.41 years in 
2002-2006 compared to men (Table 1).
In contrast to the slight decreases in AYLD, the total YLD of melanoma in the general popula-
tion rapidly increased for both sexes. For men, the YLD increased from 10 to 18 years per 100 
000 inhabitants (1989 to 2006) and from 19 (1989-1991) to 31 years (2002-2006) for women.
Years of life lost (YLL)
In 1989-1991, a male melanoma patient lost on average 19.3 life-years (AYLL) which decreased 
to 17.8 years in 2002-2006 among men who died due to their melanoma. For women the 
AYLL also decreased from 22.4 to 20.1 years. However, the total YLL to melanoma in the Dutch 
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figure 1. Incidence rates of cutaneous melanoma by age at diagnosis, 1989-2006, per 100,000 person-years.
A: men
B: women
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table 2: Percentage of men and women who develop melanoma by a specific age (Z), given cancer free at 
current age (Y), 2006.
men
Age (years) at diagnosis of melanoma
M
el
an
om
a 
fr
ee
 a
ge
 (y
ea
rs
)
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 95+
0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
5 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
10 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
15 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
20 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
25 0.0 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.2 1.4 1.5 1.5 1.6 1.6
30 0.1 0.1 0.2 0.3 0.5 0.6 0.8 1.0 1.2 1.4 1.5 1.5 1.5 1.5
35 0.1 0.2 0.3 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.5 1.5 1.5
40 0.1 0.2 0.3 0.5 0.7 0.9 1.1 1.2 1.3 1.4 1.4 1.4
45 0.1 0.2 0.4 0.6 0.8 1.0 1.1 1.3 1.3 1.3 1.3
50 0.1 0.3 0.5 0.7 0.9 1.1 1.2 1.2 1.2 1.2
55 0.2 0.4 0.6 0.8 0.9 1.1 1.1 1.1 1.1
60 0.2 0.5 0.6 0.8 0.9 1.0 1.0 1.0
65 0.2 0.4 0.6 0.7 0.8 0.8 0.8
70 0.2 0.4 0.5 0.6 0.6 0.6
75 0.2 0.4 0.5 0.5 0.5
80 0.2 0.3 0.3 0.4
85 0.2 0.2 0.2
90 0.1 0.2
95 0.3
women
Age (years) at diagnosis of melanoma
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 95+
M
el
an
om
a 
fr
ee
 a
ge
 (y
ea
rs
)
0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
5 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
10 0.0 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
15 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
20 0.0 0.1 0.2 0.3 0.5 0.6 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
25 0.1 0.2 0.3 0.4 0.6 0.8 0.9 1.1 1.3 1.5 1.7 1.8 1.9 1.9 1.9
30 0.1 0.2 0.4 0.5 0.7 0.9 1.1 1.2 1.4 1.6 1.7 1.8 1.9 1.9
35 0.1 0.3 0.4 0.6 0.8 1.0 1.1 1.3 1.5 1.6 1.7 1.8 1.8
40 0.1 0.3 0.5 0.7 0.8 1.0 1.2 1.4 1.5 1.6 1.7 1.7
45 0.2 0.3 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.5 1.5
50 0.2 0.3 0.5 0.7 0.9 1.1 1.2 1.3 1.4 1.4
55 0.2 0.4 0.6 0.8 1.0 1.1 1.2 1.2 1.2
60 0.2 0.4 0.6 0.8 0.9 1.0 1.1 1.1
65 0.2 0.4 0.6 0.8 0.8 0.9 0.9
70 0.2 0.5 0.6 0.7 0.7 0.7
75 0.2 0.4 0.5 0.6 0.6
80 0.2 0.3 0.4 0.4
85 0.2 0.3 0.3
90 0.2 0.2
95 0.1
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population almost tripled for men and more than doubled for women during the 18 year time 
period of our study. In 2002-2006 the total YLL for melanoma for women was 63 years per 100 
000 inhabitants (Table 1). Analyses of YLL per 5-year age group showed that the YLL of men 
aged 50-65 years increased most notably over 1989 to 2006. For women the YLL increased 
especially for women aged 50 to 80 years and aged 35-39 (data not shown).
YLL & AYLL FOR ALL MELANOMA DEATHS
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figure 2. Years Lived with Melanoma (YLM) and Average Years Lived with Melanoma (AYLM) by period of 
diagnosis. 
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figure 3. Years of Life Lost (YLL) and Average Years of Life Lost (AYLL) by period of diagnosis.
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Disability Adjusted Life Years (DALY)
The burden of melanoma as estimated by DALYs per 100 000 inhabitants also increased over 
1989-2006 (men: 57 to 92 and women: 73 to 94 per 100 000 inhabitants). The increase over 
1989-2006 was steeper for men than women, but the increase of the DALYs appeared compa-
rable for both sexes in the 2002-2006.
discussion
The high YLD and YLLs for melanoma patients emphasize the impact that melanoma has on 
health care, and the increasing incidence of melanoma suggests that this will further rise in the 
future. YLD and YLM are important indicators of burden of disease as they estimate the number 
of years patients might be in need for additional care (including psychological), whereas inci-
dence rates merely indicate a rising trend in the number of patients that will require treatment 
and follow-up. The high estimates of the burden of disease measures also illustrate that there is 
profit to be gained in the management of melanoma patients and its survivors.
Increases in mortality of melanoma in the Netherlands were modest and much smaller than 
those observed for incidence. On the other hand, the burden of melanoma in terms of YLL 
in the Netherlands increased considerably between 1989 and 2006 up to an AYLL of 20. The 
high YLL is due to the fact that many patients are middle aged when diagnosed with their first 
melanoma, and most of those who die of melanoma die fairly soon after the diagnosis. Our 
results cannot be compared directly with the few other studies that have examined the burden 
of disease measure for melanoma, as those studies used a cut-off value of 65 years.7-8 Although 
when calculating YLL, a cut-off of value of 65-years is commonly used to ascertain premature 
mortality in an occupational population so that loss of productivity can be estimated, in order 
to be able to assess how long people are affected by a disease, the analysis must be unrestricted 
by age. It was for this reason that we decided not to use the age cut-off of 65 years. Moreover, 
the majority of melanoma patients are diagnosed at an age of 55-65 years and thereafter, most 
patients have a 5-10 year survival rate of >90%.2 On average, melanoma patients in the Neth-
erlands live to be 75 years of age, which means that adopting a cut-off value of 65 years would 
result in an YLL being underestimated by about 10 years.
AYLL is calculated as YLL divided by the number of melanoma deaths. However, when all 
melanoma patients (dead or alive) were included in the calculation, not just those who had 
died from melanoma, then, on average, between 2002 and 2006, for an individual melanoma 
patient, melanoma was associated with a mean loss of approximately three years of life . 
Despite the gradual decline in the numbers of life years lost per patient and life years lived with 
disease, which is attributable to improving survival and a slightly higher age at diagnosis on 
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average, the burden of melanoma to society rose sharply between 1989 and 2006, mostly due 
to increases in incidence rates.
The low lifetime probability of an individual patient to die from his melanoma implies that 
most melanoma patients will live for many years after their diagnosis (YLD for men: 18 per 100 
000 men and for women: 31 per 100 000 women and AYLM ranging from 20-30 years). The 
disability weight of 0.05 (0 perfect health to 1 death)12 used when calculating the YLD is based 
on the prognosis of average melanoma patients. Disability weights for advanced melanoma 
are higher: 0.75 for metastasized disease and 0.81 for terminal disease. However, the vast 
majority of patients are not part of these groups. Previous research has shown that over a third 
of melanoma patients experience considerable levels of anxiety, mainly during diagnosis and 
treatment.13 Moreover, patients’ concerns may be very specific (e.g., in relation to UV exposure) 
and not be fully captured by generic health-related quality of life instruments. For example, 
a cross-sectional study among more than 500 melanoma survivors up to 10 years after diag-
nosis showed that most melanoma patients reported taking holidays to sunny destination 
less frequent than before their diagnosis, being more anxious about the deleterious effect of 
UV-light on their skin, and making more use of protective measures, including practicing less 
hobbies outside and wearing more protective clothing.14 Moreover, a proportion of melanoma 
survivors reported difficulty in obtaining a life insurance or a mortgage. These findings suggest 
that the YLD might not fully capture the actual number of disability-adjusted life years patients 
live with their melanoma and its consequences; the disability weight should therefore probably 
be raised, in order to capture the true impact of melanoma on quality of life. It was for this 
reason that we also calculated the Years Lived with Melanoma (YLM), not taking the disability 
weight into account.
To our knowledge, we are the first to fully report on the burden of disease measures in mela-
noma and to estimate the probability for the population of the Netherlands of being diagnosed 
with melanoma. Dutch women had a probability of 1.9% of developing a melanoma during 
their lifetime, for men this was 1.6%. The cumulative incidence rates were slightly higher, 
because these do not take other comorbidities into account nor the probability of dying from 
a disease other than melanoma. Therefore we calculated the risk of developing melanoma by 
the life table method, using the DevCan program that calculates the probability of developing 
a melanoma and the probability of someone dying from it. These calculations were based on 
a hypothetical cohort and the estimated results of the DevCan analyses were confirmed by a 
standard life table. A life table makes it possible to answer simple questions of patients pertain-
ing to their survival, or to estimate the likelihood of a melanoma in the general population, in 
certain age and sex groups. Though a person’s life time risk of developing a melanoma seemed 
relatively low, the Dutch Cancer Society has shown before that it is almost comparable to the 
likelihood of a woman developing ovarian cancer, non-Hodgkin lymphoma or lymphoma.10
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In conclusion, this study has shown that the burden of melanoma in the Netherlands is high 
and increasing substantially, suggesting a need for health care policies to be adjusted in order 
to be able to cope with this burden. Our research also shows that even though a disease may 
be relatively rare and/or has a good prognosis, it can be associated with a great burden to 
individual patients and society.
Cynthia BW 7.indd   136 28-09-11   13:35
Burden of disease in Dutch melanoma patients, 1989-2006
Ch
ap
te
r 8
137
references
 1. de Vries E, van de Poll-Franse LV, Louwman WJ, de Gruijl FR, Coebergh JW. Predictions of skin cancer 
incidence in the Netherlands up to 2015. Br J Dermatol. Mar 2005;152(3):481-488.
 2. de Vries E, Houterman S, Janssen-Heijnen ML, et al. Up-to-date survival estimates and historical 
trends of cutaneous malignant melanoma in the south-east of The Netherlands. Ann Oncol. Jun 
2007;18(6):1110-1116.
 3. Kolmel KF, Kulle B, Lippold A, Seebacher C. Survival probabilities and hazard functions of malignant 
melanoma in Germany 1972-1996, an analysis of 10433 patients. Evolution of gender differences and 
malignancy. Eur J Cancer. Jul 2002;38(10):1388-1394.
 4. MacKie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: 
an epidemiological study. Lancet. Aug 24 2002;360(9333):587-591.
 5. Smith JA, Whatley PM, Redburn JC. Improving survival of melanoma patients in Europe since 1978. 
EUROCARE Working Group. Eur J Cancer. Dec 1998;34(14 Spec No):2197-2203.
 6. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an impor-
tant measure of population burden--and should be considered when allocating research funds. Br J 
Cancer. Jan 31 2005;92(2):241-245.
 7. Brochez L, Myny K, Bleyen L, De Backer G, Naeyaert JM. The melanoma burden in Belgium; prema-
ture morbidity and mortality make melanoma a considerable health problem. Melanoma Res. Dec 
1999;9(6):614-618.
 8. Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator 
of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol. Aug 1990;23(2 Pt 
1):308-310.
 9. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity 
analysis and future directions. Bull World Health Organ. 1994;72(3):495-509.
 10. Kiemeney LA, Lemmers FA, Verhoeven RH, et al. [The risk of cancer in the Netherlands]. Nederlands 
tijdschrift voor geneeskunde. Oct 11 2008;152(41):2233-2241.
 11. Barendregt JJ, Van Oortmarssen GJ, Vos T, Murray CJ. A generic model for the assessment of disease 
epidemiology: the computational basis of DisMod II. Population health metrics. Apr 14 2003;1(1):4.
 12. WHO. Gobal Burden of Disease 2004 update: Disability weights for diseases and conditions; 2004.
 13. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-
related quality of life in cutaneous melanoma. Ann Oncol. Aug 2009;20 Suppl 6:vi51-58.
 14. Holterhues C, Cornish D, van de Poll-Franse LV, et al. Impact of melanoma on patients’ lives among 
562 survivors: a Dutch population-based study. Arch Dermatol. Feb 2011;147(2):177-185.
Cynthia BW 7.indd   137 28-09-11   13:35
Burden of 
of
Melanoma
Cynthia BW 7.indd   138 28-09-11   13:35
Burden of Melanoma
Burden of 
of
of Melanoma
Melanoma
10
 General discussion
Cynthia BW 7.indd   139 28-09-11   13:35
Cynthia BW 7.indd   140 28-09-11   13:35
General discussion
Ch
ap
te
r 1
0
141
general discussion
epidemiology
The incidence of melanoma has been rapidly rising, (chapter 1) and will continue to rise, at 
least until 2015 (chapter 2). The highest incidence rates for melanoma were reported for the 
populations living in Western and Northern Europe, most far away from the equator. It is one 
of the fastest increasing cancers in terms of incidence in the Western World, almost doubling 
between 1989 and 2005 in the Netherlands. Cutaneous melanoma might even become more 
frequent than squamous cell carcinoma, then becoming the most common malignancy after 
basal cell carcinoma in the Netherlands (chapter 1). 1-2
The Netherlands cancer registry has an excellent track record in the nationwide registration of 
cancer incidence (>95% of skin cancers). It is quite unique that one of the eight comprehensive 
cancer centers in the Netherlands, the Eindhoven Cancer Registry even records the occurrence 
of newly diagnosed basal cell carcinomas since the early 70’s.1, 3 This wealth of data has led to 
many important publications on the epidemiology of skin cancer in the Netherlands in the 
last two decades.4-7 Unfortunately, skin cancers are not always as well registered with cancer 
registries across Europe, as they do not all have a national coverage, especially not in the bigger 
countries of Europe like Germany, France, Poland , Italy and Spain. This leads to difficulties with 
the generalization of melanoma incidence between different countries, because there can be 
substantial regional variation, which is even present in a small country like the Netherlands.8 
Furthermore, there is delay of up to 3 years between recording with the cancer registry and 
publishing incidence numbers. Considering the rising trends in incidence, the most recently 
reported incidence rates are likely to be an underestimation of the real incidence rates in 2011. 
Prediction models such as those developed by Dyba et al 9-10, might be used to correct for the 
registration delay.
In order to estimate the incidence of melanoma one needs to have accurately reported 
melanoma diagnoses. Yet, some colleagues like G Welch (in the USA) question the existence 
of a true “melanoma epidemic” in the USA.11 They state that the increase in melanoma rates is 
mainly attributable to thin melanomas in most western countries and mainly due to intensive 
screening by physicians and patients and over-diagnosis by pathologists. Quite a few in situ or 
thin melanomas would in fact not be true melanomas, and therefore inflate the incidence of 
melanoma 12. But one could also say that the increase in thin melanoma is due to an increased 
awareness and patients’ are being diagnosed at an earlier stage, as mortality due to melanoma 
is stabilizing in some countries. Furthermore, analyses across Europe showed that the incidence 
of cutaneous melanomas is also increasing in countries that have no screening programmes or 
well organized health care, thus making it unlikely that the incidence of melanoma has risen just 
due to intensive screening (chapter 2). Also, trend analyses of cutaneous malignancies showed 
that the UV related malignancies (including melanoma) increased significantly in contrast to 
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the non-UV related tumours, suggesting that the incidence rise of melanoma was largely due 
to excessive UV-exposure is real (Chapter 1).
Mortality rates have stabilized in some countries but seem to be increasing still among 
people over the age of 65 years.1 Contrary to observations from many other Western countries, 
mortality rates are still increasing in the Netherlands. Recently, Hollestein et al. showed that the 
incidence of melanoma increased among all Breslow categories followed by a rise of melanoma 
mortality.1 It is therefore likely that countries with a high mortality/incidence ratio, caused by 
higher incidence of more advanced stages of melanoma, still have a too low awareness for 
which there are limited treatment options available.
Patient perspectives of having been diagnosed with melanoma
Health Related Quality of Life
For decades outcome measures such as recurrence and survival have been used to evaluate 
treatment effects in patients with cancer. However, these traditional outcome measures do not 
fully capture patients’ experiences. Since more and more cancers are treatable, cancer survivors 
are living longer with their (history of ) cancer and the effects of its treatments and adverse 
events. Patient reported outcomes (PROs) are therefore becoming increasingly important as an 
addition to clinical outcomes in disease management. This is also true for melanoma patients of 
whom the majority (>70%) survives their melanoma and may live with this diagnosis, often for 
several decades (chapter 8). The mean age at diagnosis of melanoma patients is also relatively 
young (~ 53 years chapter 1) compared to that of other cancers. This, combined with the good 
prognosis of most melanoma patients implies that a high proportion of patients will live many 
years with the diagnosis of melanoma and that survivors of melanoma may live with a more or 
less chronic condition of varying severity that might affect the quality of their lives. Melanoma 
can have an impact on a patients’ psychological well-being through anxiety for recurrence or 
progression, symptoms due to scarring, and be bothered by practical issues such as obtaining 
a mortgage of life insurance.
Evaluating PROs among melanoma patients, such as health related quality of life (HRQoL) might 
give a better impression of the influence a disease has on a patients’ physical and physiological 
well-being.
The HRQoL of cancer patients’ depends on many personal factors, such as a person’s HRQoL 
before the cancer diagnosis, their personality (e.g., ability to cope with the disease burden) and 
a supportive environment. HRQoL impairment has also been reported to be associated with 
poor recovery, increased morbidity and even disease progression in melanoma patients.13-14 
Improving HRQoL may lead to more satisfied patients and potentially have survival benefit and 
lead to reduced health care consumption.
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Our work on HRQoL of melanoma patients revealed that only since ten years there is an inter-
est in accurately reporting HRQoL of melanoma patients (Chapter 3).15 Furthermore, the few 
existing studies were limited by small sample sizes, selected patient populations, short term 
observations, and were based on patients treated in specialized centers. But the amount of 
large population-based studies on HRQoL in melanoma patients is slowly rising. We were one 
of the first to report the HRQoL in long term melanoma survivors (Chapter 4), showing that 
melanoma can have an impact on patients’ up to ten years after diagnosis.16 Most previous 
studies had used generic questionnaires only such as the SF-36 and the EORTC-QLQ C30. How-
ever, impact of melanoma seems to be fairly specific and is not driven by (long-term) adverse 
treatment effects that affect generic or cancer-specific HRQoL aspects. It is probably, therefore 
that several studies showed that HRQoL of melanoma patients, measured with generic ques-
tionnaires, seems comparable to that of normative populations 17. People who survive cancer 
(or another life changing event) are likely to evaluate HRQoL more positively than those who 
never had cancer (which is called response shift)18-19. In contrast to outcomes from generic 
questionnaires, long term melanoma survivors reported a relatively large and persistent impact 
on the melanoma specific questions regarding life style changes (related to UV exposure and 
anxiety of UV exposure), practical issues such as getting insurances, and anxiety for relapse 
of melanoma. This discrepancy between generic and melanoma-specific items illustrate that 
reporting HRQoL impairment in melanoma patients suffered from the lack of a standardized 
melanoma specific HRQoL questionnaire and that the generic measures lack content validity 
for most melanoma survivors. This might be the reason why HRQoL studies have made use of a 
variety of different HRQoL questionnaires (Chapter 3). The FACT-M questionnaire was the only 
questionnaire validated in melanoma patients, but was developed for the use in clinical trials of 
patients with advanced disease.20 Therefore, it focuses mainly on physical impairment which is 
more frequent in patients with advanced stage III or IV melanoma and very limited in patients 
with lower stages. However, over 70% of melanoma patients will be diagnosed with fairly thin 
melanoma and therefore have a relatively good prognosis.1, 21 Moreover, these patients with 
low stage disease are treated with localized surgery (but increasingly followed by sentinel node 
exploration) that has few complications and little long term side effects.
In addition to TNM stage of melanoma and melanoma-therapies, other patient characteristics 
may affect a patients’ HRQoL as well. Women report more extreme (positive and negative) 
impact of cancer on HRQoL than men. Secondly, men are diagnosed at a later age and with 
higher stages of melanoma; they might thus be less aware of the potential severity of being 
diagnosed with melanoma. Higher social economic status has also been associated with higher 
melanoma risk and better HRQoL.22-23 Having a distressed personality (Type D personality) has 
a distinctive negative impact on ones’ health status as measured by the SF-36 (Chapter 5). The 
awareness should be raised for these patients with a higher risk for impaired HRQoL as they 
might need extra care.
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Overall, it should be noted that in order to correctly estimate HRQoL of melanoma patients, 
one should use a melanoma specific HRQoL questionnaire that is also applicable to early stage 
melanoma cancer patients and survivors, which is currently non-existent in a standardized form 
for population based use. We have identified gaps in the literature on HRQoL among melanoma 
patients (chapter 3) and demonstrated that generic HRQoL measures did not reflect the impact 
of melanoma well. However, we did not introduce a new melanoma specific HRQoL instrument, 
which is very much needed for daily practice and/or clinical trials. The development of such an 
instrument would require an evaluation of the various domains of HRQoL (e.g. psychological, 
physical, daily life) that might be influenced by the melanoma, based on previous studies, but 
more importantly to evaluate patient and physician’s experiences on the impact of melanoma 
on patients’ lives. Furthermore, the questionnaire should be a helpful instrument in daily 
medical practice, which measures the need of patients for additional care such as psychological 
support. Currently the Quality of Life Group of the European Organisation for Research and 
Treatment of Cancer (EORTC) is developing such a questionnaire based on our findings.
Follow-up and information provision
Physicians play an important role in how patients cope with their cancer diagnosis. Patients 
experience the most distress in the first few months during time of diagnosis and following treat-
ment.24-26 Patients are confronted with a potentially deadly disease and need to be informed 
on their treatment options and prognosis, to cope with their disease optimally. Unfortunately, 
it has been shown that patients are often not satisfied with the information they have received, 
especially information regarding diagnosis and treatment.17, 27 A large study by Schlesinger, 
among 664 disease free melanoma patients found that two third of the patients desired more 
communication with someone who was involved in the treatment, care and attendance of the 
patient. Furthermore, more than half of these patients did not feel fully informed about their 
illness, which is comparable to reports of Dutch melanoma patients found in our study (Chapter 
6). These uncertainties on what to expect of their diagnosis as well as of their treatment might 
result in additional distress among melanoma patients.
According to the Dutch melanoma Study Group guideline, providing patients with information 
regarding their disease, treatment and prognosis by their physicians, is one of the main reasons 
of the follow-up of melanoma patients. The Dutch melanoma guideline of 2005 recommends 
patients with a melanoma with a Breslow depth <1.00mm to have one follow-up visit after 
treatment to be fully informed about their disease and to receive instructions for self examina-
tion of the lymphnodes and skin . Francken et al. showed that patients who are well informed 
on how to recognize a (new primary) melanoma were more capable to detect recurrences of 
their melanoma or new primary melanomas.28-29 This might lead to better survival and even to 
a reduction in number of follow-up visits needed, suggesting that informing patients properly 
is worthwhile. Subsequently, this may also lead to less distress.
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Optimal delivery of information on a potentially lethal disease to a patient in distress is chal-
lenging. In our study more than half of the patients were not satisfied with the information they 
received on diagnosis and treatment (chapter 6). The communication between patients and 
their health care providers needs to be improved and structured.17 A “survivorship care plan” 
can help to improve patient empowerment and has been introduced for several types of cancer 
patients to structure the follow-up care of cancer patients and to educate patients on their 
diagnosis and treatment.30-31 A survivorship care plan is a personalized document of a patient 
with cancer, providing the patient with information regarding their diagnosis, treatment and 
prognosis. It also contains information on patient association groups and contact information 
of important health organizations. The information implemented in the survivorship care plan 
is carefully selected by physicians and patients who have considered the information helpful. 
This type of information provision might help to structure the information provision from 
physician to patient and it provides the patient with a quick reference-book. A survivorship 
care plan for melanoma patients and their relatives is likely to improve patients’ HRQoL and 
reduce their distress.
the burden of melanoma on society
Melanoma has an impact on the individual patient (e.g., treatment, survival, and HRQoL) but 
also places a burden on society in terms of treatment costs, demands on the healthcare system, 
days of work lost due to treatment, years of life lost, etc. There is a large group of patients being 
diagnosed at a relatively young age, with a potentially deadly disease that affects one’s life 
for many years. The amount of years living with the disease/diagnosis is increasing as patients 
are diagnosed at an earlier age and life-expectancy in general is increasing. This increasingly 
large group of patients will require health care and assistance in coping with their disease. 
Unfortunately, there is no consensus on how to deal with these patients and how to prevent 
unnecessary health care consumption as is illustrated by the diversity of follow up regimens 
(i.e., frequency and duration of follow up ranging from 2 to 4 times per year for 5 to 10 years) in 
the different national melanoma guidelines across the world.32-33 The Dutch melanoma guide-
line is one of the most medically restrained reserved guidelines of Europe with one follow-up 
visit recommended 3 months after treatment for 70% of melanoma patients (those with stage 
I disease) and additional X-rays or (ultrasound) scans are made only when considered clinically 
necessary by the treating physician. Other European countries are used to more frequent follow-
up visits and routine X-rays and CT-scans and even PET scans during follow-up. 34-35 Whether 
or not this difference in follow-up affects melanoma mortality remains unknown, as there is no 
study available that compares the different approaches of melanoma patients and their disease 
free survival. However, differences between guidelines with regards to follow-up frequency and 
contents of the visits are not likely to greatly influence patients’ prognosis as survival studies 
did not show large differences in survival across most European countries.1, 36-40 It is more likely 
that in time survival of melanoma patients will be influenced by treatment effects. 41-43 For 
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now, intense monitoring has the disadvantage of detecting false positive events that need 
further (invasive) investigations and makes patients unnecessarily worry about the outcome 
in the absence of a therapeutic consequence. This conservative attitude may change with the 
introduction of new effective therapies of advanced melanoma.
A large group of our patients (15-30%) reported to experience difficulty obtaining health insur-
ance, life insurance or a mortgage. A few patients also reported to have felt the necessity to 
change or adapt their working environment (chapter 4), which can cause financial problems for 
an individual and affects society as well. A study in the United States by Seidler et al44, assessing 
the economic burden on melanoma in 1858 people of 65 years and older, based on the SEER- 
Medicare data (Surveillance, Epidemiology, and End Results) showed that mainly late stage 
melanoma presented a significant economic burden in the elderly population, resembling the 
costs of colon cancer.
Mortality due to melanoma mainly occurs in this group of elderly people. In 2008, approxi-
mately 50% of people who died from malignant melanoma in the Netherlands were older than 
65 years (www.ikcnet.nl). The sample of patients in the study by Seidler et al. accounted for 
12% of elderly in the United States. Direct annual costs were estimated to be $ 249 million. 
Observed life-time costs per-patient were $ 28 210 (during an average survival of 26 months). 
Costs included: office visits and consultations, imaging by radiology, laboratory tests, visits to 
the emergency department, hospital stay and treatment costs (surgery, chemotherapy and 
external radiation). Costs were lower with lower stages. However, the costs made by patients 
in de US are difficult to compare with health care costs of other countries, as there are great 
differences in availability of health Insurance. It is for this reason that cost-effectiveness analysis 
should be done for each country separately.
Francken et al 45 found that only taking a medical history and performing a physical examina-
tion seems to be cost effective in patients with localized disease. Instructing patients to detect a 
recurrence themselves could be cost effective as they might need lesser follow-up visits. In her 
study patients were diagnosed at an earlier stage which is reducing the melanoma associated 
costs. However, economic evaluations often included direct medical costs (from an insurers 
perspective) but did not consider patients’ HRQoL (i.e., QALYs were not calculated) making 
it difficult to construct informed choices based on these studies. It seems obvious that the 
aforementioned survivorship care plans are of even more interest if the frequency of follow 
up visits should be (further) reduced as it provides the opportunity to instruct patients on self-
examination.
A well known measure of disease burden is QALY (Quality Adjusted Life Years), which includes 
both the quality and the quantity of years of life lived. In addition to QALY’s, the WHO has 
recommended to use burden of disease expressed by disability adjusted life years (DALY) to 
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compare the impact of different diseases consistently. DALYs are time-based measures which 
combine years of life lost due to premature mortality and years of life lost due to time in states 
of less than full health.46 Both concepts may be important in the allocation of limited health 
care resources. An advantage of measuring burden of disease compared to QALY is that DALYs 
are less influenced by the direct costs related to follow-up and treatments.
For melanoma we have now demonstrated that DALYs for burden of disease for melanoma 
are comparable with other more common cancers, such as breast cancer and prostate cancer 
(chapter 8). This is surprising as people in the general population but also physicians are consid-
ering cutaneous melanoma as a generally easy to treat disease with relatively good prognoses 
for most patients.
Estimating the degree of someone’s disability in life is extremely difficult but necessary 
for evaluating the impact of different diseases on society. However, both QALY and DALY use 
generic QoL questionnaire in assessing the burden of disease. Therefore, a melanoma specific 
QoL instrument should be considered within weighing the disability factor for calculations of 
burden of diasease, as additional care to cope with melanoma contributes to the costs.
Currently, the disability weight of a disease in different phases of disease (diagnosis and 
treatment, preterminal, terminal phase), used for estimating DALYs is established by a group 
of experts, and weighed against disability caused by other cancers. This is quite strange as 
different types of cancer have different treatment options, different kind of follow-up and 
different survival rates. These characteristics of a disease will influence the psychological and 
physical well-being of a patient quite differently, depending on the type (and stage) of cancer. 
The experts of the burden of disease project also considered that the disability of a disease 
decreases immediately when a follow-up period is completed. Most likely this leads to an 
underestimation of the burden melanoma has on a patients’ life. Therefore, we have calculated 
the years lived with melanoma (YLM), without correction of the disability weight, to get an 
impression of the actual years that patients live with melanoma. Additionally, we calculated 
the years of life lived with disability (YLD) with use of the disability weight 0.05 (from time of 
diagnosis until death). However, the disability weight should be raised considering that the 
current disability weight does not take HRQoL and influence on daily practice into account.
future perspectives
With this thesis we have made the following contributions to the current epidemiology and 
quality of life research on melanoma: We have placed the incidence of melanoma into the 
perspective of the rising incidence rates of other skin cancers, showing that the incidence 
of melanoma rises more rapidly than other types of skin cancer. Our study showed that the 
incidence of all UV-related skin cancers has risen rapidly in the past years, whereas the non-UV 
related skin cancers exhibited a stable incidence. Trend analyses showed that the incidence 
of melanoma will continue to rise across different European countries with great differences 
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in availability of health care and registries between them. This shows that the incidence of 
melanoma is not just rising because of early detection and better registration or even over-
detection as has been suggested previously. There is a need for effective health care campaigns 
that raise the awareness of the deleterious effects of UV-exposure. It is still of importance that 
over-exposure to UV-radiation is avoided.
The doubts regarding the existence of a real melanoma epidemic could also be reduced by 
improving cancer registration in the various areas of the European Union. Upon evaluating the 
cancer registration data, large variations between registries in coverage, registry of stage and 
survival data appeared, making it difficult to compare data from different countries in much 
more depth than age-adjusted incidence data. There is need for uniformity in registration of 
cancer data, such as registering melanoma incidence ideally according to the AJCC classifica-
tion.47 Furthermore, monitoring applied treatments and the occurrence of second primary 
melanomas would be an indicator of treatment effect and prognosis, which are difficult items 
to register but would offer a wealth of possibilities for cancer surveillance, particularly now 
that new treatments for advanced melanoma are expected to be introduced in the short term. 
Uniformity in registering cancer data would improve the generalizability and is of great impor-
tance for the introduction and evaluation of new treatments and follow-up plans. However, this 
uniformity of intense registration will bring additional costs which might be the reason why 
cancer registries are restricted in their way of registering new primary melanomas.
The increasing group of melanoma patients that require health care puts a great burden on 
health care providers. Considering HRQoL and burden of disease for melanoma, the burden 
that melanoma has on an individual patient as well on society is comparable to those of other 
more common cancers. The prognosis of most melanoma patients who are diagnosed at an 
early stage, is relatively good as illustrated by Hollestein et al1 (relative survival of 77% for men 
and 88% for women), but still these patients have to deal with their diagnosis and the anxiety of 
recurrence for many years.37 Melanoma can be seen as a chronic disease that has a great impact 
on daily life, as shown by the high number of years lived with disability (YLD) (chapter 8).
We have shown that measuring HRQoL of melanoma patients is diverse and influenced by 
several patient characteristics (e.g. sex, co-morbidity and personality). Generic QoL instruments 
seem to be unable to detect the true impact of melanoma on a patients’ life. Furthermore, it 
seems that melanoma can have a long term (up to ten years) influence on a patients’ well-
being.(chapter 4) Health care providers should be aware that characteristics, such as sex and 
personality, of their patients could have negative influence on their treatment effects and that 
these patients might need additional care. They should also be aware that patients are affected 
by their diagnosis long after they have completed their treatment and/or follow-up and might 
need additional care. However, we have also detected a lack in communication between health 
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care providers and melanoma patients.27 Improving communication might improve HRQoL of 
melanoma patients in general and allow health care providers notice the need for additional 
care earlier.24, 48-49
Including patients’ perspectives in clinical decision making requires the creation of a melanoma 
specific HRQoL instrument that can be used in the entire spectrum of melanoma patients. 
This is now even more important because it allows to measure, in addition to using generic 
measures, the impact of the new and costly therapies for advanced melanoma, that recently 
appeared to be effective 41-43, 50 Moreover, such a questionnaire could be part of monitoring 
melanoma patients with or without a survivorship care plan. Increasing patient education on 
diagnosis, treatment and how to detect recurrence of melanoma by introducing a survivorship 
care plan is likely to improve patient care and to result in more satisfied patients while not 
increasing their health care consumption.
There is a tension between minimizing costs and being cost-effective. A restricted melanoma 
guideline, such as the Dutch melanoma guideline of 2005, is based on the limited available 
evidence on detecting recurrence of melanoma (i.e., disease progression) and melanoma 
survival. However, minimal follow-up may also lead to dissatisfaction with care, distress and 
reduced HRQoL in some melanoma patients. Increasing the frequency of follow up, which is 
relatively inexpensive, (and to a lesser extent expanding technical investigations during these 
visits) may result in more satisfied and better informed melanoma patients that are less affected 
by their melanoma.
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 summary
Melanoma is one of the most common but also the most deadly type of skin cancer. It currently 
aff ects about 15% of the Caucasian population, and the incidence is increasing annually with 
4-5%. The exact pathogenesis of melanoma is still unknown; both UV-exposure and genetic 
mutations seem to play a role, especially in familial melanoma. Primary treatment of melanoma 
is surgery, but therapy for metastasized melanoma is limited, leading to a poor prognosis. 
However >70% of melanoma patients will be diagnosed with a thin melanoma and have to 
live many years with the consequences of being diagnosed with melanoma. Therefore, it can 
have a great impact on a patients’ quality of life but also on society, as this group of patient who 
require treatment and after care is rapidly increasing. This thesis describes the epidemiology of 
melanoma in the Netherlands and in Europe. It also describes patient perspectives on having 
been diagnosed with melanoma and the impact it has on an individual patient as on society.
ePidemiology
chapter 2 describes the incidence and trends in incidence of all skin malignancies in the Neth-
erlands between 1989 and 2005, based on data provided by the Netherlands Cancer Registry. 
A total of 356,620 skin tumors were diagnosed between 1989 and 2005. Excluding basal cell 
carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma, the remaining skin tumors 
constituted about 2% of all skin malignancies. The incidence of melanoma showed the steep-
est increase, with incidence rates approaching the European standardized incidence rate of 
SCC. The incidence of UV-related skin tumors increased signifi cantly and more steeply than did 
those of other skin malignancies, which is contradicting with assumptions that the incidences 
are rising due to misdiagnosis and early diagnosis.
Predictions based on data provided by cancer registries across Europe, showed that the 
incidence of melanoma has risen and is expect to continue to do so until 2015 (chapter 3). 
The highest incidence rates have been reported for countries in Northern and Western Europe. 
Estimations of the occurrence of more advanced stages of melanoma by calculating the 
mortality/incidence ratio showed that advanced stages of melanoma may be more frequent 
in Eastern European countries. Results showed that melanoma can be seen as a true epidemic 
across Europe.
Patients’ PersPectiVes of haVing Been diagnosed with melanoma
chapter 4 describes the fi ndings of a systematic review on the available literature on health-
related quality of life (HRQoL) and melanoma. Thirteen studies were selected out of 44 articles. 
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Studies were written in English and published between 2001 and 2008. Most studies assessed 
patients from specialised centres with varying, but relatively advanced, disease stages. The 
most commonly used instruments were the SF-36 and EORTC QLQ-C30. Studies showed that 
approximately one-third of melanoma patients experienced considerable levels of distress, 
mostly at the time of diagnosis and following treatment. Systemic therapies affected HRQoL 
negatively in the short term, but to a lesser extent in the long term. Health status and patients’ 
psychological characteristics were associated with higher levels of HRQoL impairment. Further-
more, the impact of melanoma on patients’ HRQoL seems to be comparable to that of other 
cancers. 
In chapter 5 we describe the findings of our cross-sectional study assessing the impact 
of melanoma on HRQoL of melanoma survivors from the general population in the south 
Netherlands. With use of the Eindhoven Cancer Registry, 699 melanoma survivors, diagnosed 
with melanoma between 1998 and 2008 were invited to participate. Eighty percent op patients 
were willing to participate. Patients were asked to fill out a postal survey that included the 
36-Item Short-Form Health Survey (SF-36), Impact of Cancer (IOC) questionnaire and specific 
melanoma-related questions. The average age of respondents was 57.3 years, 62% was female 
and 76% was diagnosed with a thin melanoma (Brelow thickness < 2mm)
The SF-36 component scores of patients with melanoma were similar to those of the norma-
tive population. In a multiple linear regression model, stage at diagnosis, female sex, age, and 
comorbidity were significantly associated (P 0.05) with the physical and mental component 
scores. Women were significantly more likely to report higher levels of both positive and 
negative impact of cancer. Time since diagnosis, tumor stage, and comorbidity were significant 
predictors of negative IOC scores. Women also seemed to have adjusted their sun behaviour 
more often (54% vs. 67%; P 0.001) than men and were more worried about the deleterious 
effects of UV radiation (45% vs. 66%; P 0.001). In conclusion, the impact of melanoma seemed 
to be specific and more substantial in women, suggesting that they may need additional care 
to cope with their melanoma optimally.
chapter 6 describes the findings of a cross-sectional study on the prevalence of Type D 
personality (the conjoint effects of negative affectivity and social inhibition) among melanoma 
survivors. Furthermore the study aimed to obtain insight into its effects on health status, 
impact of cancer and health care utilisation. All patients diagnosed with melanoma between 
1998 and 2007 from three large regional hospitals in the Netherlands were selected. In total, 
699 survivors, alive in January 2008, received a questionnaire including Type D personality scale 
(DS14), impact of cancer questionnaire (IOC) and SF-36, of whom 80% responded. Twenty-two 
percent of survivors were classified as having a Type D personality. They reported a clinically 
and statistically significant worse general health (57.8 vs. 75.6), social functioning (73.1 vs. 88.7), 
mental health (61.7 vs. 80.6), more emotional role limitations (67.8 vs. 89.4) and less vitality 
(54.5 vs. 72.8) than non-Type D patients. Additionally, they reported a statistically and clinically 
relevant higher impact of cancer on body changes, negative self-evaluation, negative outlook 
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on life, life interferences and health worry. Furthermore, they were more worried about the 
influence of the sun on their skin and acted accordingly. No differences were found in health 
care utilisation.
Type D personality seems to have a distinct negative impact on health status in melanoma 
survivors and might be an important factor to screen for in clinical practice. Giving special 
attention to these patients is important while they are more likely to experience a strong 
impact of cancer which cannot be explained by socio-demographical or clinical characteristics.
The perceived level of and satisfaction with received information was investigated in a 
cross-sectional study among 562 melanoma survivors, with use of the EORTC-QLQ-INFO26 
questionnaire (chapter 7). Melanoma survivors indicated that they received no information 
about different aspects of their disease (9-37%), treatment (38%) and aftercare (84-94%). More 
than half of the survivors (61%) were not or only a little bit satisfied with the amount of informa-
tion received; a quarter of the patients indicated that they wanted to receive more information. 
The amount of information perceived was associated with a higher disease stage, less years 
since diagnosis, higher educational level and younger age, while satisfaction with information 
was associated with hospital of treatment, higher educational level and use of the internet. 
Several areas of information disclosure are underexposed and a majority of the melanoma 
survivors is not satisfied with the received information. More patient-tailored information 
disclosure is needed in order to give every patient the most optimal information. In addition, 
attention must be paid to patient characteristics that might influence information disclosure. A 
good opportunity for appropriate information disclosure is the implementation of a survivor-
ship care plan. 
In chapter 8 we discuss patients’ perspectives of melanoma patients on follow-up according 
to the guideline of 2005, in a Dutch population from the south-east area of the Netherlands. The 
patients’ satisfaction over said follow-up was also taken into account. Melanoma survivors were 
questioned about treatment, symptoms, impact on daily life and follow-up. Sixteen patients 
with multiple melanomas were excluded as it could influence the reported outcomes. Of 546 
respondents, 418 survivors were still under surveillance for their melanoma. The average time 
since diagnoses was 4 years and 71% had stage I melanoma. Almost 80% of patients with a 
Breslow thickness <1mm, reported more frequent follow-up visits than recommended by the 
Dutch melanoma guideline of 2005. Only 5% of the patients wanted to reduce their amount of 
follow-up visits. Most patients were under supervision of a dermatologist. They reported that 
physical examination, lymph node palpation and/or scar inspection did not regularly occur in 
25%, 11% and/or 20%, respectively. These proportions were significantly higher among other 
specialisms.
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Burden of melanoma
chapter 9 describes the burden of disease in Dutch melanoma patients. Burden of disease 
describes loss of health and death due to a disease which had not been adequately studied for 
melanoma. 
For this study age- and gender-specific incidence data from all patients diagnosed with 
melanoma in the Netherlands between 1989 and 2006 were obtained from the Netherlands 
Cancer registry. Mortality numbers and rates were extracted from the Statistics Netherlands 
database. Life tables with the probability of developing a melanoma were calculated per 
5-year period with use of the DevCan software. The standard life expectancy for both men and 
women per 5-year age group were estimated using DISMOD software. The Years of Life lived 
with Disability (YLD) and Years of Life Lost (YLL) due to melanoma were calculated using these 
life tables and life expectancies. The disability adjusted life years (DALY), a general measure for 
the burden of a disease, was estimated by adding YLD and YLL. 
The incidence of melanoma almost doubled between 1989 and 2006 (cumulative incidence 
rate increased from 1.03-1.31% to 2.02-2.11%). The burden of melanoma to society increased 
rapidly between 1989 and 2006. On average, patients lived 21.6-28.2 years with a melanoma 
diagnosis. Melanoma resulted in a loss of 17.8-20.1 years per before the age of 95, for those that 
died of their melanoma. 
In chapter 10 the findings of the studies presented in this thesis are discussed and placed 
into perspective. The value of registering cancer incidence is discussed and whether or not 
melanoma can be seen as a true epidemic. The diversity in patient characteristics that seems 
to influence the HRQoL of melanoma patients, are making it difficult to establish the HRQoL of 
melanoma patients in population based studies. The need for a melanoma specific question-
naire to capture the impact of melanoma on a patients’ live, is pointed out. Also, the satisfaction 
of melanoma patients with the received follow-up and information on treatment and diagno-
ses is discussed. The discussion ends with future perspectives that include the development 
of a melanoma specific questionnaire which can be used in clinical practice and population-
based studies. Moreover, the development of a possible survivorship care plan is suggested 
to improve the communication between melanoma patients and their health care providers. 
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samenvatting
Het melanoom is een van de meest voorkomende en een van de meest dodelijke vormen van 
huidkanker. Ongeveer 15% van de blanke bevolking wordt gediagnosticeerd met een mela-
noom, deze incidentie stijgt met 4-5% per jaar. De exacte pathogenese van een melanoom is 
nog steeds onbekend, zowel blootstelling aan UV-straling als genetische mutaties lijken een 
belangrijke rol te spelen. Chirurgie is eerste keus behandeling, maar de behandeling van het 
gemetastaseerde melanoom is beperkt, wat leidt tot een slechte prognose. Echter, meer dan 
70% van de patiënten wordt gediagnosticeerd met een dun melanoom en zal nog vele jaren 
met de gevolgen van een melanoom leven. Een melanoom kan dus veel invloed hebben op de 
kwaliteit van leven van en individuele patiënt, maar ook op de algemene bevolking wanneer 
deze mensen meer nazorg nodig hebben. 
Dit proefschrift beschrijft de epidemiologie van melanoom in Nederland en in Europa. 
Tevens wordt het perspectief van patiënten gediagnosticeerd met een melanoom belicht en 
invloed die melanoom heeft op het dagelijks leven van de patiënt als wel op de maatschappij.
ePidemiologie
In hoofdstuk 2 beschrijven we de incidentie en trends in incidentie van alle maligne huidtu-
moren in Nederlands gediagnosticeerd van 1989-2005, gebaseerd op data van de Nederlandse 
Kankerregistratie. In totaal werden 356 620 huidtumoren gediagnosticeerd tussen 1989-2005. 
De incidentie van zeldzame huidtumoren bedroeg 2%. The incidentie van melanoom toonde 
de sterkste stijging met incidentie rates die de incidentie rates van het plaveiselcelcarcinoom 
sterk benaderen. De incidentie van UV- gerelateerde tumoren toonde sterkere toename in 
incidentie dan andere maligniteiten. Dit spreekt tegen dat de toename in incidentie van 
huidtumoren veroorzaakt zou worden door verkeerde diagnoses en diagnoses van een vroeg 
stadium melanoom.
Berekeningen gebaseerd op data aangeleverd door verschillende kankerregistraties in 
Europa (hoofdstuk 3), laten zien dat de incidentie van melanoom is toegenomen en zal blijven 
toenemen tot 2015. De hoogste incidentiecijfers werden gezien voor Noord en West-Europa. 
Schattingen van het voorkomen van gemetastaseerde melanomen door de mortaliteit/
incidentie ratio uit te rekenen, laten zien dat stadium III en IV melanomen mogelijk meer voor-
komen in Oost Europese landen. 
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het PersPectief Van Patiënten oVer gediagnosticeerd zijn met een 
melanoom
hoofdstuk 4 beschrijft de beschikbare literatuur over kwaliteit van leven (KvL) van melanoom-
patiënten. Er werden 13 studies geselecteerd van 44 artikelen. De studies waren geschreven in 
het Engels en gepubliceerd tussen 2001 en 2008. De meeste studies beschreven resultaten van 
patiënten van gespecialiseerde klinieken met verschillende, maar relatief vaak vergevorderde 
stadia van melanoom. The meeste frequent gebruikte vragenlijsten waren de SF-36 en de 
EORTC QLQ-C30. De studies beschreven dat ongeveer een derde van de melanoompatiënten 
hoge mate van stress beleven vooral tijdens de periode rondom diagnose en behandeling. 
Systemische therapieën beïnvloeden KvL voornamelijk negatief op korte termijn, maar minder 
op lange termijn. Gezondheidsstatus en de psychologische karakteristieken van een patiënt 
waren geassocieerd met beperkte KvL. Tevens lijkt de invloed van melanoom op KvL van 
patiënten net zo van invloed te zijn als andere kankers.
In hoofdstuk 5 wordt een cross-sectionele studie beschreven die de invloed van melanoom 
op KvL van melanoompatiënten uit de algemene bevolking in het zuiden van Nederland 
beschreven. Met behulp van het Integraal Kankercentrum Zuid in Eindhoven werden 699 
melanoompatiënten, die gediagnosticeerd waren met een melanoom tussen 1998 en 2008 
aangeschreven. Tachtig procent van de patiënten was bereidt om mee te werken aan de studie. 
Patiënten werd gevraagd om een vragenlijst in te vullen die de 36-Item Short-Form Survey 
(SF-36) en de Impact of Cancer (IOC) vragenlijsten bevatten en een aantal melanoomspecifieke 
vragen. Patiënten waren gemiddeld 57,3 jaar, 62% was vrouw en 76% was gediagnosticeerd 
met een dun melanoom (Breslowdikte < 2mm). De SF-36 component scores van melanoom-
patiënten ware vergelijkbaar met de scores van de normatieve populatie. Ine en multipele 
lineaire regressie model waren stadium, vrouwelijk geslacht, leeftijd en comorbiditeit signifi-
cant geassocieerd met de lichamelijke en mentale component scores van de SF-36. Vrouwen 
rapporteerden significant hogere levels op zowel de negatieve als positieve schalen van de 
impact of cancer vragenlijst. Tijd sinds diagnose, stadium en comorbiditeit waren significante 
voorspellers van negatieve invloed van kanker. Vrouwen rapporteerden dat ze vaker hun 
zongedrag hadden aangepast en meer angst te hebben voor de schadelijke effecten van de 
zon dan mannen. Een melanoom heeft een specifieke invloed op het leven van een patiënt en 
lijkt invloed te hebben op vrouwen. Dit suggereert dat zij mogelijk meer behoefte hebben aan 
nazorg om te kunnen omgaan met de diagnose melanoom.
hoofdstuk 6 beschrijft de resultaten van een cross-sectionele studie naar de prevalentie 
van Type D persoonlijkheid (de gelijktijdige aanwezigheid van zowel negatieve affectiviteit en 
sociale inhibitie) onder melanoompatiënten. Tevens was het doel om meer inzicht te krijgen 
in de invloed van gezondheidsstatus, invloed van kanker en consumptie van de gezondheids-
zorg. Alle patiënten gediagnosticeerd met een melanoom tussen 1998 en 2007 in een van de 
3 regionale ziekenhuizen in Nederlands werden geselecteerd voor deelname. In totaal, werd 
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een vragenlijst verstuurd aan 699 overlevenden. Tachtig procent van de patiënten vulden een 
vragenlijst in die de Type D personality scale (DS14), impact of cancer en SF-36 vragenlijsten 
bevatten. Tweeëntwintig procent van de overlevenden werden geclassificeerd als het hebben 
van een Type D persoonlijkheid. Deze patiënten rapporteerden klinisch en statistisch significant 
slechtere scores op de general health, social functioning, mental health, emotional role limitations 
en vitality schalen van de SF-36 dan patiënten die geen Type D persoonlijkheid hadden. Verder, 
rapporteerden zij klinisch en statistisch significant hogere scores op impact of cancer schalen 
(body changes, negative self-evaluation, negative outlook on life, life interferences and health 
worry). Ook waren zij angstiger voor de schadelijke effecten van UV-licht op hun huid en paste 
hun zongedrag daarop aan. Er werden geen verschillende gevonden voor gezondheidszorg-
consumptie.
Een Type D persoonlijkheid lijkt een negatieve invloed te hebben op gezondheidsstatus in 
overlevenden van een melanoom en kan mogelijk een belangrijke factor zijn bij de screening 
in de dagelijke praktijk. Speciale aandacht voor deze patiënten is belangrijk, aangezien een 
melanoom meer van invloed kan zijn op deze patiënten.
Met behulp van de EORTC-QLQ-INFO26 vragenlijst werd de hoeveelheid informatie 
verkregen door 562 melanoompatiënten en de tevredenheid met de informatie onderzocht 
(hoofdstuk 7). Patiënten gaven aan dat zij geen informatie hadden ontvangen betreffende 
hun ziekte (9-37%), behandeling (38%) en nazorg (84-94%). Meer dan de helft van de patiënten 
(61%) was niet tot een klein beetje tevreden met de hoeveelheid informatie; een kwart van de 
patiënten wilden meer informatie. De verkregen hoeveelheid van informatie was geassocieerd 
met hogere stadia van melanoom, minder jaren sinds diagnose, hoger opleidingsniveau en 
jongere leeftijd. Tevredenheid met de informatie was geassocieerd met het ziekenhuis die de 
behandeling uitvoerden, hoger opleidingsniveau en gebruik van internet.
Meerdere gebieden van de informatievoorziening zijn onderbelicht en een meerderheid 
van melanoompatiënten is ontevreden met de verkregen informatie. Er is behoefte aan meer 
informatie toegespitst op patiënten om iedere patiënt te voorzien van de meest optimale 
informatie. Ook dient er aandacht besteed te worden aan de karakteristieken van een patiënt 
die van invloed kunnen zijn op de behoefte aan informatie. Dit biedt mogelijkheid aan het 
implementeren van een survivorship care plan. 
In hoofdstuk 8 wordt het perspectief van patiënten in het zuidoosten van Nederland 
met follow-up volgens de richtlijn van 2005 beschreven. De tevredenheid van patiënten over 
hun follow-up werd hierbij ook in acht genomen. Melanoompatiënten werd gevraagd naar 
hun behandeling, symptomen, invloed op dagelijks leven en follow-up. Zestien patiënten 
met meerdere melanomen werden geexcludeerd, aangezien dit van invloed kon zijn op de 
follow-up. Van de 546 deelnemers waren 418 patiënten nog steeds onder controle ten tijde van 
het invullen van de vragenlijst. De gemiddelde tijd sinds diagnose was 4 jaar en 71% had een 
stadium I melanoom. Bijna 80% van de patiënten met een melanoom met een Breslowdikte 
<1mm,  rapporteerden meer follow-up bezoeken dan geadviseerd in de richtlijn van 2005. 
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maar 5% van de patiënten wilden het aantal controlebezoeken verminderen. De meeste 
patiënten waren on controle bij een dermatoloog. Zij rapporteerden dat volledig inspectie van 
de huid (25%), onderzoek van de lymfeklieren (11%) en/of inspectie van het litteken (20%) niet 
standaard werd verricht. Deze aantallen waren signifi cant hoger bij andere specialismen. 
ziektelast door melanoom
hoofdstuk 9 beschrijft burden of disease in melanoompatiënten. Burden of disease beschrijft 
het verlies van gezondheid en sterfte door een ziekte, dit was nog niet adequaat onderzocht 
voor melanomen. Voor deze studie werden leeftijd- en geslachtsspecifi eke data van alle patiën-
ten gediagnosticeerd met een melanoom tussen 1998 en 2006 verkregen van de Nederlandse 
Kankerregistratie. Mortaliteitdata werden verkregen van het Bureau van Statistiek. Met behulp 
van DevCan software werden levenstabellen berekend die de kans op het krijgen van een 
melanoom vergaven per 5-jaarsinterval. De standaard levensverwachting voor mannen en 
vrouwen per 5-jaarsleeftijdsgroep werd geschat met behulp van DISMOD software. Het aantal 
jaren geleefd met een melanoom (YLD) en het aantal jaren verloren door vroege sterfte (YLL) 
door een melanoom weren berekend met deze levenstabellen en levensverwachtingen. De 
disability adjusted life years (DALY), een generieke maat voor burden of diasease, werd berekend 
door YLD en YLL bij elkaar op te tellen. De incidentie van melanoom was bijna verdubbeld van 
1989 tot 2006 ( cumulatieve incidentie rate variërend van 1.03-1.31% to 2.02-2.11%). De invloed 
van melanoom op de maatschappij berekend als burden of disease nam snel toe tussen 1989 
en 2006. gemiddeld leefden patiënten 21,6 -28,2 jaar met een diagnose melanoom. Melanoom 
resulteerden in een verlies van 17,8-20,1 levensjaren voor een leeftijd van 95 jaar, bij mensen 
die overleden waren door een melanoom.
In hoofdstuk 10 worden de resultaten van dit proefschrift besproken en in perspectief 
geplaatst. De waarde van het registerend van de incidentie van kanker wordt besproken en of 
melanoom gezien kan worden als een epidemie. De diversiteit aan patiëntkarakteristieken die 
van invloed lijken te zijn op de KvL van patiënt, maken het moeilijk om de KvL van melanoom-
patiënten in de algemene bevolking vast te stellen. De behoefte voor een melanoom-specifi eke 
vragenlijst die de invloed van een melanoom of het leven van een patiënt kan vaststellen wordt 
belicht. Ook wordt de tevredenheid van patiënten met de verkregen informatie over hun ziekte 
en de behandeling besproken. De discussie wordt beëindigd met de perspectieven voor de 
toekomst met het implementeren van een melanoom-specifi eke vragenlijst die gebruikt kan 
worden voor trials maar ook in de dagelijkse praktijk. Tevens wordt ook mogelijkheid van een 
survivorship care plan besproken als hulpmiddel om de communicatie tussen patiënten hun 
behandelaars te verbeteren.
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En dan nu het hoofdstuk wat voor veel mensen waarschijnlijk het eerste en meteen het laatste 
hoofdstuk is wat ze van dit proefschrift zullen lezen. Ik neem het deze mensen niet kwalijk, 
want dat geeft mij wel de gelegenheid om een aantal mensen goed te bedanken. Tijdens een 
promotietraject leer je vooral hoe belangrijk goede samenwerking en begeleiding is. Ik heb het 
geluk gehad te mogen profi teren van een samenwerking tussen experts in de epidemiologie 
en dermatologie, wat goed te zien is aan de lijst met promotoren en copromotoren.
Professor Neumann, ik heb het u niet gemakkelijk gemaakt. Ook na mijn overstap naar de 
interne geneeskunde heeft u mij altijd het idee geven dat ik welkom ben. Bedankt voor uw 
geduld en begrip. 
Professor Jan Willem Coebergh, het is een eer om een van uw eerste promovendi te zijn net na 
u “pensioen”. Heel erg bedankt voor de altijd kritische beoordeling van mijn manuscripten en 
kennismaking met experts op het gebied van huidkanker. 
Les 1 bij promoveren is, zoek een goede begeleider. Ik had er teveel om uit te kiezen.
Tamar, bedankt voor de goede en vooral gestructureerde begeleiding. Het was fi jn om te weten 
dat je deur altijd open stond voor advies. Je leerde mij nooit de klinische blik uit het oog te 
verliezen bij onderzoek. Dank je wel.
Lonneke, bij jou is het mede allemaal begonnen. De basis van epidemiologie en statistiek heb 
ik bij jou geleerd. Dankzij jouw hulp bij de strakke tijdsplanning, hebben Darren en ik een vlie-
gende start kunnen maken met ons afstudeeronderzoek wat de basis is voor dit proefschrift. Ik 
heb het altijd een enorm fi jne samenwerking gevonden.
Esther, je bent mijn paranimf, maar ik vind dat jij zeker ook in het lijstje hoort van copromo-
toren. Je bent erg belangrijk geweest bij de laatste stukken van dit proefschrift en wanneer 
Tamar het te druk had was je altijd beschikbaar voor het beantwoorden van vragen, advies 
en gezelligheid. Zonder jouw begeleiding was dit proefschrift zeker niet tot een goed einde 
gekomen, dank je wel.
Een promotie gaat pas door, als de kleine commissie ook het proefschrift goedgekeurd heeft. 
Ik wil daarom de leden van de kleine commissie, Prof.dr. van Busschbach, Prof.dr. Eggermont 
en Prof.dr. Bergman bedanken voor het kritisch beoordelen van dit proefschrift in een zeer snel 
tempo.
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Minstens zo belangrijk als goede begeleiding, zijn fi jne collega’s die altijd voor je klaar staan 
en waarmee je kunt discussiëren over belangrijke en onbelangrijke zaken. Ik wil daarom in het 
bijzonder mijn kamergenootjes van GK-016 bedanken. Marlies, Suzan, Sophie, Robert en Enes, 
jullie waren echt enorm fi jne collega’s. Behulpzaam en altijd in voor een grapje. We hebben vele 
uren samen doorgebracht in een veel te kleine kamer, maar ik heb nooit behoefte gehad om te 
gaan verhuizen. Ik kon altijd rekenen op jullie kritische beoordeling van analyses, artikelen en 
presentaties. Bedankt voor alle gezelligheid en de nodige afl eiding.
Tijd is o zo kostbaar bij het afronden van een proefschrift, ik wil daarom mijn opleider Prof. 
van Saase bedanken om mij in de gelegenheid te stellen dit proefschrift tot een goed einde te 
brengen, maar zeker ook mijn collega’s van de interne geneeskunde die hier alle begrip voor 
hadden. Bedankt voor jullie steun en belangstelling.
Darren, mijn partner in crime. Vijf maanden, samen in de trein naar Eindhoven, samen zieken-
huizen bezoeken, samen vragenlijsten versturen, samen invoeren, samen analyses doen, samen 
schrijven, samen achter de computer in de computerzaal of bij het IKZ. Het is een wonder dat 
we elkaar niet in de haren gevlogen zijn. We waren een goed team. Ik heb genoten van onze 
samenwerking.
Monique, mijn 2e paranimf(je) en goede vriendin, bedankt voor al je steun, hulp en de nodige 
afl eiding. Heel veel succes met het afronden van je eigen promotie!
Last but not least, mijn ouders en broertje. Bedankt voor jullie altijd luisterend oor, steun en 
hulp, en dat terwijl jullie vaak geen idee hadden waarvoor het nou was. Hopelijk is het nu iets 
duidelijker. (Mam, wees gerust er zit ook een Nederlandse samenvatting in dit boekje ;)) 
Cynthia BW 7.indd   166 28-09-11   13:35
Burden of Melanoma
Burden of 
of
of Melanoma
Melanoma
 List of publications
Cynthia BW 7.indd   167 28-09-11   13:35
Burden of 
of
Cynthia BW 7.indd   168 28-09-11   13:35
Burden of 
of
169
Li
st
 o
f p
ub
lic
at
io
ns
list of publications
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A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol. 2009 
Aug;20 Suppl 6:vi51-8.
Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers D, et al. Impact 
of melanoma on patients’ lives among 562 survivors: a Dutch population-based study. Arch 
Dermatol. 2011 Feb;147(2):177-85.
Holterhues C, Vries E, Louwman MW, Koljenovic S, Nijsten T. Incidence and trends of cutaneous 
malignancies in the Netherlands, 1989-2005. J Invest Dermatol. 2010 Jul;130(7):1807-12.
Husson O, Holterhues C, Mols F, Nijsten T, van de Poll-Franse LV. Melanoma survivors are dis-
satisfi ed with perceived information about their diagnosis, treatment and follow-up care. Br J 
Dermatol. 2010 Oct;163(4):879-81.
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and impact of cancer among melanoma survivors. Eur J Cancer. 2010 Feb;46(3):573-80.
Holterhues C, Hollestein L, Coeberg JW, Nijsten T, Pukkala E, Holleczek, Truggvadottir L, Comber 
H, Bento, MJ, Diba, CS, Primic Zakelj M, Izarzugaza MI, Gonzalez JP, Marcos-Gragera, R, Galceran 
J, Aicua EA, Schaff ear R, Pring A, de Vries E. Trends in incidence and predictions of cutaneous 
melanoma across Europe up to 2015. Submitted
Holterhues C, van de Poll-Franse, de Vries E, Neumann HAM, Nijsten T. Melanoma patients 
receive more follow–up care than current guideline recommendations:  A study of 546 patients 
from the general Dutch population.
JEADV, accepted
Holterhues C, Nijsten T, Koomen ER, Nusselder W, Karim-Kos HE, de Vries E .
Burden of disease in Dutch melanoma patients, 1989-2006. Submitted
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curriculum Vitae
Cynthia Holterhues werd geboren op 19 augustus 1984 in Rotterdam. In 2002 behaalde zij haar 
VWO diploma aan de OSG De Ring van Putten in Spijkenisse waarna zij begon aan de studie 
Geneeskunde aan de Erasmus Universiteit te Rotterdam. Na haar reguliere co-schappen ver-
richtte zij haar afstudeeronderzoek naar “ Health-Related Quality of Life of melanomapatients”, 
onder supervisie van Tamar Nijsten en Lonneke van de Poll-Franse. Het afstudeeronderzoek 
betrof een samenwerking tussen de afdeling Dermatologie van het Erasmus MC in Rotterdam 
en het Integraal Kankercentrum Zuid, te Eindhoven. De resultaten hiervan bedragen een groot 
deel van dit proefschrift. Na het afstudeeronderzoek haalde zij haar doctoraalexamen in juli 
2008 en vervolgens het artsexamen in november 2008. Aansluitend werkte zij als arts -onder-
zoeker op de afdeling Dermatologie van het Erasmus MC, waar zij in november 2008 begon aan 
het huidige proefschrift onder leiding van Tamar Nijsten, Lonneke van de Poll-Franse en Esther 
de Vries. In januari 2011 werd zij aangenomen voor de opleiding interne geneeskunde van het 
Erasmus MC, te Rotterdam.
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Phd Portfolio summary
summary of Phd training and teaching actiVities
Name PhD student: Cynthia Holterhues
Erasmus MC Department: Dermatology
Research School: NIHES
PhD period: November 2008 – October 2011
Promotors: Prof.Dr. H.A.M. Neumann 
 Prof. Dr. Coebergh
Supervisor: Dr. T.E.C. Nijsten 
 Dr. L.V. van de Poll-Franse
1. Phd training year workload
(hours/ects)
general academic skills 
Biomedical English Writing and Communication 2009 4 ECTS
research skills
NIHES course: Biostatistics for Clinicians 2009 1 ECTS
EORTC programme: Quality of Life, Symptom 
Research and Patient Reported Outcomes in Cancer 
Clinical trials
2009 20 hours
Minicursus Methodologie van patiëntgebonden 
onderzoek en voorbereiding van subsidieaanvragen
2009 8 hours
Basiscursus regelgeving en organisatie voor klinische 
onderzoekers (BROK)
2009 8 hours
Presentations
Holterhues C, Cornish D, van de Poll-Franse LV, 
Nijsten T. “Impact of melanoma on patients’ lives: 
cross-sectional population based study in the South 
Netherlands”. Presented at the Dermato-Epidemiol-
ogy Association (IDEA) congress, September 7, 2008, 
Nothingham.
2008 1 ECTS
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Holterhues C, van de Poll-Franse LV, Nijsten T. “Quality 
of life in melanoma patients”. Presented at EGAM 
meeting, EORTC melanoma group, March 20, 2009, 
Brussels.
2009 1 ECTS
Holterhues C. “Health care utilisation of melanoma 
patients in the general population”. Presented at the 
7th World Congress on Melanoma and 5th congress 
of the European Association of Dermato-Oncology 
(EADO), May 16, 2009, Vienna.
2009 1 ECTS
Holterhues C. “ Kwaliteit van leven en follow-up van 
melanoompatiënten”. Presented at VIKC Nederlandse 
Melanoomwerkgroep, November 11, 2009, Utrecht.
2009 1 ECTS
Holterhues C. Kwaliteit van leven van melanoom-
patiënten”. Presented at “Huidfondsmiddag”, 
Rotterdam, November 18, 2009.
2010 1 ECTS
Holterhues C. “Melanoompatiënten frequenter 
opgevolgd dat geadviseerd door de richtlijn: 
een studie onder 546 patiënten uit de algemene 
bevolking”. Presented at the 11de wetenschappelijke 
jaarvergadering van de Nederlandse Vereniging 
voor Experimentele Dermatologie, February 5 2010, 
Lunteren.
2010 1 ECTS
Holterhues C, Nijsten T. “ De huidkankerepidemie. 
Storm in een glas water?”. Presented at thema-avond 
IKW-werkgroep huitumoren, April 12, 2010, Leiden.
2010 1 ECTS
Holterhues C, de Vries E. “ Trends in incidence of 
cutaneous malignant melanoma in Europe: analysis 
of population based cancer registry data”. Presented 
at 6th EADO congress, June 16, 2010, Athens. (invited 
speaker)
2010 1 ECTS
Holterhues C, de Vries E, Nijsten T. “Incidence and 
trends of cutaneous malignancies in the Netherlands, 
1989-2005”. Presented at the 6th EADO congress, June 
16, 2010, Athens.
2010 1 ECTS
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international conferences
Dermato-Epidemiology Association (IDEA) congress, 
September 7, 2008, Nothingham.
2008 1 ECTS
7th World Congress on Melanoma and 5th congress 
of the European Association of Dermato-Oncology 
(EADO), May 16, 2009, Vienna.
2009 1 ECTS
EGAM meeting, EORTC melanoma group, March 20, 
2009, Brussels.
2009 1 ECTS
6th EADO congress, June 16, 2010, Athens 2010 1 ECTS
seminars and workshops
PhD day, Erasmus MC 2009 6 hours
Success in research: Learn from the experts 2009 1 hour
Publishing and Acceptance Criteria for Scientific 
Journals, by Ian Cressie
2009 2 hours
CPO autumn symposium 2009, Cost- Effective 
Interventions in Health Care: From Evaluation to 
Application
2009 2.5 hours
other
“Oncologie is de parel van de Ardennen”, Spa, May 
30 - June 1, 2010
2010 3 days
occasional reviewer for:
Archives of Dermato-Venereologica 2009 4 hours
Journal of Investigative Dermatology 2010 4 hours
European Journal of Cancer 2010 4 hours
Journal of the American Academy of Dermatology 2010 4 hours
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2. teaching actiVities
assisting/ supervising junior researchers:
S.C. Flohil, MD, PhD student Dermatology, Erasmus 
MC Rotterdam 2010. Thesis on basal cell carcinoma
R.J.T. van der Leest, PhD student and resident 
Dermatology, Erasmus MC Rotterdam, 2010. Thesis 
on melanoma
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